
U.S. ARMY MEDICAL DEPARTMENT CENTER AND SCHOOL FORT SAM HOUSTON, TEXAS 78234-6100



IMMUNOLOGY

SUBCOURSE MD0838 EDITION 100

DEVELOPMENT

This subcourse is approved for resident and correspondence course instruction. It reflects the current thought of the Academy of Health Sciences and conforms to printed Department of the Army doctrine as closely as currently possible. Development and progress render such doctrine continuously subject to change.

ADMINISTRATION

Students who desire credit hours for this correspondence subcourse must enroll in the subcourse. Application for enrollment should be made at the Internet website: http://www.atrrs.army.mil. You can access the course catalog in the upper right corner. Enter School Code 555 for medical correspondence courses. Copy down the course number and title. To apply for enrollment, return to the main ATRRS screen and scroll down the right side for ATRRS Channels. Click on SELF DEVELOPMENT to open the application; then follow the on-screen instructions.

For comments or questions regarding enrollment, student records, or examination shipments, contact the Nonresident Instruction Section at DSN 471-5877, commercial (210) 221-5877, toll-free 1-800-344-2380; fax: 210-221-4012 or DSN 471-4012, e-mail accp@amedd.army.mil, or write to:

NONRESIDENT INSTRUCTION BRANCH AMEDDC&S ATTN: MCCS-HSN 2105 11TH STREET SUITE 4191 FORT SAM HOUSTON TX 78234-5064

Be sure your social security number is on all correspondence sent to the Academy of Health Sciences.

CLARIFICATION OF TERMINOLOGY

When used in this publication, words such as "he," "him," "his," and "men" 'are intended to include both the masculine and feminine genders, unless specifically stated otherwise or when obvious in context.

USE OF PROPRIETARY NAMES

The initial letters of the names of some products may be capitalized in this subcourse. Such names are proprietary names, that is, brand names or trademarks. Proprietary names have been used in this subcourse only to make it a more effective learning aid. The use of any name, proprietary or otherwise, should not be interpreted as endorsement, deprecation, or criticism of a product; nor should such use be considered to interpret the validity of proprietary rights in a name, whether it is registered or not.

TABLE OF CONTENTS

Lesson		Paragraphs			
	INTRODUCTION				
1	IMMUNITY				
	Section I. Section II. Exercises	Introduction to Immunity Immune Response			
2	OVERVIEW OF	THE IMMUNE SYSTEM			
	Section I. Section II. Section III. Exercises	Antigens Antibodies Complement	2-12-2 2-32-5 2-62-12		
3	CELLS OF THE IMMUNE SYSTEM				
	Section I. Section II. Section III. Exercises	Introduction B Cells and Humoral Immunity T Cells and Cellular Immunity	3-13-4 3-53-8 3-93-10		
4	HLA COMPLEX				
	Section I. Section II. Exercises	Immunogenetics HLA Complex	4-14-2 4-34-4		
5	5 IMMUNOLOGICAL TECHNIQUES				
	Section I. Section II. Section III. Section IV. Section V. Exercises	Introduction Precipitation Reactions Serum Protein Electrophoresis (SPE) Immunoelectrophoresis (IEP) Enzyme Immunoassay Techniques	5-15-2 5-35-4 5-55-6 5-75-8 5-95-13		
6	ANTINUCLEAR ANTIBODIES AND TESTING				
	Section I. Section II. Section III. Exercises	Immunofluorescent Microscopy Antinuclear Antibodies Fluorescent Antinuclear Antibody Test	6-16-3 6-46-6 6-76-10		

<u>Lesson</u>

7 VIRAL IMMUNITY

APPENDIX

CORRESPONDENCE COURSE OF UNITED STATES ARMY MEDICAL DEPARTMENT CENTER AND SCHOOL

SUBCOURSE MD0838

IMMUNOLOGY

INTRODUCTION

This subcourse was developed to prepare you for your future course work at the Academy of Health Sciences. Study it carefully so that you will be ready to achieve the specific instructional objectives of your future course.

You've heard that an ounce of prevention is worth a pound of cure. Well, immunity is one way the body has of giving itself both prevention and sometimes a cure. The body develops an immune response to prevent the growth of foreign invaders that might cause disease. Incidentally, there are also times when the immune response becomes a problem in itself, as with allergies, and the rejection of transplanted organs.

Subcourse Components:

This subcourse consists of 7 lessons and an appendix:

Lesson 1, Immunity.

Lesson 2, Overview of the Immune System.

Lesson 3, Cells of the Immune System.

Lesson 4, HLA Complex.

Lesson 5, Immunological Techniques.

Lesson 6, Antinuclear Antibodies and Testing.

Lesson 7, Viral Immunity.

Appendix. References.

Here are some suggestions that may be helpful to you in completing this subcourse:

--Read and study each lesson carefully.

--Complete the subcourse lesson by lesson. After completing each lesson, work the exercises at the end of the lesson, marking your answers in this booklet.

--After completing each set of lesson exercises, compare your answers with those on the solution sheet that follows the exercises. If you have answered an exercise incorrectly, check the reference cited after the answer on the solution sheet to determine why your response was not the correct one.

Credit Awarded:

Upon successful completion of the examination for this subcourse, you will be awarded 10 credit hours.

To receive credit hours, you must be officially enrolled and complete an examination furnished by the Nonresident Instruction Section at Fort Sam Houston, Texas.

You can enroll by going to the web site <u>http://atrrs.army.mil</u> and enrolling under "Self Development" (School Code 555).

A listing of correspondence courses and subcourses available through the Nonresident Instruction Section is found in Chapter 4 of DA Pamphlet 350-59, Army Correspondence Course Program Catalog. The DA PAM is available at the following website: http://www.usapa.army.mil/pdffiles/p350-59.pdf.

LESSON ASSIGNMENT

Immunity

TEXT ASSIGNMENT	Paragraphs 1-1 through 1-8.		
LESSON OBJECTIVES	After completing this lesson, you should be able to:		
	1-1.	Identify the types of immunity.	
、	1-2.	Explain concepts related to the immune response, including specificity, heterogeneity, memory, and three phases of antigen removal.	
	1-3.	Describe induction of the immune response, including the primary and secondary immune response.	
	1-4.	Identify beliefs associated with the clonal selection theory and the template or instructive theory.	
	1-5.	Identify two nonspecific immune responses.	
SUGGESTION	After completing the assignment, complete the exercises at the end of this lesson. These exercises will help you to achieve the lesson objectives.		

LESSON 1

LESSON 1

IMMUNITY

Section I. INTRODUCTION TO IMMUNITY

1-1. INTRODUCTION

The concepts of immunology are ancient and pragmatic and are derived primarily from the study of resistance to infection. Immunity is defined as the physical, chemical, and cellular defense against antigens and the specific activities of certain body cells and/or chemical constituents of body fluids that aid in its defense.

1-2. TYPES OF IMMUNITY

Resistance or immunity to disease can be classified as innate immunity (also known as natural, native, or inherited) and acquired immunity. If the disease-resisting ability is a result of one's genetic makeup, and not acquired by exposure to infectious agents, it is said to be innate immunity. In contrast, acquired immunity develops after birth and as a result of contact with a foreign substance.

a. **Innate Immunity.** Innate immunity, known also as natural immunity or inherited immunity, refers to that type of resistance which each individual has by virtue of being the individual he or she is in terms of species, race, sex, or other factors associated with genetically controlled resistance. Natural immunity is commonly thought of as a nonspecific barrier that is effective against many different kinds of infectious agents.

b. Acquired Immunity. Acquired immunity is the type of immunity which an individual develops during a lifetime. It is antigen specific and may be based on antibodies or may be cell-mediated in origin and more closely associated with the activities of macrophages and T lymphocytes. This form of immunity is subdivided into that which is actively acquired and that which is passively acquired. In active immunity, the individual synthesizes his or her own antibodies; in passive immunity, the individual receives antibodies from some other individual. Both active and passive immunity are subdivided into two categories, depending on whether the immunity is acquired by natural or artificial means.

(1) <u>Active immunity</u>. Active immunity refers to that type of immunity in which production of significant amounts of antibody occurs about 7 to 14 days (or longer) after initial exposure to antigen. Upon subsequent exposure, antibody is detectable in 1 to 3 days.

(a) Naturally acquired active immunity. Active immunity may be naturally acquired either by having a subclinical infection with a particular microorganism or by actually having the disease. During the illness, the individual receives an antigenic stimulus which initiates antibody production against a specific pathogen. On a subsequent exposure to the same or antigenically related pathogen, these antibodies will assist in the body's defenses.

(b) Artificially acquired active immunity. A major role of immunologists interested in preventing infectious diseases has been the development of vaccines or toxoids that are used in immunization. The immunity resulting from the injection of these immunogens is said to be of the artificially acquired type, since this is a man-made procedure. Killed and attenuated strains of bacteria and viruses now are widely used forms of immunization against many diseases, including tuberculosis, mumps, poliomyelitis, yellow fever, and measles. Toxoids, which are detoxified but still antigenically active poisons excreted by certain bacteria, are excellent antigens. Antibodies against toxoids are fully reactive with the native toxin and provide excellent immunity against diseases caused by toxigenic bacteria such as tetanus and diphtheria.

(2) <u>Passive immunity</u>. Passive immunity is another type of acquired immunity because antibodies are involved. It differs from active immunity by the fact that the antibodies are produced in another individual or animal and injected into the patient, thus providing immediate protection. Although protection is provided upon completion of the injection, the duration of passive immunization is relatively short, a few days to several weeks, compared to years for active immunity. This is due to the natural degradation of injected antibody from the circulation without internal replacement. Passive immunity also may be acquired by natural means or by artificial means.

(a) Naturally acquired passive immunity. This type of immunity is significant mainly in the survival of the newborn infant. The infant passively acquires antibodies from its mother. The antibodies may pass from the immune mother to the fetus across the placental barrier. In addition, the infant may acquire these antibodies through breast feeding. The mother's milk is rich in antibodies for a short time. Of course, immunity is transferred only for the diseases to which the mother is immune. Passive immunity is especially important to the newborn; newborns are incapable of producing antibodies on their own for a few months after birth. The antibodies received via natural transfer from the mother are relatively short-lived with protection seldom exceeding 6 months. Fortunately, by this time the infant's immunologic system is functional.

(b) Artificially acquired passive immunity. Antibodies that have been produced in another individual or animal and then administered to the patient provide this type of immunity. This method has been used extensively in the past in the treatment of diphtheria and tetanus through the injection of antibodies produced in horses. Before the advent of antibiotics, passively administered antibodies were used as the treatment for pneumococcal pneumonia. Currently, passive immunization is mainly used for prophylaxis following exposure to such diseases as rubella and infectious hepatitis. This is usually accomplished by injecting the patient with gamma globulin which has been extracted from the blood of immune persons. These antibodies provide protection for a relatively short time. Other examples of this type of immunization are injections of hyperimmune serum and antiserum.

Section II. IMMUNE RESPONSE

1-3. **DEFINITION**

Immune response is defined as a reaction due to an antigenic stimulus characterized by the formation of humoral antibodies or the development of cellular immunity or both.

1-4. SPECIFIC IMMUNE RESPONSE

Specific immune responses are concerned with the recognition and ultimate disposal of foreign substances. The responses are made up of a series of cellular interactions, including the elaboration of specific cell products. Three general characteristics that distinguish specific immune responses are:

a. **Specificity.** This is the property of the specific immune response that distinguishes one antigen from another. The products of the immune response will react solely with the antigenic configuration identical or very similar to that which initiated the response.

b. **Heterogeneity.** This is characterized by the induction and interaction of a variety of new cell types specific for the inducing antigen. Heterogeneity contributes a fine degree of homeostatic control with which the host can respond in a highly variable and specific manner to foreign structures. In other words, heterogeneity is the body's way of proving "There's more than one way to skin a cat."

c. **Memory.** This is the property that results in proliferation and differentiation of sensitized cells upon subsequent exposure to an immunogen.

1-5. ANTIGEN ELIMINATION

Three phases of antigen removal take place following exposure.

a. The first phase takes only 10 to 20 minutes and represents the time required for equilibration of the antigen with the tissues and fluids. Because of extensive phagocytosis in the liver, lungs, and spleen, nearly 90of the antigen is removed from the circulation in its first passage through these organs.

b. The second phase of antigen elimination is a phase of gradual catabolic degradation and removal. This phase lasts for 4 to 7 days and represents the gradual enzymatic hydrolysis and digestion of the antigen. Consequently, the limits of this period are regulated by the enzymatic capability of the host for the particular type of substrate making up the antigen.

c. During the third phase, there is accelerated removal of antigen, as a result of the combination of newly formed antibody molecules with the antigen, enhancing the phagocytic process.


1-6. INDUCTION OF THE IMMUNE RESPONSE

a. **Primary Immune Response.** A primary antibody response occurs when an individual first encounters a foreign antigen. After antigen exposure there is a lag of several hours to several days before antibody is detected. This latent period depends upon the kind and amount of antigen given, the route of administration, and other host-dependent factors. Antibody appears between the fifth and tenth day.

(1) The latent period in antibody production is due to two factors. First, since only few cells are producing antibody at this time, it may take several days before antibody is measurable in the blood. Second, the first antibody molecules to appear in the blood may find residual antigen still in circulation. When these antigen and antibody molecules combine, they will be excreted, and the antibody will not be detected.

(2) After the latent period ends, the primary antibody response becomes detectable. The titer of antibody gradually increases over a period of a few days to a few weeks, plateaus, and then begins to drop. The initial antibody formed in the primary response is IgM. During the first and second week, IgM production declines. Although the mechanism is not well understood, evidence strongly suggests that a single precursor B cell can give rise to a clone, which can switch from IgM to IgG production. This phenomenon is referred to as the IgM-IgG shift. IgG production declines after a few weeks.

b. **Secondary Immune Response.** With subsequent exposure to antigen, the antibody response differs dramatically from the primary antibody response. This secondary response is characterized by a sharp drop in circulating antibody because it complexes with the newly injected antigen. Immediately thereafter, a marked increase in antibody levels becomes evident; the antibody is primarily IgG. This increase continues for several days, and ultimately the titer far surpasses that of the primary response. The titer also has a longer duration when compared to the primary response. The secondary response is often called the memory, anamnestic, or booster response (Figure 1-1).



COMPARISON OF PRIMARY AND SECONDARY RESPONSES

	Primary Response	Secondary Response
Memory Cells	Absent	Present
Time for Ig Production	Lengthy	Short
Major Ig Produced	Lg M	Lg G
Major Ig Produced	Lg M	Lg G

PC indicates plasma cell, Ab is antibody, and Ag is antigen.

Figure 1-1. Comparison of primary and secondary responses.

1-7. THEORIES OF IMMUNOGLOBULIN FORMATION

The current theories of antibody formation are modifications of selective type theories or of the template theory. Each of these theories has evidence to support it, but the clonal selection theory seems to be the most widely accepted.

a. **Clonal Selection Theory.** This theory is based upon the idea that each individual has a population of committed lymphocytes. Their surfaces contain receptors determining which antigens they are capable of recognizing. When unstimulated by antigen, only small amounts of surface IgM and IgD immunoglobulin are found. When these cells come into contact with that particular antigenic determinant, the cells multiply and differentiate into a clone of immunoglobulin-producing plasma cells.

b. **Template or Instructive Theory.** The basic tenet of the template theory is that antigen penetrates an antibody-forming cell and serves as a template for antibody synthesis. The result is that globulin is configured complementary to the antigen.

1-8. NONSPECIFIC RESPONSES REPRESENT THE BODY'S INITIAL ENCOUNTER WITH A FOREIGN AGENT

Two nonspecific immune responses worthy of mention are:

a. **Inflammation.** The inflammatory process is characterized by an increase in the number of leukocytes at the site of injury, the formation of fibrin in limiting the spread of bacteria from the invasion site, and increased blood and lymph flow, which dilutes and flushes away toxic substances.

b. **Phagocytosis.** Both neutrophils and macrophages are capable of phagocytosis. Neutrophils are concerned primarily with destruction of extracellular pathogens while macrophages are involved with the control of microorganisms that are able to survive intracellular residence and against which neutrophils are ineffective.

Continue with Exercises

EXERCISES, LESSON 1

INSTRUCTIONS: Answer the following items by completing the statement or by writing the answer in the space provided.

After you have completed all of these items, turn to "Solutions to Exercises" at the end of the lesson and check your answers with the solutions.

- 1. Immunity is defined as the <u>p_l</u>, <u>c_l</u>, and <u>c_r</u> defense against <u>a_s</u>. Immunity also refers to specific activities of certain body cells and/or chemical constituents of body fluids that aid in the body's <u>d_e</u>.
- 2. There are two types of immunity: <u>i e and a d</u>. In innate immunity, the disease-resisting ability is a result of one's <u>g c</u> makeup, and not acquired by exposure to infectious agents. In contrast, acquired immunity develops (before)(after) birth and as a result of contact with a <u>f</u> substance.
- 3. Innate immunity is also known as <u>n_l</u> immunity or <u>ted</u> immunity. Innate immunity refers to that type of resistance which each individual has by virtue of being the individual he or she is in <u>g_</u> terms, such as species and other factors. Natural immunity is commonly thought of as a <u>non_c</u> barrier that is effective against many different kinds of infectious agents.
- 4. Acquired immunity is the type of immunity which an individual develops during a $\underline{\text{time}}$. It is a <u>n sp</u> <u>c</u> and may be based on <u>a</u> <u>ies</u> or may be \underline{c} <u>l</u>-mediated in origin and more closely associated with the activities of macro <u>s</u> and <u>T l</u> <u>tes</u>. This form of immunity is subdivided into that which is a <u>ly</u> acquired and that which is <u>p</u> <u>ly</u> acquired. In active immunity, the individual <u>s</u> <u>sizes</u> his or her own antibodies. In passive immunity, the individual receives antibodies from some other <u>i</u> <u>al</u>. Both active and passive immunity are subdivided into two categories, depending on whether the immunity is acquired by <u>n</u> <u>l</u> or <u>art l</u> means.
- 5. Active immunity refers to that type of immunity in which production of significant amounts of antibody occurs about 7 to 14 <u>s</u> after initial exposure to antigen.
- 6. <u>ve</u> immunity may be <u>n</u> <u>ly</u> acquired either by having a subclinical infection with a particular microorganism or by actually having the disease.
- 7. The immunity resulting from the injection of a vaccine or toxoid is said to be <u>a ly</u> <u>a da ei y</u>. Killed and attenuated strains of bacteria and viruses now are widely used forms of immunization against many diseases; for example, <u>t sis</u>, <u>m s</u>, <u>p myelitis</u>, <u>y w</u> fever, and <u>me s</u>. Artificially acquired active immunity against tetanus and diphtheria is created by the injection of <u>t s</u>, which are <u>de ed</u> but still <u>an ly</u> active poisons excreted by bacteria.

- 8. Passive immunity is a type of acquired immunity because <u>ies</u> are involved. It differs from active immunity by the fact that the antibodies are produced in another <u>in l</u> or <u>an l</u> and <u>in d</u> into the patient to provide immediate protection. The duration of passive immunization is relatively short, a few <u>d s</u> to several <u>w s</u> compared to <u>s</u> for active immunity. There is no internal <u>re nt</u> of antibodies.
- Naturally acquired passive immunity is significant mainly in the survival of the <u>n</u> <u>n</u>. The fetus or infant <u>p</u> <u>ly</u> acquires <u>es</u> from its mother through the <u>pl lb r</u> and later through <u>br f g</u>.
- 10. Antibodies that have been produced in another individual or animal and then administered to the patient provide <u>a ly a d p</u> immunity. Currently, passive immunization is mainly accomplished by injecting the patient with <u>g a g n</u> which has been extracted from the blood of <u>i e p s</u>. These antibodies provide protection for a relatively (short) (long) time.
- 11. Immune response is defined as a <u>re n</u> due to an <u>an c</u> stimulus characterized by the formation of humoral <u>a s</u> or the development of <u>c r</u> <u>i y</u> or both.
- 12. Specific immune responses are concerned with the recognition and ultimate disposal of \underline{f} <u>n s</u> <u>s</u> and encompass a series of \underline{c} <u>r</u> interactions expressed by the elaboration of specific <u>l</u> products. Three general characteristics that distinguish specific immune responses are \underline{sp} <u>ty</u>, <u>h</u> <u>ty</u>, and <u>m</u> <u>y</u>.
- 13. The property of the specific immune response that distinguishes one antigen from another is called <u>ty</u>. The products of the immune response will react solely with the antigenic configuration <u>id I</u> or very <u>s r</u> to that which initiated the response.
- 14. Heterogeneity is characterized by the induction and interaction of a <u>v v</u> of new <u>l</u> types specific for the inducing <u>a</u>. It contributes a fine degree of homeostatic control with which the host can respond in a highly <u>v</u> and <u>c</u> manner to foreign structures.
- 15. Memory is the property that results in proliferation and differentiation of sensitized cells upon <u>nt ex e</u> to an immunogen.
- 16. Following exposure, antigen removal takes place in how many phases? ___.

- 17. The first phase of antigen removal takes only 10 to 20 <u>m</u> <u>s</u> and represents time required for <u>e</u> <u>bration</u> of the antigen with the tissues and fluids. Nearly 90% of the antigen is removed from the circulation in its first passage through the <u>r</u>, <u>s</u>, and <u>s</u> <u>n</u> by extensive <u>p</u> <u>osis</u>.
- 18. The second phase of antigen elimination is a phase of gradual <u>bolic</u> degradation and <u>r al</u>. This phase lasts for 4 to 7 <u>s</u> and represents the gradual enzymatic <u>h sis</u> and <u>d n</u> of the antigen.
- 19. During the third phase, removal of antigen is <u>a ated</u> by the combination of newly formed <u>y</u> molecules with the <u>en</u>, enhancing <u>is</u>.
- 20. A primary immune response occurs when an individual first <u>en</u> rs a foreign antigen. After antigen exposure, there is a lag of several hours to several days before antibody is detected. This latent period depends upon the kind and <u>nt</u> of antigen given, the <u>te</u> of administration, and other <u>h</u> t-dependent factors. Antibody appears between the fifth and tenth <u>y</u>.
- 21. After the first exposure to an antigen, the lag before response is called the <u>l_____nt</u> period. This lag is due to two factors. First, it may take several days before enough antibody is produced for it to be <u>m_____ble</u>. Second, the first antibody molecules may be excreted in combination with <u>r_____dual</u> antigen and thus not detected.
- 22. After the latent period ends, the primary antibody response becomes <u>d</u> e. The titer of antibody gradually in <u>s</u> over a period of a few days to a few weeks, plateaus, and then <u>b</u> s to <u>d</u> p. The initial antibody formed in the primary response is <u>.</u>. During the first and second week, IgM production <u>s</u>. Evidence suggests that a single precursor B cell can give rise to a <u>cl</u> e, which can switch from IgM to <u>production</u>. This phenomenon is referred to as the <u>lg</u> -lg shift. IgG production declines after a few <u>s</u>.
- 23. With subsequent exposure to antigen, the antibody response differs dramatically from the primary antibody response. This secondary response is characterized by a sharp <u>p</u> in circulating antibody because it <u>c xes</u> with the newly injected <u>a n</u>. Immediately thereafter, a marked (decrease) (increase) in antibody levels becomes evident; the antibody is primarily <u>lg</u>. Ultimately, the titer far surpasses that of the primary response and has a more extended <u>d n</u>.
- 24. Current theories of immunoglobulin formation include \underline{c} <u>I s</u> tion theory and <u>temp</u> or <u>tive</u> theory.

- 25. Clonal selection theory is based upon the idea that each individual has a population of <u>c</u> tted <u>l</u> cytes. Their surfaces contain <u>r</u> rs determining which antigens they are capable of <u>r</u> zing. When unstimulated by antigen, only small amounts of surface <u>lg</u> and <u>lg</u> immunoglobulin are found. When these cells come into contact with that particular antigenic determinant, the cells multiply and differentiate into a <u>cl</u> of <u>immuno</u>-producing plasma cells.
- 26. The basic tenet of the template theory is that antigen \underline{p} ates an antibody-forming cell and serves as a <u>t</u> ate or pattern for antibody synthesis. The result is that globulin is configured to be <u>com</u> ary to the antigen.
- 27. Nonspecific responses represent the body's initial encounter with a \underline{f} agent. Two nonspecific immune responses are \underline{in} tion and \underline{ph} s.

Check Your Answers on Next Page

SOLUTIONS TO EXERCISES, LESSON 1

- Immunity is defined as the <u>physical</u>, <u>chemical</u>, and <u>cellular</u> defense against <u>antigens</u>. Immunity also refers to specific activities of certain body cells and/or chemical constituents of body fluids that aid in the body's <u>defense</u>. (para 1-1)
- 2. There are two types of immunity: <u>innate and acquired</u>. In innate immunity, the disease-resisting ability is a result of one's <u>genetic</u> makeup, and not acquired by exposure to infectious agents. In contrast, acquired immunity develops <u>after</u> birth and as a result of contact with a <u>foreign</u> substance. (para 1-2)
- 3. Innate immunity is also known as <u>natural</u> immunity or <u>inherited</u> immunity. Innate immunity refers to that type of resistance which each individual has by virtue of being the individual he or she is in <u>genetic</u> terms, such as species and other factors. Natural immunity is commonly thought of as a <u>nonspecific</u> barrier that is effective against many different kinds of infectious agents. (para 1-2a)
- 4. Acquired immunity is the type of immunity which an individual develops during a lifetime. It is antigen specific and may be based on antibodies or may be <u>cell</u>-mediated in origin and more closely associated with the activities of <u>macrophages</u> and <u>T lymphocytes</u>. This form of immunity is subdivided into that which is <u>actively</u> acquired and that which is <u>passively</u> acquired. In active immunity, the individual <u>synthesizes</u> his or her own antibodies. In passive immunity, the individual receives antibodies from some other <u>individual</u>. Both active and passive immunity are subdivided into two categories, depending on whether the immunity is acquired by <u>natural</u> or <u>artificial</u> means. (para 1-2b)
- 5. Active immunity refers to that type of immunity in which production of significant amounts of antibody occurs about 7 to 14 <u>days</u> after initial exposure to antigen. (para 1-2b(1))
- 6. <u>Active</u> immunity may be <u>naturally</u> acquired either by having a subclinical infection with a particular microorganism or by actually having the disease.(para 1-2b(1)(a))
- 7. The immunity resulting from the injection of a vaccine or toxoid is said to be <u>artificially acquired active immunity</u>. Killed and attenuated strains of bacteria and viruses now are widely used forms of immunization against many diseases; for example, <u>tuberculosis</u>, <u>mumps</u>, <u>poliomyelitis</u>, <u>yellow fever</u>, and <u>measles</u>. Artificially acquired active immunity against tetanus and diphtheria is created by the injection of <u>toxoids</u>, which are <u>detoxified</u> but still <u>antigenically</u> active poisons excreted by bacteria. (para 1-2b(1)(b))

- 8. Passive immunity is a type of acquired immunity because <u>antibodies</u> are involved. It differs from active immunity by the fact that the antibodies are produced in another <u>individual</u> or <u>animal</u> and <u>injected</u> into the patient to provide immediate protection. The duration of passive immunization is relatively short, a few <u>days</u> to several <u>weeks</u> compared to <u>years</u> for active immunity. There is no internal <u>replacement</u> of antibodies. (para 1-2b(2))
- Naturally acquired passive immunity is significant mainly in the survival of the <u>newborn</u>. The fetus or infant <u>passively</u> acquires <u>antibodies</u> from its mother through the <u>placental barrier</u> and later through <u>breast feeding</u>. (para 1-2b(2)(a))
- Antibodies that have been produced in another individual or animal and then administered to the patient provide <u>artificially acquired passive immunity</u>. Currently, passive immunization is mainly accomplished by injecting the patient with <u>gamma globulin</u> which has been extracted from the blood of <u>immune persons</u>. These antibodies provide protection for a relatively <u>(short)</u> time. (para 1-2b(2)(b))
- 11. Immune response is defined as a <u>reaction</u> due to an <u>antigenic</u> stimulus characterized by the formation of humoral <u>antibodies</u> or the development of <u>cellular immunity</u> or both. (para 1-3)
- 12. Specific immune responses are concerned with the recognition and ultimate disposal of <u>foreign substances</u> and encompass a series of <u>cellular interactions</u> expressed by the elaboration of specific <u>cell</u> products. Three general characteristics that distinguish specific immune responses are <u>specificity</u>, <u>heterogeneity</u>, and <u>memory</u>. (para 1-4)
- 13. The property of the specific immune response that distinguishes one antigen from another is called <u>specificity</u>. The products of the immune response will react solely with the antigenic configuration <u>identical</u> or very <u>similar</u> to that which initiated the response. (para 1-4a)
- 14. Heterogeneity is characterized by the induction and interaction of a <u>variety</u> of new <u>cell types</u> specific for the inducing <u>antigen</u>. It contributes a fine degree of homeostatic control with which the host can respond in a highly <u>variable and</u> <u>specific</u> manner to foreign structures. (para 1-4b)
- 15. Memory is the property that results in proliferation and differentiation of sensitized cells upon <u>subsequent exposure</u> to an immunogen. (para 1-4c)
- 16. 3 (para 1-5)

- 17. The first phase of antigen removal takes only 10 to 20 <u>minutes</u> and represents time required for <u>equilibration</u> of the antigen with the tissues and fluids. Nearly 90% of the antigen is removed from the circulation in its first passage through the <u>liver</u>, <u>lungs</u>, and <u>spleen</u> by extensive <u>phagocytosis</u>. (para 1-5)
- 18. The second phase of antigen elimination is a phase of gradual <u>catabolic</u> degradation and <u>removal</u>. This phase lasts for 4 to 7 <u>days</u> and represents the gradual enzymatic <u>hydrolysis</u> and <u>digestion</u> of the antigen. (para 1-5)
- 19. During the third phase, removal of antigen is <u>accelerated</u> by the combination of newly formed <u>antibody</u> molecules with the <u>antigen</u>, enhancing <u>phagocytosis</u>. (para 1-5)
- 20. A primary immune response occurs when an individual first <u>encounters</u> a foreign antigen. After antigen exposure, there is a lag of several hours to several days before antibody is detected. This latent period depends upon the kind and <u>amount</u> of antigen given, the <u>route</u> of administration, and other <u>host</u>-dependent factors. Antibody appears between the fifth and tenth <u>day</u>. (para 1-6a)
- 21. After the first exposure to an antigen, the lag before response is called the <u>latent</u> period. This lag is due to two factors. First, it may take several days before enough antibody is produced for it to be <u>measurable</u>. Second, the first antibody molecules may be excreted in combination with <u>residual antigen</u> and thus not detected. (para 1-6a(1))
- 22. After the latent period ends, the primary antibody response becomes <u>detectable</u>. The titer of antibody gradually <u>increases</u> over a period of a few days to a few weeks, plateaus, and then <u>begins to drop</u>. The initial antibody formed in the primary response is <u>IgM</u>. During the first and second week, IgM production <u>declines</u>. Evidence suggests that a single precursor B cell can give rise to a <u>clone</u>, which can switch from IgM to <u>IgG</u> production. This phenomenon is referred to as the <u>IgM-IgG</u> shift. IgG production declines after a few <u>weeks</u>. (para 1-6a(2))
- 23. With subsequent exposure to antigen, the antibody response differs dramatically from the primary antibody response. This secondary response is characterized by a sharp <u>drop</u> in circulating antibody because it <u>complexes</u> with the newly injected <u>antigen</u>. Immediately thereafter, a marked <u>increase</u> in antibody levels becomes evident; the antibody is primarily <u>IgG</u>. Ultimately, the titer far surpasses that of the <u>primary</u> response and has a more extended <u>duration</u>. (para 1-6b)
- 24. Current theories of immunoglobulin formation include <u>clonal selection</u> theory and <u>template</u> or <u>instructive</u> theory. (para 1-7)

- 25. Clonal selection theory is based upon the idea that each individual has a population of <u>committed lymphocytes</u>. Their surfaces contain <u>receptors</u> determining which antigens they are capable of <u>recognizing</u>. When unstimulated by antigen, only small amounts of surface <u>IgM</u> and <u>IgD</u> immunoglobulin are found. When these cells come into contact with that particular antigenic determinant, the cells multiply and differentiate into a <u>clone</u> of <u>immunoglobulin</u>-producing plasma cells. (para 1-7a)
- 26. The basic tenet of the template theory is that antigen <u>penetrates</u> an antibodyforming cell and serves as a <u>template</u> or pattern for antibody synthesis. The result is that globulin is configured to be <u>complementary</u> to the antigen. (para 1-7b)
- 27. Nonspecific responses represent the body's initial encounter with a <u>foreign</u> agent. Two nonspecific immune responses are <u>inflammation</u> and <u>phagocytosis</u>. (para 1-8)

End of Lesson 1

LESSON ASSIGNMENT

LESSON 2	Over	view of the Immune System	
TEXT ASSIGNMENT	Paragraphs 2-1 through 2-12.		
LESSON OBJECTIVES	After completing this lesson, you should be able to:		
	2-1.	Define terms related to the immune system, including antigen, immunogen, hapten, carrier, immunogenicity, antigenicity, antibodies, and immunoglobulins.	
	2-2.	Name and explain antigen factors and host-related factors in immunogenicity.	
	2-3.	Name and describe the five major immunoglobulin classes.	
	2-4.	Explain the complement system, including the roles of complement, the classical pathway, the alternative pathway, the membrane attack complex (MAC), control mechanisms for the complement system, and biological effects of complement activation.	
SUGGESTION	After completing the assignment, complete the exercises at the end of this lesson. These exercises will help you to achieve the lesson objectives.		

LESSON 2

OVERVIEW OF THE IMMUNE SYSTEM

Section I. ANTIGENS

2-1. **DEFINITIONS**

a. An **antigen** is traditionally defined as any substance that will cause production of antibodies and which reacts specifically with those antibodies. This term, however, is incomplete because it emphasizes the production of immunoglobulins. Therefore, the term **immunogen** was introduced to include biological processes involving proliferation of lymphocytes and synthesis of specific substances or recognition molecules which can specifically combine with the inducing antigen. In physiochemical terms, **antigens** are macromolecules that possess a high degree of internal chemical complexity. They are soluble or easily solubilized by phagocytic cells of the animal and are foreign to the animal.

b. A **hapten** is defined as a small molecule which by itself cannot stimulate antibody synthesis but will combine with the antibody once formed. When the hapten is conjugated to a protein molecule called a **carrier**, it can elicit an immune response.

2-2. IMMUNOGENICITY

Immunogenicity may be defined as that property of a substance (immunogen) that endows it with the capacity to provoke a specific immune response. **Antigenicity**, on the other hand, is the property of a substance (antigen) that allows it to react with the products of the specific immune response. Substances that are immunogenic are always antigenic, but antigens are not necessarily immunogenic.

a. Antigen Factors.

(1) <u>Molecular weight</u>. As a general rule, for a molecule to be immunogenic it should have a molecular weight of 10,000 or more. The greater the molecular weight of a substance, the more likely it is to function as an antigen.

(2) <u>Molecular complexity</u>. Large molecular size alone is not enough to confer antigenicity on a substance. A molecule must possess a certain degree of chemical complexity; generally, immunogenicity increases with structural complexity.

(3) <u>Solubility</u>. Molecules that are insoluble in body fluids and cannot be converted to a soluble form by tissue enzymes are poor antigens.

(4) <u>Foreignness</u>. A substance that the body does not recognize as belonging to or being a part of itself.

b. Host-Related Factors.

(1) <u>Nonspecific factors</u>. The response to a given immunogen is not only a function of the physiochemical properties of the substance, but also is influenced by several host-related factors, including genetic makeup, age, and host environmental and nutritional status. Existing disease in the host may alter immune response capability.

(2) <u>Antigen dose and administration route</u>. As a rule, low antigen doses induce the formation of small amounts of antibody with high affinity and specificity. Low doses injected frequently over long periods of time will induce greater response than large doses over a short period of time. The route of antigen administration greatly affects the nature of the immune response.

Section II. ANTIBODIES

2-3. **DEFINITIONS**

Just as antigens are defined in terms of their reactivity with antibodies, all **antibodies** are intimately associated with their antigens. Antibodies belong to a group of proteins called globulins. More specifically, since they are active in immunity, they are frequently called **immunoglobulins**. They are a collection of protein molecules capable of specifically combining with the antigen that caused their formation.

2-4. STRUCTURE

a. Each immunoglobulin is composed of at least one basic unit or monomer, consisting of four polypeptide chains (Figure 2-1). This basic four-chain subunit consists of two identical heavy chains (H) and two identical light chains (L). The hinge region is found at the central junction of Figure 2-1. The chains above the hinge region yield Fab (antigen-binding) fragments. The chains below the hinge region yield Fc (crystallizable) fragments.

b. Based on structural differences in the constant regions, there are five classes of heavy chains. The different forms of heavy chains are designated gamma, alpha, mu, delta, and epsilon. The type of heavy chain determines the class of the immunoglobulin. There are five classes of immunoglobulins, designated as IgG, IgM, IgA, IgD, and IgE. Light chains can be classified as kappa and lambda on the basis of multiple structural differences in the constant region.




Figure 2-1. Basic immunoglobulin structure (V indicates variable region; C indicates constant region).

2-5. CHARACTERISTICS OF IMMUNOGLOBULIN CLASSES

a. **IgG.** In normal human adults, IgG constitutes approximately 75% of total serum immunoglobulins. It is the best known and most fully studied of the immunoglobulins. The molecule is made up of one basic structural unit known as a monomer, consisting of two heavy chains and two light chains (Figure 2-1). IgG is the only class of immunoglobulin that can cross the placenta, and it is responsible for the protection of the newborn during the first few months of life.

b. **IgM.** This high-molecular-weight macromolecule constitutes approximately 10% of the normal serum immunoglobulins. It exists as a pentamer consisting of ten heavy chains and ten light chains joined together by a J chain (Figure 2-2).

c. **IgA.** IgA represents approximately 15% of the serum immunoglobulins. It normally exists in serum both in monomeric and polymeric forms. The IgA dimer consists of two monomeric units (Figure 2-3). It is the predominant immunoglobulin class found in body secretions.

d. **IgD.** The IgD molecule is a monomer and is normally present in serum in trace amounts. Its main function has not been determined.

e. **IgE.** IgE comprises only 0.004% of the total serum immunoglobulins. It normally exists in monomeric form.




Figure 2-2. Pentameric polypeptide chain structure of human IgM.




Figure 2-3. Structure of human secretory IgA1 (sIgA1).

Section III. COMPLEMENT

2-6. INTRODUCTION

Complement is a system of serum proteins that is the primary dissolved mediator of antigen-antibody reactions. The complement system plays an integral role in the basic defense mechanisms of the body. It is a complex series of enzymatic proteins occurring in normal serum which interact to enhance the immune response.

a. In normal individuals, the complement system enables the body to respond in several ways to infections: production of **anaphylatoxins** which contract smooth muscle and increase vascular permeability and cause edema, production of chemotactic agents which cause an influx of leukocytes, and facilitation of phagocytosis by which infective agents are consumed and destroyed. **Opsonization** is the term for rendering bacteria and other cells susceptible to phagocytosis.

b. The system involves the sequential activation and interaction of at least 14 serum proteins and may occur via the classical pathway or the alternative pathway. These two pathways are parallel but independent. However, the two pathways do become identical at the point of the membrane attack complex. Natural inhibitors and instability of the complexes act to balance the system so that uncontrolled activation does not occur. Thus, total consumption of the components does not occur every time there is activation.

c. The key step in these pathways is the cleavage of C3. C3a promotes inflammatory changes useful for fighting infection. C3b promotes adherence of phagocytes and continuation of the alternative pathway. The alternative pathway is notable because it can be activated without an antibody reaction.

d. One way to appreciate the importance of the complement system is to observe what happens in those rare individuals with hereditary deficiencies of the classical pathway. These individuals are predominantly ill with a variety of diseases and repeated infections, including Neisseria organisms.

2-7. ROLES OF COMPLEMENT

a. Activated complement components affect the inflammatory and immune response in the following manner:

(1) Increased vascular permeability.

(2) Smooth muscle contraction.

(3) Mast cell and basophil degranulation with the subsequent release of histamines.

- (4) Neutrophil activation and chemotaxis.
- (5) Enhanced opsonization and phagocytosis.
- (6) Lysis of target cells, bacteria, and viruses.

b. Many of these effects are due to complement cleavage products known as **anaphylatoxins**. You are probably already familiar with the related term **anaphylaxis**, which is used to refer to an exaggerated allergic reaction.

2-8. THE CLASSICAL PATHWAY

a. Activators of the classical pathway are primarily antigen-antibody complexes or aggregated immunoglobulins. Human immunoglobulins belonging to IgG1, IgG2, and IgG3 subclasses and IgM are capable of initiating the classical pathway. The most effective activator, however, is the large pentamer IgM. Nonimmunologic activators of this pathway include DNA, C-reactive protein, certain cellular membranes, and trypsin-like enzymes.

b. Activation of the classical pathway begins with the interaction of C1 with an antigen-antibody complex. The C1 component is comprised of three distinct protein molecules: C1q, C1r, and C1s. The binding of the C1q component to the Fc portion of the IgG or IgM molecule initiates the pathway (Figure 2-4). Changes in C1q causes C1r to enzymatically activate C1s.






Figure 2-4. C1 molecule.

c. Activated C1s cleaves C4 into two fragments: C4a which is released into the fluid phase as an anaphylatoxin and C4b which may bind directly to the activating surface (Figure 2-5). C4b may also be released into the fluid phase as an opsonin. Activated C1s is also capable of cleaving and activating C2, generating C2a and C2b. A site on the C2a fragment allows it to bind to the surface-bound C4b to form the complex C4b2a.

d. The C4b2a complex is known as C3 convertase and is capable of cleaving and activating C3. C3a is the smaller of the two fragments produced and is released into the fluid phase as an anaphylatoxin. The larger C3b fragment may either be released into the fluid phase as an opsonin or attach to the activating surface at a site distinct from the **C4b2a** and antibody. Only a small portion of the total number of C3b molecules bind to the activating surface and interact with C4b2a. The resulting C4b2a3b complex is known as C5 convertase and is capable of cleaving and activating C5. This is the first step to the formation of the membrane attack complex.





2-9. THE ALTERNATIVE PATHWAY

a. The primary activators of the alternative pathway are usually nonimmunological in nature. They include bacterial lipopolysaccharides, erythrocytes of certain species, viruses, fungi, and parasites. Immunological activators of this pathway are aggregated IgE, IgA, and IgG subclass 4.

b. An initial requirement for activation of the alternative pathway is the presence of C3b, which is continuously generated in small amounts by natural hydrolysis of C3. Continuation of the alternative pathway occurs only if an activating surface is present to provide a binding site for the C3b and protect it from control protein activity (Figure 2-6).

c. In the presence of C3b, factor B is cleaved by factor D into two fragments, Bb and Ba. The Bb fragment forms a complex with C3b and the resultant **C3b**, **Bb** complex is known as C3 convertase. This complex has enzymatic properties and is capable of cleaving and activating more C3. Properdin (P) acts as a stabilizer for the **C3b**, **Bb** complex by protecting it from decay and control mechanisms. Large amounts of C3b are generated and resupply the reaction cycle. The C3b may release to the fluid phase as an opsonin, bind directly to the activating surface, or attach to C3 convertase forming the complex, **C3b**, **Bb**, **3b**. This complex is known as C5 convertase and is capable of cleaving and activating C5, the first component of the membrane attack complex.




Figure 2-6. Alternative pathway.

2-10. THE MEMBRANE ATTACK COMPLEX (MAC)

The membrane attack complex (MAC), beginning with the cleavage and activation of C5, is common to both complement pathways. The activation of C5 by either **C4b2a3b** or **C3b**, **Bb**, **3b** results in two fragments. The smaller C5a fragment is released into the fluid phase as an anaphylatoxin or chemotactic factor. The larger C5b fragment binds directly to the activating surface, followed by the binding of C6 and C7 (Figure 2-7). The **C5b67** complex provides a binding site for C8 which initiates some membrane damage. However, the subsequent binding of multiple molecules of C9 is required for efficient cell lysis.




Figure 2-7. Membrane attack complex.

2-11. CONTROL MECHANISMS

Several control mechanisms are involved in the complement system which preclude uncontrolled activation and consumption of its protein components.

a. Labile binding sites on the activated proteins decay rapidly causing dissociation of complexes. This decay results in failure to achieve membrane or surface attachment of the complex, which restricts the complement activation to a local area.

b. C1 Inactivator binds to activated C1s and inhibits further activation of C4 and C2 in the classical pathway.

c. Factor I prevents further activation of C3b by cleaving the molecule into inactive fragments, C3c and C3d. Factor I and C4 binding protein displace C4b from the **C4b2a** complex and cleaves C4b into the inactive fragments, C4c and C4d.

d. Factor H accelerates the action of factor I on C3b and also displaces the Bb from the **C3b**, **Bb** complex of the alternative pathway, rendering it inactive.

2-12. BIOLOGICAL EFFECTS OF COMPLEMENT ACTIVATION

Several substances are released to produce the biological effects of complement activation.

a. **Anaphylatoxins (C3a, C4a, C5a).** Anaphylatoxins cause the release of histamine from mast cells and basophils. Histamine in turn enhances vascular permeability and causes smooth muscle contractions, resulting in edema and inflammation.

b. **Opsonins (C3b, C4b).** Many cells, including polymorphonuclear cells, B lymphocytes, and macrophages, have receptor sites for C3b and C4b. Also many of the nonimmunological activators have receptors for C3b and C4b. These fragments bind to their receptors and act to facilitate adherence and phagocytosis of the target cell.

c. **Chemotactic Factor (C5a).** The function of the chemotactic factor is to induce and direct the migration and accumulation of phagocytic cells at the site of the immune reaction.

Continue with Exercises

EXERCISES, LESSON 2

INSTRUCTIONS: Answer the following items by completing the statement or by writing the answer in the space provided.

After you have completed all of these items, turn to "Solutions to Exercises" at the end of the lesson and check your answers with the solutions.

- An antigen is traditionally defined as any substance that will cause production of <u>a s</u> and which reacts specifically with those <u>a s</u>. This term, however, is <u>i e</u> because it emphasizes the production of immunoglobulins. Therefore, the term <u>i n</u> was introduced to include other biological processes, such as proliferation of <u>I s</u> and synthesis of <u>r tion m les</u> which can specifically combine with the inducing <u>a n</u>. Antigens are <u>macro s</u> that possess a high degree of internal chemical <u>c ty</u>. They are soluble or easily <u>s zed</u> by <u>p c</u> cells of the animal and are foreign to the animal.
- 2. A **hapten** is defined as a small \underline{m} <u>e</u> which by itself cannot stimulate <u>a</u> <u>y</u> <u>s</u> <u>s</u> but will combine with the <u>a</u> <u>y</u> once formed. When the hapten is conjugated to a protein molecule called a <u>c</u> <u>r</u>, it can elicit an immune response.
- The capacity to provoke a specific immune response is called <u>i city</u>. The capacity to react with the products of the specific immune response is called <u>a y</u>. Substances that are immunogenic are always <u>a c</u>, but antigens are not necessarily <u>i c</u>.
- 4. The greater the <u>m r w t</u> of a substance, the more likely it is to function as an antigen. Immunogenicity increases with <u>str l c y</u>. Poor antigens often consist of molecules that are <u>i ble</u> in body fluids and which cannot be converted to a <u>s e</u> form by tissue <u>e s</u>.
- 5. A substance not recognized as belonging to or being a part of the body is said to be a \underline{f} <u>n</u> substance. This characteristic is \underline{f} <u>ness</u>.
- Some host-related factors in immunogenicity are called <u>no cf s</u>. These host-related factors include <u>g c m p</u>, <u>a e</u>, and host <u>e l</u> and <u>n l</u> status. Existing disease in the host may alter the capability for <u>i e</u> <u>r e</u>.

- Other host-related factors are the <u>a n</u> dose and <u>a n r e</u>. A greater immune response can be expected with low doses injected <u>f ly</u> over <u>(long) (short)</u> periods of time.
- 8. You've already learned that antigens are defined in terms of their reactivity with <u>a s</u>. Likewise, all antibodies are intimately associated with their <u>a s</u>. Antibodies belong to a group of proteins called <u>g s</u>. More specifically, since they are active in immunity, these proteins are frequently called <u>i s</u>. They are a collection of <u>p n</u> molecules capable of specifically combining with the <u>a n</u> that caused their formation.
- Each immunoglobulin is composed of at least one basic unit or <u>m</u> <u>r</u> comprised of four <u>p</u> <u>e</u> chains. This basic four-chain subunit consists of two identical <u>h</u> <u>y</u> chains (H) and two identical <u>l</u> <u>t</u> chains (L).
- 10. Based on structural differences in the constant regions, there are five classes of \underline{h} y chains. The different forms of heavy chains are designated \underline{g} a, \underline{a} , \underline{a} , \underline{n} , \underline{n} , \underline{d} a, and \underline{e} n. The type of heavy chain determines the class of the immunoglobulin. There are five classes of immunoglobulins, designated as \underline{lg} , \underline{lg} , \underline{lg} , and \underline{lg} . Light chains can be classified as \underline{k} a and \underline{l} a on the basis of multiple structural differences in the \underline{c} t region.
- 11. The immunoglobulins are divided into how many classes? ____. The most common of these classes is lg__. In normal human adults, IgG constitutes approximately (25%) (50%) (75%) total serum immunoglobulins. The molecule is made up of one basic structural unit known as a m____r, consisting of (1) (2) (3) (4) heavy chains and (1) (2) (3) (4) light chains. IgG is the only class of immunoglobulin that can cross the p_____a, and it is responsible for the protection of the n_____n during the first few m______s of life.
- 12. The third most common form of immunoglobulin in serum is <u>lg_</u>. It has a (<u>high)(low)</u> molecular weight. The macromolecule makes up about (<u>10%) (20%) (30%)</u> of the normal serum immmunoglobulins. It exists as a <u>p_____r</u> consisting of (<u>2) (4) (6) (8) (10)</u> heavy chains and (<u>2) (4) (6) (8) (10)</u> light chains joined together by a <u>J</u> chain.

- The second most common form of immunoglobulin in serum is <u>lg</u>. It represents approximately (5%) (10%) (15%) total serum immunoglobulins. It normally exists in serum both in <u>m</u> <u>c</u> and <u>p</u> <u>c</u> forms. The IgA <u>dimer</u> consists of two <u>m</u> <u>ic</u> units. It is the predominant immunoglobulin class found in body <u>s</u> <u>tions</u>.
- 14. The IgD molecule is a <u>m</u> r and is normally present in serum in <u>t</u> e amounts. Its main function has not been determined. IgE comprises only 0.004% of the total serum <u>i</u> s. IgE normally exists in <u>m</u> ic form.
- 15. Complement is a system of <u>mps</u> that is the primary dissolved <u>m tor</u> of antigen-antibody reactions. The complement system is one of the basic <u>d e</u> mechanisms of the body. It is a complex series of <u>e tic</u> proteins occurring in normal serum which interact to enhance the <u>i er e</u>. The system involves the sequential <u>a tion</u> and <u>interaction</u> of at least (<u>4) (14) (24)</u> serum proteins and may occur via the <u>c l</u> pathway or the <u>a e</u> pathway. These two pathways are <u>p l</u> but <u>i t</u>. The two pathways do become identical at the point of the <u>m e a k c x</u>. Natural inhibitors and instability of the complexes act to balance the system so that <u>u d</u> activation does not occur. Thus, total <u>c tion</u> of the components does not occur every time there is activation.
- 16. Activated complement components affect the <u>i tory</u> and immune response in the following manner:
 - a. Increased vascular <u>p y</u>.
 - b. Smooth muscle <u>c tion</u>.
 - c. Mast cell and basophil <u>de tion</u> with the subsequent release of <u>h</u> s.
 - d. <u>N l</u> activation and <u>c xis</u>.
 - e. Enhanced <u>o tion</u> and <u>p s</u>.
 - f. <u>L</u> s of target cells, <u>b</u> a, and <u>v</u> s.

Many of these effects are due to complement cleavage products known as \underline{a} <u>ns</u>. A related term is \underline{a} <u>s</u>, which is used to refer to an exaggerated allergic reaction.

- 17. Activators of the classical pathway are primarily <u>a n-a y</u> complexes or aggregated <u>i s</u>. Activators of the classical pathway include the IgG subclasses <u>IgG</u>, <u>IgG</u>, and <u>IgG</u>, but the most effective activator is the large pentamer <u>Ig</u>. Nonimmunologic activators of this pathway include DNA, C-reactive <u>p n</u>, certain <u>c r</u> membranes, and <u>t n</u>-like enzymes.
- Activation of the classical pathway begins with the interaction of <u>C</u> with an <u>a n-a y</u> complex. The C1 component is comprised of three distinct protein molecules: <u>C1</u>, <u>C1</u>, and <u>C1</u>. The binding of the C1q component to the Fc portion of the IgG or IgM molecule initiates the <u>p y</u>. Changes in C1q causes <u>C1</u> to enzymatically activate <u>C1</u>.
- 19. In the classical pathway, activated C1s cleaves C4 into two fragments: C4a which is released into the <u>fl</u> d phase as an <u>a</u> n and C4b which may bind directly to the <u>a</u> ing surface. C4b may also be released into the fluid phase as an <u>o</u> n. Activated C1 also is capable of <u>cl</u> ing and <u>a</u> ing C2 generating <u>C2</u> and <u>C2</u>. A site on the C2a fragment allows it to bind to the surface-bound C4b to form the complex <u>C4b</u>.
- 20. In the classical pathway, the **C4b2a** complex is known as C3 <u>c</u> <u>e</u> and is capable of cleaving and activating <u>C</u>. C3a is the smaller of the two fragments produced and is released into the fluid phase as an <u>a</u> <u>n</u>. A (<u>small</u>) (large) portion of the total number of C3b molecules bind to the activating surface and interact with **C4b2a**. The resulting **C4b2a3b** complex is known as C5 <u>c</u> <u>e</u> and is capable of cleaving and activating C5. This is the first step to the formation of the <u>m</u> <u>e</u> <u>a</u> <u>k</u> <u>c</u> <u>x</u>.
- The primary activators of the alternative pathway are usually non-i l in nature. They include bacterial l s, erythrocytes of certain species, v s, f i, and p s. Aggregated IgE, IgA, and IgG subclass 4 are i l activators of this pathway.
- 22. An initial requirement for activation of the alternative pathway is the presence of <u>C3</u>, which is <u>c ly</u> generated in (<u>small</u>) (large) amounts by natural hydrolysis of C3. Continuation of the alternative pathway occurs only if an activating <u>s e</u> is present to provide a <u>b g</u> site for the C3b and <u>p t</u> it from control protein activity.

- 23. In the alternative pathway, in the presence of C3b, factor B is cleaved by factor ______ into two <u>f</u> nts, Bb and Ba. The Bb fragment forms a complex with <u>C3</u> and the resultant **C3b**, **Bb** complex is known as C3 <u>c</u> <u>e</u>. This complex has enzymatic properties and is capable of cleaving and activating more <u>C</u>. Properdin (P) acts as a <u>s</u> <u>r</u> for the **C3b**, **Bb** complex by <u>p</u> <u>g</u> it from decay and control mechanisms. Large amounts of C3b are generated and <u>r</u> <u>y</u> the reaction cycle. The C3b may release to the fluid phase as an <u>o</u> <u>n</u>, bind directly to the activating <u>s</u> <u>e</u>, or attach to C3 <u>c</u> <u>e</u> forming the complex, **C3b**, **Bb**, **3b**. This complex is known as C5 convertase and is capable of <u>c</u> <u>g</u> and <u>a</u> <u>g</u> C5, the first component of the membrane <u>a</u> <u>k</u> complex.
- 24. The membrane attack complex (MAC), beginning with the cleavage and activation of C5, is common to both complement <u>p</u>s. The activation of C5 results in two <u>f</u>s. The smaller C5a fragment is released into the fluid phase as an <u>a</u> <u>xin</u> or <u>c</u> <u>ctic</u> factor. The larger C5b fragment binds directly to the <u>a</u><u>g</u>s<u>e</u>, followed by the binding of C6 and C7 (Figure 2-7). The **C5b67** complex provides a <u>b</u> ing site for C8 which initiates some <u>m</u><u>e</u><u>d</u><u>e</u>. However, the subsequent binding of multiple molecules of C9 is required for efficient cell <u>l</u><u>s</u>.
- 25. There are control mechanisms in the complement system that preclude uncontrolled <u>a n</u> and <u>c n</u> of its protein components. For example, binding sites on activated proteins <u>d y</u> rapidly, causing dissociation of <u>c s</u>. This restricts the complement activation to a <u>l l a a</u>.
- 26. Several substances are released to produce the biological effects of <u>c</u> t activation.

For example, anaphylatoxins cause the release of <u>h</u> <u>e</u> from mast cells and basophils. Histamine in turn enhances vascular <u>p</u> <u>y</u> and causes smooth muscle <u>c</u> <u>s</u>, resulting in edema and inflammation.

Many cells, including polymorphonuclear cells, B lymphocytes, and macrophages, have receptor sites for <u>o</u>s (C3b and C4b). Also many of the nonimmunological activators have receptors for these <u>o</u>s. Opsonin fragments bind to their receptors and act to facilitate adherence and <u>p</u>s of the target cell.

The function of the chemotactic factor (C5a) is to induce and direct the <u>migration</u> and <u>a tion</u> of phagocytic cells at the site of the immune reaction.

Check Your Answers on Next Page

SOLUTIONS TO EXERCISES, LESSON 2

- An antigen is traditionally defined as any substance that will cause production of <u>antibodies</u> and which reacts specifically with those <u>antigens</u>. This term, however, is <u>incomplete</u> because it emphasizes the production of immunoglobulins. Therefore, the term <u>immunogen</u> was introduced to include other biological processes, such as proliferation of <u>lymphocytes</u> and synthesis of <u>recognition</u> <u>molecules</u> which can specifically combine with the inducing <u>antigen</u>. Antigens are <u>macromolecules</u> that possess a high degree of internal chemical <u>complexity</u>. They are soluble or easily <u>solubilized</u> by <u>phagocytic</u> cells of the animal and are foreign to the animal. (para 2-1a)
- A hapten is defined as a small <u>molecule</u> which by itself cannot stimulate <u>antibody</u> <u>synthesis</u> but will combine with the <u>antibody</u> once formed. When the hapten is conjugated to a protein molecule called a <u>carrier</u>, it can elicit an immune response. (para 2-1b)
- The capacity to provoke a specific immune response is called <u>immunogenicity</u>. The capacity to react with the products of the specific immune response is called <u>antigenicity</u>. Substances that are immunogenic are always <u>antigenic</u>, but antigens are not necessarily <u>immunogenic</u>. (para 2-2)
- 4. The greater the <u>molecular weight</u> of a substance, the more likely it is to function as an antigen. Immunogenicity increases with <u>structural complexity</u>. Poor antigens often consist of molecules that are <u>insoluble</u> in body fluids and which cannot be converted to a <u>soluble</u> form by tissue <u>enzymes</u>. (para 2-2a)
- 5. A substance not recognized as belonging to or being a part of the body is said to be a <u>foreign</u> substance. This characteristic is <u>foreignness</u>. (para 2-2a(4))
- Some host-related factors in immunogenicity are called <u>nonspecific factors</u>. These host-related factors include <u>genetic makeup</u>, <u>age</u>, and host <u>environmental</u> and <u>nutritional</u> status. Existing disease in the host may alter the capability for <u>immune</u> <u>response</u>. (para 2-2b(1))
- Other host-related factors are the <u>antigen</u> dose and <u>administration route</u>. A greater immune response can be expected with low doses injected <u>frequently</u> over <u>short</u> periods of time. (para 2-2b(2))
- You've already learned that antigens are defined in terms of their reactivity with <u>antibodies</u>. Likewise, all antibodies are intimately associated with their <u>antigens</u>. Antibodies belong to a group of proteins called <u>globulins</u>. More specifically, since they are active in immunity, these proteins are frequently called <u>immunoglobulins</u>. They are a collection of <u>protein</u> molecules capable of specifically combining with the <u>antigen</u> that caused their formation. (para 2-3)

- Each immunoglobulin is composed of at least one basic unit or <u>monomer</u> comprised of four <u>polypeptide</u> chains. This basic four-chain subunit consists of two identical <u>heavy</u> chains (H) and two identical <u>light</u> chains (L). (para 2-4a)
- Based on structural differences in the constant regions, there are five classes of <u>heavy</u> chains. The different forms of heavy chains are designated <u>gamma</u>, <u>alpha</u>, mu, <u>delta</u>, and <u>epsilon</u>. The type of heavy chain determines the class of the immunoglobulin. There are five classes of immunoglobulins, designated as <u>lgG</u>, <u>lgM</u>, <u>lgA</u>, <u>lgD</u>, and <u>lgE</u>. Light chains can be classified as <u>kappa</u> and <u>lambda</u> on the basis of multiple structural differences in the <u>constant</u> region. (para 2-4b)
- 11. The immunoglobulins are divided into how many classes? <u>5</u> The most common of these classes is <u>IgG</u>. In normal human adults, IgG constitutes approximately <u>75%</u> of total serum immunoglobulins. The molecule is made up of one basic structural unit known as a <u>monomer</u>, consisting of <u>2</u> heavy chains and <u>2</u> light chains. IgG is the only class of immunoglobulin that can cross the <u>placenta</u>, and it is responsible for the protection of the <u>newborn</u> during the first few <u>months</u> of life. (para 2-5a)
- The third most common form of immunoglobulin in serum is <u>IgM</u>. It has a <u>high</u> molecular weight. The macromolecule makes up about <u>10%</u> of the normal serum immmunoglobulins. It exists as a <u>pentamer</u> consisting of <u>10</u> heavy chains and <u>10</u> light chains joined together by a <u>J</u> chain. (para 2-5b)
- The second most common form of immunoglobulin in serum is <u>IgA</u>. It represents approximately 15% of the total serum immunoglobulins. It normally exists in serum <u>both</u> in monomeric and polymeric forms. The IgA dimer consists of two monomeric units. It is the predominant immunoglobulin class <u>found in body</u> secretions. (para 2-5c)
- The IgD molecule is a <u>monomer</u> and is normally present in serum in <u>trace</u> amounts. Its main function has not been determined. IgE comprises only 0.004% of the total serum <u>immunoglobulins</u>. IgE normally exists in <u>monomeric</u> form. (para 2-5d, e)
- 15. Complement is a system of <u>serum proteins</u> that is the primary dissolved <u>mediator</u> of antigen-antibody reactions. The complement system is one of the basic <u>defense</u> mechanisms of the body. It is a complex series of <u>enzymatic</u> proteins occurring in normal serum which interact to enhance the <u>immune response</u>. The system involves the sequential <u>activation</u> and <u>interaction</u> of at least <u>14</u> serum proteins and may occur via the <u>classical</u> pathway or the <u>alternative</u> pathway. These two pathways are <u>parallel</u> but <u>independent</u>. The two pathways do become identical at the point of the <u>membrane attack complex</u>. Natural inhibitors and instability of the complexes act to balance the system so that <u>uncontrolled</u> activation does not occur. Thus, total <u>consumption</u> of the components does not occur every time there is activation. (para 2-6)

- 16. Activated complement components affect the <u>inflammatory</u> and immune response in the following manner:
 - a. Increased vascular permeability.
 - b. Smooth muscle contraction.
 - c. Mast cell and basophil <u>degranulation</u> with the subsequent release of <u>histamines</u>.
 - d. <u>Neutrophil</u> activation and <u>chemotaxis</u>.
 - e. Enhanced opsonization and phagocytosis.
 - f. Lysis of target cells, bacteria, and viruses.

Many of these effects are due to complement cleavage products known as <u>anaphylatoxins</u>. A related term is <u>anaphylaxis</u>, which is used to refer to an exaggerated allergic reaction. (para 2-7)

- Activators of the classical pathway are primarily <u>antigen-antibody</u> complexes or aggregated <u>immunoglobulins</u>. Activators of the classical pathway include the IgG subclasses <u>IgG1</u>, <u>IgG2</u>, and <u>IgG3</u>, but the most effective activator is the large pentamer <u>IgM</u>. Nonimmunologic activators of this pathway include DNA, Creactive <u>protein</u>, certain <u>cellular</u> membranes, and <u>trypsin-like</u> enzymes.(para 2-8a)
- Activation of the classical pathway begins with the interaction of <u>C1</u> with an <u>antigen-antibody</u> complex. The C1 component is comprised of three distinct protein molecules: <u>C1q</u>, <u>C1r</u>, and <u>C1s</u>. The binding of the C1q component to the Fc portion of the IgG or IgM molecule initiates the <u>pathway</u>. Changes in C1q causes <u>C1r</u> to enzymatically activate <u>C1s</u>. (para 2-8b)
- In the classical pathway, activated C1s cleave C4 into two fragments: C4a which is released into the <u>fluid</u> phase as an <u>anaphylatoxin</u> and C4b which may bind directly to the <u>activating</u> surface. C4b may also be released into the fluid phase as an <u>opsonin</u>. Activated C1 also is capable of <u>cleaving</u> and <u>activating</u> C2 generating <u>C2a</u> and <u>C2b</u>. A site on the C2a fragment allows it to bind to the surface-bound C4b to form the complex <u>C4b2a</u>. (para 2-8c)
- 20. In the classical pathway, the C4b2a complex is known as C3 <u>convertase</u> and is capable of cleaving and activating C3. C3a is the smaller of the two fragments produced and is released into the fluid phase as an <u>anaphylatoxin</u>. A <u>small</u> portion of the total number of C3b molecules bind to the activating surface and interact with C4b2a. The resulting C4b2a3b complex is known as C5 <u>convertase</u> and is capable of cleaving and activating C5. This is the first step to the formation

of the membrane attack complex. (para 2-8d)

- The primary activators of the alternative pathway are usually non-<u>immunological</u> in nature. They include bacterial <u>lipopolysaccharides</u>, erythrocytes of certain species, <u>viruses</u>, <u>fungi</u>, and <u>parasites</u>. Aggregated IgE, IgA, and IgG subclass 4 are <u>immunological</u> activators of this pathway. (para 2-9a)
- An initial requirement for activation of the alternative pathway is the presence of <u>C3b</u>, which is <u>continuously</u> generated in <u>small</u> amounts by natural hydrolysis of C3. Continuation of the alternative pathway occurs only if an activating <u>surface</u> is present to provide a <u>binding</u> site for the C3b and <u>protect</u> it from control protein activity. (para 2-9b)
- 23. In the alternative pathway, in the presence of C3b, factor B is cleaved by factor <u>D</u> into two <u>fragments</u>, Bb and Ba. The Bb fragment forms a complex with <u>C3b</u> and the resultant **C3b**, **Bb** complex is known as C3 <u>convertase</u>. This complex has enzymatic properties and is capable of cleaving and activating more <u>C3</u>. Properdin (P) acts as a <u>stabilizer</u> for the **C3b**, **Bb** complex by <u>protecting</u> it from decay and control mechanisms. Large amounts of C3b are generated and <u>resupply</u> the reaction cycle. The C3b may release to the fluid phase as an <u>opsonin</u>, bind directly to the activating <u>surface</u>, or attach to C3 <u>convertase</u> forming the complex, **C3b**, **Bb**, **3b**. This complex is known as C5 convertase and is capable of <u>cleaving</u> and <u>activating</u> C5, the first component of the membrane <u>attack</u> complex. (para 2-9c)
- 24. The membrane attack complex (MAC), beginning with the cleavage and activation of C5, is common to both complement <u>pathways</u>. The activation of C5 results in two <u>fragments</u>. The smaller C5a fragment is released into the fluid phase as an <u>anaphylatoxin</u> or <u>chemotactic</u> factor. The larger C5b fragment binds directly to the <u>activating surface</u>, followed by the binding of C6 and C7 (Figure 2-7). The **C5b67** complex provides a <u>binding</u> site for C8 which initiates some <u>membrane</u> <u>damage</u>. However, the subsequent binding of multiple molecules of C9 is required for efficient cell <u>lysis</u>. (para 2-10)
- 25. There are control mechanisms in the complement system that preclude uncontrolled <u>activation</u> and <u>consumption</u> of its protein components. For example, binding sites on activated proteins <u>decay</u> rapidly, causing dissociation of <u>complexes</u>. This restricts the complement activation to a <u>local area</u>. (para 2-11)
- 26. Several substances are released to produce the biological effects of <u>complement</u> activation.

For example, anaphylatoxins cause the release of <u>histamine</u> from mast cells and basophils. Histamine in turn enhances vascular <u>permeability</u> and causes smooth muscle <u>contractions</u>, resulting in edema and inflammation. Many cells, including polymorphonuclear cells, B lymphocytes, and macrophages, have receptor sites

for <u>opsonins</u> (C3b and C4b). Also many of the nonimmunological activators have receptors for these <u>opsonins</u>. Opsonin fragments bind to their receptors and act to facilitate adherence and <u>phagocytosis</u> of the target cell.

The function of the chemotactic factor (C5a) is to induce and direct the <u>migration</u> and <u>accumulation</u> of phagocytic cells at the site of the immune reaction. (para 2-12)

End of Lesson 2

LESSON ASSIGNMENT

LESSON 3	Cells of the Immune System		
TEXT ASSIGNMENT	Paragraphs 3-1 through 3-10.		
LESSON OBJECTIVES	After completing this lesson, you should be able to:		
	3-1.	Name and describe the functions of major types of cells involved in immunity: T cells, B cells, and macrophages.	
	3-2.	Describe a simplified model of humoral immunity, describe B cell proliferation to form antibodies, describe a simplified model for cell-mediated immunity, and describe T cell proliferation to produce T cell subsets.	
	3-3.	Distinguish the functions of helper T cells, suppressor T cells, and other special types of T cells.	
SUGGESTION	After completing the assignment, complete the exercises at the end of this lesson. These exercises will help you to achieve the lesson objectives.		

LESSON 3

CELLS OF THE IMMUNE SYSTEM

Section I. INTRODUCTION

3-1. LYMPHOID TISSUES

Acquired immunity is the work of the body's lymphoid tissues. Lymphoid tissue can be divided into two major groups. The central lymphoid organs consist of the bone marrow and thymus (and the fetal liver). In these areas, stem cells give rise to proliferating and differentiating lymphocytes through processes completely independent of antigen stimulation. The peripheral lymphatic tissue includes lymph nodes, spleen, and gut-associated lymphoid tissue. Lymphoid development is antigen-dependent in these areas.

3-2. LYMPHOCYTES

When studied with a microscope, most of the lymphocytes found in the lymphoid tissue look pretty much alike. However, there are two distinct types when studied further. One group is responsible for cellular immunity; they are called **T cells** because they must be preprocessed in the thymus gland. The other group, whose purpose is to form antibodies, is called **B cells**, because they were first discovered in birds (in which B cells are preprocessed in a structure unique to birds, the bursa of Fabricius).

3-3. DEVELOPMENT OF B CELLS AND T CELLS

a. Two types of lymphocytes are produced, and the bone marrow (and fetal liver) is the site of origin. These lymphocytes are called T lymphocytes and B lymphocytes. While the major role of the bone marrow in adults is to replenish blood cells, it also serves as a protected environment in which T and B lymphocytes undergo antigen-independent proliferation.

b. Precursor T cells move through the bloodstream and pass through the walls of blood vessels to the thymus. They rapidly proliferate within the gland and acquire new surface markers. T cells pass from the thymus to the blood and seed peripheral lymphoid tissue, where they begin to function as immunocompetent T cells.

c. Changes in T cell specific surface markers occur at various stages of T cell development. The end stage of differentiation results in two distinct T cell subsets: (1) those which express T4 (helper/inducer T cells) and (2) those which express T8 (suppressor/cytotoxic T cells). Helper versus suppressor T cells will be discussed in more detail later in this lesson. Monoclonal antibodies have been produced to several T cell specific antigens.

d. Maturation of B cells in humans takes place first in the fetal liver and later in the bone marrow of the adult.

e. At various stages of maturation, a B cell expresses unique markers on its surface that are characteristic of a particular developmental stage. Examples include IgM and IgD, and Fc markers. Monoclonal antibodies can be used to detect B-specific markers.

3-4. MACROPHAGES

a. The macrophage is a relatively large, phagocytic cell that belongs to a family of cells that are collectively referred to as "mononuclear phagocytes." They play an essential role in many different types of immune and inflammatory reactions. Macrophages are unique in that unlike most cell types, they have multiple diverse functions. They are important effector cells in killing intracellular parasites and tumor cells; they act as scavengers for foreign material and extracellular debris; and they act as regulators of immune responsiveness.

b. The major functional roles of macrophages in the immunological process are antigen processing and antigen presentation.

c. An additional function attributed to macrophages is the production of factors that influence the activity of lymphocytes. Macrophages secrete over 50 products, many related to immunity. These include enzymes, plasma proteins (including coagulation proteins and complement components), lipids, and factors regulating cellular functions. One of the factors regulating cellular functions is interleukin-1, which has a number of important effects. For example, interleukin-1, also called lymphocyte-activating factor (LAF), induces lymphocytes to produce interleukin-2, which in turn encourages short-term proliferation of lymphocytes.

Section II. B CELLS AND HUMORAL IMMUNITY

3-5. ANTIGEN PROCESSING AND PRESENTATION

a. Antigen bound to macrophage surfaces or internalized by macrophages is more immunogenic than antigen that has not been "processed" by macrophages. Macrophages function in processing the antigen and subsequently presenting it to lymphocytes. It is thought that processing may expose determinants otherwise not available or change pre-existing determinants into a recognizable form.

b. Once the antigen is processed by the macrophage, it is presented to lymphocytes. There is evidence that small amounts of antigen bound to the macrophage surface are important in the induction phase of the immune response. Evidence also suggests that macrophage processing is not essential for all antigens. The size of the antigen may determine whether macrophage processing is necessary. c. The mechanism of macrophage interaction with B and T cells is not completely understood. A common opinion is that macrophages digest complex antigens to make them "palatable" for B cells. Another concept is that macrophages ingest antigens and then manufacture some informational type of ribonucleic acid (RNA) which is transferred to B lymphocytes and triggers antibody production.

3-6. ANTIGEN TRIGGERING OF SPECIFIC T CELLS

a. The triggering of specific T cells occurs with most, but not all, antigens. Those antigens that are called T-dependent antigens cannot trigger B cells to synthesize antibodies in the absence of T cells. T-independent antigens, on the other hand, can stimulate B cells without the aid of T cells.

b. Most antigens are T-dependent. They include microorganisms, proteins, and haptens on various carriers. T-dependent antigens react either directly with a T cell, or with a macrophage which processes the information and transfers it to a T cell. T cells that function in this mechanism are designated as helper T cells. These antigens may induce IgG, IgE, IgA, or IgM responses and produce immunological memory.

c. T-independent antigens are generally large polymers with many repeating units. It appears that each T-independent antigen carries a specific antigenic signal and a nonspecific signal which acts as a mitogen. (A mitogen is a substance that induces mitosis or cell transformation, particularly transformation of lymphocytes.) This mitogenic signal is directly capable of activating B cells irrespective of their antigen reactivity. Although T-independent antigens can initiate antibody production in the absence of T cells, substantial production of antibody does not occur. The antibody produced is largely IgM and little or no immunological memory is produced (Figure 3-1).




Figure 3-1. Simplified model for humoral immunity.

3-7. B CELL ACTIVATION

a. Early evidence about hapten-carrier systems suggests that T cells recognize the carrier while B cells recognize the hapten. As discussed previously, haptens alone are not able to induce immune responses. If the hapten is coupled to a carrier, antibody that reacts with the hapten will be produced. The B cell which binds the hapten will make antihapten antibody.

b. It was recognized that helper T cells were actively involved in helping rather than passively focusing antigen. Another mechanism proposed that helper T cells exert their effect through the release of diffusible factors called lymphokines which act on local B cells. These factors may be immunologically specific or nonspecific.

3-8. ANTIBODY AND MEMORY B CELL PRODUCTION

Once B cells are stimulated, they become metabolically active and undergo morphological changes (Figure 3-2). This process is called blast transformation. B lymphocytes are small oval cells, but after transformation they become enlarged. B cells then go through several cell divisions called clonal expansion in order to increase the number of activated cells. They then differentiate into plasma cells and memory B cells. Plasma cells secrete antibodies. They are end cells and survive only about two weeks. Memory cells have the same appearance as small lymphocytes. Exactly how they arise is not known. Memory cells are responsible for the anamnestic response, the rapid production of antibody on re-exposure to antigen.




Figure 3-2. B cell proliferation to form antibodies.

Section III. T CELLS AND CELLULAR IMMUNITY

3-9. ANTIGEN STIMULATED T CELLS

The cell-mediated reaction is initiated by the binding of antigen with an antigen receptor on the surface of a sensitized T lymphocyte. In recent years, one of the most vigorous controversies in cellular immunology concerns the nature of receptors used by T cells to recognize antigen. Although B cells use surface immunoglobulin for this purpose, studies with antisera against immunoglobulins have failed to identify such immunoglobulins on the T cell surface. Binding of the T cell receptor may occur directly or may be mediated by macrophage-bound antigen (Figure 3-3).




Figure 3-3. Simplified model for cell- mediated immunity.

3-10. BIOLOGIC EXPRESSION

See figure 3-4.




Figure 3-4. T cell proliferation to produce T cell subsets.

a. Helper cells (Th), also called T4 cells, proliferate in the cell-mediated immune response. These Th cells function to present antigen to antibody-forming B cells in such a way to facilitate the interaction between antigen and the B cell. The cells also aid in cell-mediated immune responses.

b. Suppressor cells (Ts), also called T8 cells, are defined as cells capable of aborting an otherwise anticipated immune response and of terminating an ongoing immune response. If no brake is applied to the immune response, the ultimate response may be a malignant process. The suppressor cells probably evolved to terminate the immunologically induced proliferation of antibody-forming cells at a point beyond which further proliferation is unnecessary to provide the appropriate level of immunity. It has been shown that there exists Ts cells which are specific for the cell-mediated immune response and other Ts cells specific for humoral immune responses.

c. Cytotoxic T cells (Tc) kill antigen-modified self-cells or allogeneic cells (cells which are of genetically dissimilar members of the same species) after direct contact. The mechanism by which Tc cells kill target cells is not well understood. Direct contact between killer and target cell membranes, via undefined receptors, apparently leads to membrane changes that cause lysis. These Tc cells are important in transplantation and tumor immunity.

d. Another mechanism by which T cells bring about cell-mediated immune reactions is through proliferation of delayed hypersensitivity T cells (Tdh). These cells are involved in delayed hypersensitivity reactions such as contact sensitivity. They promote inflammation by the release of lymphokines which in turn activate nonlymphoid cells to enhance destruction of the antigen. Lymphokines generally act on non-immunocompetent cell populations, such as macrophages and neutrophils, inciting them to increased levels of normal activity.

e. The final event is the generation of memory T cells which function in the anamnestic response upon subsequent encounter with antigen.

Continue with Exercises

EXERCISES, LESSON 3

INSTRUCTIONS: Answer the following items by completing the statement or by writing the answer in the space provided at the end of the item.

After you have completed all of these items, turn to "Solutions to Exercises" at the end of the lesson and check your answers with the solutions.

- Acquired immunity is the work of the body's <u>I</u> d tissues. Lymphoid tissue can be divided into two major groups: the <u>c</u> I lymphoid organs and the <u>p</u> I lymphatic tissue. The central lymphoid organs consist of the <u>b</u> e <u>m</u> w and <u>t</u> s (and the fetal <u>I</u>). In these areas, <u>s</u> m cells give rise to proliferating and <u>d</u> <u>g</u> <u>I</u> s through processes completely independent of antigen stimulation. The peripheral lymphatic tissue includes lymph <u>n</u> s, <u>s</u> n, and <u>g</u> <u>t</u>-associated lymphoid tissue.
- 2. One group of lymphocytes called (<u>T) (B)</u> cells are responsible for cellular <u>i y</u>. They are called this because they must be preprocessed in the <u>t</u> <u>s</u> gland. The other group, whose purpose is to form <u>a</u> <u>s</u>, is called (<u>T) (B)</u> cells.

At the end stage of T cell differentiation, there are two distinct subsets of T cells: (1) <u>h r (inducer)</u> T cells, which express <u>T</u> and (2) <u>s sor</u> (cytotoxic) T cells, which express <u>T</u>.

Maturation of B cells in humans takes place first in the \underline{f} <u>l</u> <u>r</u> and later in the <u>b</u> <u>e</u> <u>m</u> <u>w</u> of the adult.

 \underline{M} nal <u>a</u> <u>s</u> can be used to detect B-specific markers. At various stages of <u>m</u> <u>n</u>, a B cell expresses unique <u>m</u> <u>s</u> on its surface that are characteristic of a particular <u>d</u> <u>tal</u> stage. 4. The macrophage is a relatively large, <u>p</u> <u>c</u> cell. They play an essential role in many different types of <u>i</u> <u>e</u> and <u>i</u> <u>y</u> reactions. Macrophages have <u>m</u> <u>ple</u> functions. They are important in killing intracellular <u>p</u> <u>s</u> and <u>t</u> <u>or</u> cells. They act as <u>s</u> <u>rs</u> for <u>f</u> <u>n</u> material and <u>ext</u> <u>r</u> debris. They also act as regulators of immune <u>r</u> <u>ness</u>. The major functional roles of macrophages in the immunological process are antigen <u>pr</u> <u>ing</u> and antigen <u>pr</u> <u>tion</u>.

An additional function attributed to macrophages is the production of factors that influence the activity of <u>l</u> cytes. Macrophages secrete over 50 products, many related to <u>i</u> <u>y</u>. These include enzymes, plasma proteins (including <u>c</u> tion proteins and <u>c</u> ment components), lipids, and factors regulating <u>c</u> <u>r</u> functions. One of the factors regulating cellular functions is <u>i</u> <u>n</u>-1, which has a number of important effects. For example, interleukin-1, also called lymphocytea ing factor (LAF), induces lymphocytes to produce <u>i</u> <u>n</u>-2, which in turn encourages short-term proliferation of <u>l</u> <u>cytes</u>.

5. Antigen bound to macrophage <u>s</u> <u>s</u> or <u>i</u> <u>d</u> by macrophages is more i mmunogenic than antigen that has not been "processed" by macrophages. Macrophages function in processing the <u>a</u> <u>n</u> and subsequently <u>pr</u> <u>ing</u> it to lymphocytes. It is thought that processing may <u>ex</u> <u>e</u> determinants otherwise not available or change pre-existing <u>d</u> <u>nants</u> into a <u>r</u> <u>able</u> form.

Once the antigen is processed by the macrophage, it is <u>p</u> ted to lymphocytes. There is evidence that small amounts of antigen bound to the macrophage <u>s</u> <u>e</u> are important in the <u>i</u> <u>ction</u> phase of the immune response. Evidence also suggests that <u>macro</u> <u>e</u> processing is not essential for all antigens. The size of the antigen may determine whether macrophage processing is <u>n</u> <u>y</u>.

A common opinion about the interaction of macrophages with B and T cells is that macrophages \underline{d} t complex antigens to make them "palatable" for _ cells. Another concept is that macrophages ingest \underline{a} and then manufacture some informational type of \underline{r} c a d which is transferred to B <u>l</u> s and triggers \underline{a} y production. Antigens which trigger specific T cells are called T-<u>d_t</u> antigens. In the absence of T cells, these antigens cannot <u>t_r</u> B cells to synthesize <u>antibodies</u>. T-independent antigens, on the other hand, can stimulate _ cells without the aid of _ cells.

Most antigens are _-dependent. They include \underline{m} sms, proteins, and \underline{h} ns on various carriers. T-dependent antigens react either directly with a T cell, or with a <u>macro</u> <u>e</u> which processes the information and transfers it to a T cell. T cells that function in this mechanism are called <u>h</u> <u>r</u> T cells. These antigens may induce IgG, IgE, IgA, or IgM responses and produce immunological <u>m</u> <u>y</u>.

T-independent antigens are generally large polymers with many \underline{r} g units. It appears that each T-independent antigen carries a specific <u>a</u> <u>c</u> signal and a nonspecific <u>s</u> <u>nal</u> which acts as a mitogen. (A **mitogen** is a substance that induces <u>m</u> <u>s</u> or cell \underline{tr} <u>tion</u>, particularly transformation of lymphocytes.) This mitogenic signal is directly capable of <u>a</u> <u>ting</u> B cells irrespective of their antigen reactivity.

Although T-independent antigens can initiate antibody production in the absence of T cells, substantial production of antibody (does) (does not) occur. The antibody produced is largely IgM and little or no immunological $\underline{m} \underline{y}$ is produced.

- 7. Early evidence about hapten-carrier systems suggests that T cells recognize the <u>c r</u> while B cells recognize the <u>h n</u>. As discussed previously, <u>h s</u> alone are not able to induce immune responses. If the hapten is coupled to a <u>c r</u>, antibody that reacts with the <u>h n</u> will be produced. The B cell which binds the hapten will make antihapten <u>a y</u>.

- 9. When T cells are stimulated by antigens, the cell-mediated reaction is initiated by the <u>b</u> ing of antigen with an antigen <u>r</u> on the <u>s</u> <u>e</u> of a sensitized T lymphocyte. Binding of the T cell receptor may occur <u>d</u> <u>ly</u> or may be mediated by <u>m</u> <u>ge</u>-bound antigen.
- Helper cells (Th) proliferate and function to <u>pr t</u> antigen to <u>a y</u>-forming B cells in such a way to facilitate the interaction between antigen and the B cell. The cells also aid in <u>c l</u>-mediated immune responses.

Suppressor cells (Ts) are defined as cells capable of <u>a</u> ing an otherwise anticipated immune response and of <u>t</u> ting an ongoing immune response. It has been shown that there exists Ts cells which are specific for the <u>c</u> <u>I</u>-mediated immune response and other Ts cells specific for <u>h</u> <u>I</u> immune responses.

The mechanism by which Tc cells kill target cells is not well understood. Direct contact between killer and target cell <u>m</u> nes, via undefined receptors, apparently leads to <u>m</u> <u>e</u> changes that cause <u>l</u> is. These Tc cells are important in <u>t</u> tion and <u>t</u> or immunity.

Another mechanism by which T cells bring about cell-mediated immune reactions is through proliferation of delayed h ty T cells (Tdh).

The final event is the generation of $\underline{m} \underline{y}$ T cells which function in the anamnestic response upon subsequent encounter with $\underline{a} \underline{n}$.

Check Your Answers on Next Page

SOLUTIONS TO EXERCISES, LESSON 3

- Acquired immunity is the work of the body's <u>lymphoid</u> tissues. Lymphoid tissue can be divided into two major groups: the <u>central</u> lymphoid organs and the <u>peripheral</u> lymphatic tissue. The central lymphoid organs consist of the <u>bone</u> <u>marrow</u> and <u>thymus</u> (and the fetal <u>liver</u>). In these areas, <u>stem</u> cells give rise to proliferating and <u>differentiating lymphocytes</u> through processes completely independent of antigen stimulation. The peripheral lymphatic tissue includes lymph <u>nodes</u>, <u>spleen</u>, and <u>gut</u>-associated lymphoid tissue. (para 3-1)
- One group of lymphocytes called <u>T</u> cells are responsible for cellular <u>immunity</u>. They are called this because they must be preprocessed in the <u>thymus</u> gland. The other group, whose purpose is to form <u>antibodies</u>, is called <u>B</u> cells. (para 3-2)
- 3. While the major role of the bone marrow in adults is to replenish blood cells, it also serves as a <u>protected</u> environment in which T and B lymphocytes undergo <u>antigen</u>-independent proliferation. Precursor T cells then move through the bloodstream and pass through the walls of blood vessels to the <u>thymus</u>. They rapidly proliferate within the gland and acquire new surface <u>markers</u>. T cells pass from the thymus to the blood and seed peripheral <u>lymphoid</u> tissue, where they begin to function as <u>immunocompetent</u> T cells.

At the end stage of T cell differentiation, there are two distinct subsets of T cells: (1) <u>helper (inducer)</u> T cells, which express <u>T4</u> and (2) <u>suppressor</u> (cytotoxic) T cells, which express <u>T8</u>.

Maturation of B cells in humans takes place first in the <u>fetal liver</u> and later in the <u>bone marrow</u> of the adult.

<u>Monoclonal antibodies</u> can be used to detect B-specific markers. At various stages of <u>maturation</u>, a B cell expresses unique <u>markers</u> on its surface that are characteristic of a particular <u>developmental</u> stage.

(para 3-3)

4. The macrophage is a relatively large, <u>phagocytic</u> cell. They play an essential role in many different types of <u>immune</u> and <u>inflammatory</u> reactions. Macrophages have <u>multiple</u> functions. They are important in killing intracellular <u>parasites</u> and <u>tumor</u> cells. They act as <u>scavengers</u> for <u>foreign</u> material and <u>extracellular</u> debris. They also act as regulators of immune <u>responsiveness</u>.

The major functional roles of macrophages in the immunological process are antigen processing and antigen presentation.

An additional function attributed to macrophages is the production of factors that influence the activity of <u>lymphocytes</u>. Macrophages secrete over 50 products, many related to <u>immunity</u>. These include enzymes, plasma proteins (including <u>coagulation</u> proteins and <u>complement</u> components), lipids, and factors regulating <u>cellular</u> functions. One of the factors regulating cellular functions is <u>interleukin-1</u>, which has a number of important effects. For example, interleukin-1, also called lymphocyte-<u>activating</u> factor (LAF), induces lymphocytes to produce <u>interleukin-2</u>, which in turn encourages short-term proliferation of <u>lymphocytes</u>.

(para 3-4)

 Antigen bound to macrophage <u>surfaces</u> or <u>internalized</u> by macrophages is more immunogenic than antigen that has not been "processed" by macrophages. Macrophages function in processing the <u>antigen</u> and subsequently <u>presenting</u> it to lymphocytes. It is thought that processing may <u>expose</u> determinants otherwise not available or change pre-existing <u>determinants</u> into a <u>recognizable</u> form.

Once the antigen is processed by the macrophage, it is <u>presented</u> to lymphocytes. There is evidence that small amounts of antigen bound to the macrophage <u>surface</u> are important in the <u>induction</u> phase of the immune response. Evidence also suggests that <u>macrophage</u> processing is not essential for all antigens. The size of the antigen may determine whether macrophage processing is <u>necessary</u>.

A common opinion about the interaction of macrophages with B and T cells is that macrophages <u>digest</u> complex antigens to make them "palatable" for <u>B</u> cells. Another concept is that macrophages ingest <u>antigens</u> and then manufacture some informational type of <u>ribonucleic</u> <u>acid</u> which is transferred to B <u>lymphocytes</u> and triggers <u>antibody</u> production.

(para 3-5)

 Antigens which trigger specific T cells are called T-<u>dependent</u> antigens. In the absence of T cells, these antigens cannot <u>trigger</u> B cells to synthesize <u>antibodies</u>. T-independent antigens, on the other hand, can stimulate <u>B</u> cells without the aid of <u>T</u> cells.

Most antigens are <u>T</u>-dependent. They include <u>microorganisms</u>, proteins, and <u>haptens</u> on various carriers. T-dependent antigens react either directly with a T cell, or with a <u>macrophage</u> which processes the information and transfers it to a T cell. T cells that function in this mechanism are called <u>helper</u> T cells. These antigens may induce IgG, IgE, IgA, or IgM responses and produce immunological <u>memory</u>.

T-independent antigens are generally large polymers with many <u>repeating</u> units. It appears that each T-independent antigen carries a specific <u>antigenic</u> signal and a nonspecific <u>signal</u> which acts as a mitogen. (A **mitogen** is a substance that induces <u>mitosis</u> or cell <u>transformation</u>, particularly transformation of lymphocytes.)

This mitogenic signal is directly capable of <u>activating</u> B cells irrespective of their antigen reactivity. Although T-independent antigens can initiate antibody production in the absence of T cells, substantial production of antibody <u>does not</u> `occur. The antibody produced is largely IgM and little or no immunological <u>memory</u> is produced.

(para 3-6)

- Early evidence about hapten-carrier systems suggests that T cells recognize the <u>carrier</u> while B cells recognize the <u>hapten</u>. As discussed previously, <u>haptens</u> alone are not able to induce immune responses. If the hapten is coupled to a <u>carrier</u>, antibody that reacts with the <u>hapten</u> will be produced. The B cell which binds the hapten will make antihapten <u>antibody</u>. (para 3-7)
- 8. Once B cells are stimulated, they become metabolically active and undergo <u>morphological</u> changes. This process is called blast <u>transformation</u>. B lymphocytes are small oval cells, but after transformation they become <u>enlarged</u>. B cells then go through several cell divisions called <u>clonal</u> expansion in order to increase the number of activated cells. They then differentiate into <u>plasma</u> cells and <u>memory</u> B cells. Plasma cells secrete <u>antibodies</u>. They are <u>end</u> cells and survive only about two <u>weeks</u>. Memory cells have the same appearance as small <u>lymphocytes</u>. Memory cells are responsible for the <u>anamnestic</u> response, the rapid production of antibody on re-<u>exposure</u> to antigen. (para 3-8)

- When T cells are stimulated by antigens, the cell-mediated reaction is initiated by the <u>binding</u> of antigen with an antigen <u>receptor</u> on the <u>surface</u> of a sensitized T lymphocyte. Binding of the T cell receptor may occur <u>directly</u> or may be mediated by <u>macrophage</u>-bound antigen. (para 3-9)
- 10. Helper cells (Th) proliferate and function to <u>present</u> antigen to <u>antibody</u>-forming B cells in such a way to facilitate the interaction between antigen and the B cell. The cells also aid in <u>cell</u>-mediated immune responses.

Suppressor cells (Ts) are defined as cells capable of <u>aborting</u> an otherwise anticipated immune response and of <u>terminating</u> an ongoing immune response. It has been shown that there exists Ts cells which are specific for the <u>cell</u>-mediated immune response and other Ts cells specific for <u>humoral</u> immune responses.

The mechanism by which Tc cells kill target cells is not well understood. Direct contact between killer and target cell <u>membranes</u>, via undefined receptors, apparently leads to <u>membrane</u> changes that cause <u>lysis</u>. These Tc cells are important in <u>transplantation</u> and <u>tumor</u> immunity.

Another mechanism by which T cells bring about cell-mediated immune reactions is through proliferation of delayed <u>hypersensitivity</u> T cells (Tdh).

The final event is the generation of <u>memory</u> T cells which function in the anamnestic response upon subsequent encounter with <u>antigen</u>.

(para 3-10)

End of Lesson 3

LESSON ASSIGNMENT

LESSON 4	HLA Complex		
TEXT ASSIGNMENT	Paragraphs 4-1 through 4-4.		
LESSON OBJECTIVES	After completing this lesson, you should be able to:		
	4-1.	Define immunogenetics, the major histocompatibility complex (MHC), the HLA complex, and histocompatibility.	
	4-2.	Describe the two broad areas of immunogenetics, the role of the HLA complex in immunity, the nomenclature for the HLA complex, and the classification of antigens.	
SUGGESTION	After completing the assignment, complete the exercises at the end of this lesson. These exercises will help you to achieve the lesson objectives.		

LESSON 4

HCLA COMPLEX

Section I. IMMUNOGENETICS

4-1. INTRODUCTION

a. Immunogenetics is the study of processes involved in the immune response that may have a genetic basis. These processes include all the factors that control the immune response of the host, as well as the transmission of antigenic specificities from generation to generation.

b. The field of immunogenetics can be divided into two broad areas of study.

(1) The first major area concerns the genetic regulation and control of the immune system itself. The maturation of the immune cells in a given individual is an example of genetic control of cellular proliferation and differentiation. Interruption or alterations of these developmental sequences lead to immunodeficiency disorders, autoimmune disorders, and perhaps malignancies, as the cells escape the influence of their normal control mechanisms.

(2) The second area with the broadest application is the use of antibodies and sensitized immune cells, the products of the immune system, as probes to detect and characterize various antigens that may show genetic variation.

c. The **major histocompatibility complex** (MHC) is the region of a specific chromosome that controls histocompatibility. This is related in concept to concerns that donated tissues or organs not be rejected by their host, that is, be compatible. The term **histocompatibility** refers to the presence of certain antigens which mean that the host of an organ or tissue graft will not reject the graft. In humans, the MHC is called the HLA complex, which refers to "human leukocyte antigens." Histocompatibility is a relationship of donor and host based upon the presence of compatible HLA antigens.

4-2. GENETICS OF IMMUNE REGULATION


Several early observations had suggested a genetic basis for the immune response. Studies on human immune response (Ir) genes had been stimulated by the recognition of the overall homology of the HLA complex with major histocompatibility complexes of animals. A large number of genes exist that code for the regulatory components of the complex network of the immune system. It was originally thought that the genes controlling the immune response were located within the genetic segment coding for histocompatibility antigens. Although the histocompatibility-linked Ir genes play an important role, they compose only a part of the immune system. Certain Ir genes may code for cellular receptors for antigen and others may control mediator secretion. Thus, the system controls not only have the ability to respond to antigens but also to control the level and duration of the response.

Section II. HLA COMPLEX

4-3. NOMENCLATURE

a. The HLA complex is a region on chromosome 6 that codes for three functionally different proteins: those that regulate the immune response, those that determine the acceptance or rejection of transplanted tissues between individuals within that species, and those that are a part of the complement system (Figure 4-1). The two MHC systems that have been most extensively characterized are the H-2 system in the mouse and the HLA (human leukocyte antigen) system in man. The MHC of mice has provided information for the understanding of the human MHC.

b. In 1975, the World Health Organization established a nomenclature committee for the human MHC system. HLA designates the region on chromosome 6 that carries the MHC gene segment. A letter after the HLA, such as HLA-D, refers to a gene locus. International exchanges of typing reagents are organized every two to four years by International Histocompatibility Workshops for HLA Genetics that engaged in studying the genetics and serologic behavior of these proteins. These scientists frequently reassign the position of a certain antigen (specificity) that in turn alters the number of antigens (specificities) within the A, B, or other locus.



Notes:

The HLA complex is enlarged to depict the A, B, C, and D loci.

The numbers 17, 15, 20, 0.8-1.0, and 0.8 represent approximate distances in centimorgans (cM).

PGM3 = phosphoglucomutase 3.

PG5 = urinary pepsinogen.

PGM3 and PG5 are shown to illustrate the position of the HLA complex relative to other markers.

The numbers in parentheses (>11, 31, >6, >11) indicate the number of recognized antigens for each locus.

Figure 4-1. Two representations of human chromosome number 6.

4-4. CLASSIFICATIONS

a. **Class I Antigens.** Class I molecules are coded for by the HLA-A, B, and C genes. Each gene is highly pleomorphic, that is, occurring in various distinct forms. The A gene is currently recognized to have at least 23 specificities, the B gene 50 specificities, and the C gene 8 specificities. The Class I antigen consists of two polypeptides: one MHC-encoded peptide and the other non-MHC encoded peptide, beta microglobulin, which is a small globular peptide. HLA-A, B, and C antigens are found on virtually every human cell.

b. **Class II Antigens.** They are different structurally and functionally from Class I. The exact number of genes in the D region is uncertain but three are widely accepted. These are DR, DP, and DQ. DP and DQ replace the earlier designation SB and DC, respectively. The number of alleles for each gene is not known. At least six different specificities for each of the DP and DQ genes are known. Each Class II protein consists of two peptides, an alpha chain and a beta chain that is slightly smaller. HLA-DR, DP, and DQ are found chiefly on the surface of immunocompetent cells, including macrophage/monocytes, resting T lymphocytes, activated T lymphocytes, and particularly B lymphocytes.

c. **Class III Antigens.** Four gene loci, located between the HLA-B and the HLA-D loci on chromosome 6, are associated with the complement system. These Class III genes are the structural genes for proteins C2, C4A, C4B, and factor B of the complement system.

Continue with Exercises

EXERCISES, LESSON 4

INSTRUCTIONS: Answer the following items by completing the statement or by writing the answer in the space provided.

After you have completed all of these items, turn to "Solutions to Exercises" at the end of the lesson and check your answers with the solutions.

- Immunogenetics is the study of processes involved in the <u>i</u> e response that may have a <u>g</u> c basis. These processes include the factors that control the <u>i</u> e <u>r</u> e of the host and the transmission of antigenic <u>s</u> ties from generation to generation.
- The first major area of immunogenetics is concerned with the genetic <u>re_ation</u> and <u>c_l</u> of the immune system itself. Interruption or alterations of developmental sequences may lead to <u>i_cy</u> disorders, <u>auto_e</u> disorders, and perhaps <u>m_cies</u>.

The second major area of immunogenetics, the one with the broadest application, is the use of <u>a dies</u> and <u>s d</u> immune cells, products of the <u>i e</u> system, as probes to detect and characterize various <u>a ns</u> that may show genetic variation.

- 3. The major histocompatibility complex (MHC) is the region of a specific <u>c</u> me that controls <u>hi</u> <u>y</u>. The term histocompatibility refers to the presence of certain <u>a</u> <u>s</u> which mean that the <u>host</u> of an organ or tissue graft will not reject the graft. In humans, the MHC is called the HLA complex, which refers to "<u>h</u> <u>n</u> <u>l</u> <u>e</u> <u>a</u> <u>s</u>." Histocompatibility is a relationship of <u>d</u> <u>r</u> and host based upon the presence of compatible HLA <u>a</u> <u>s</u>.
- 4. The histocompatibility-linked Ir genes play an important role but compose only a <u>p_t</u> of the immune system. Certain Ir genes may code for <u>c_r</u> receptors for antigen and others may control mediator <u>s_n</u>. The system controls not only have the ability to <u>r_d</u> to antigens but also to control the <u>l_l</u> and <u>d_n</u> of the response.
- 5. The HLA complex is a region on chromosome _ that codes for three functionally different proteins: those that <u>r late</u> the immune response, those that determine the <u>a ce</u> or <u>r tion</u> of transplanted tissues between individuals within that species, and those that are a part of the <u>c ment</u> system (Figure 4-1). The MHC of <u>m e</u> has provided information for the understanding of the human MHC.

- 6. A letter after HLA, such as HLA-D, refers to a gene <u>l</u>.s.
- 7. Class I antigens are coded for by the HLA-_, _, and _ genes. Each gene is highly pleomorphic, which means it occurs in various distinct \underline{f} . The A gene is currently recognized to have at least 23 <u>s</u> ties, the B gene 50 <u>s</u> s, and the C gene 8 <u>s</u>. HLA-A, B, and C antigens are found on virtually <u>e</u> <u>y</u> human cell.
- Class II antigens are different <u>s</u> ly and <u>f</u> ly from Class I. The exact number of <u>g</u> <u>s</u> in the D region is uncertain but three are widely accepted. These are DR, DP, and DQ. HLA-DR, DP, and DQ are found chiefly on the <u>s</u> <u>e</u> of immunocompetent cells, including <u>m</u> <u>ge</u>/monocytes, <u>r</u> <u>ing</u> T lymphocytes, <u>a</u> <u>ted</u> T lymphocytes, and particularly B <u>l</u> <u>s</u>.
- Class III genes are the structural genes for <u>p</u> ns C2, C4A, C4B, and factor B of the <u>c</u> t system.

Check Your Answers on Next Page

SOLUTIONS TO EXERCISES, LESSON 4

- Immunogenetics is the study of processes involved in the <u>immune</u> response that may have a <u>genetic</u> basis. These processes include the factors that control the <u>immune response</u> of the host and the transmission of antigenic <u>specificities</u> from generation to generation. (para 4-1a)
- 2. The first major area of immunogenetics is concerned with the genetic <u>regulation</u> and <u>control</u> of the immune system itself. Interruption or alterations of developmental sequences may lead to <u>immunodeficiency</u> disorders, <u>autoimmune</u> disorders, and perhaps <u>malignancies</u>.

The second major area of immunogenetics, the one with the broadest application, is the use of <u>antibodies</u> and <u>sensitized</u> immune cells, products of the <u>immune</u> system, as probes to detect and characterize various <u>antigens</u> that may show genetic variation.

(para 4-1b)

- 3. The major histocompatibility complex (MHC) is the region of a specific <u>chromosome</u> that controls <u>histocompatibility</u>. The term histocompatibility refers to the presence of certain <u>antigens</u> which mean that the <u>host</u> of an organ or tissue graft will not reject the graft. In humans, the MHC is called the HLA complex, which refers to "<u>human leukocyte antigens</u>." Histocompatibility is a relationship of <u>donor</u> and host based upon the presence of compatible HLA <u>antigens</u>. (para 4-1c)
- 4. The histocompatibility-linked Ir genes play an important role but compose only a <u>part</u> of the immune system. Certain Ir genes may code for <u>cellular</u> receptors for antigen and others may control mediator <u>secretion</u>. The system controls not only have the ability to <u>respond</u> to antigens but also to control the <u>level</u> and <u>duration</u> of the response. (para 4-2)
- 5. The HLA complex is a region on chromosome <u>6</u> that codes for three functionally different proteins: those that <u>regulate</u> the immune response, those that determine the <u>acceptance</u> or <u>rejection</u> of transplanted tissues between individuals within that species, and those that are a part of the <u>complement</u> system (Figure 4-1). The MHC of <u>mice</u> has provided information for the understanding of the human MHC. (para 4-3a)
- 6. A letter after HLA, such as HLA-D, refers to a gene <u>locus</u>. (para 4-3b)

- Class I antigens are coded for by the HLA-<u>A</u>, <u>B</u>, and <u>C</u> genes. Each gene is highly pleomorphic, which means it occurs in various distinct <u>forms</u>. The A gene is currently recognized to have at least 23 <u>specificities</u>, the B gene 50 <u>specificities</u>, and the C gene 8 <u>specificities</u>. HLA-A, B, and C antigens are found on virtually <u>every</u> human cell. (para 4-4a)
- Class II antigens are different <u>structurally</u> and <u>functionally</u> from Class I. The exact number of <u>genes</u> in the D region is uncertain but three are widely accepted. These are DR, DP, and DQ. HLA-DR, DP, and DQ are found chiefly on the <u>surface</u> of immunocompetent cells, including <u>macrophage</u>/monocytes, <u>resting</u> T lymphocytes, <u>activated</u> T lymphocytes, and particularly B <u>lymphocytes</u>. (para 4-4b)
- Class III genes are the structural genes for proteins C2, C4A, C4B, and factor B of the <u>complement</u> system. (para 4-4c)

End of Lesson 4

LESSON ASSIGNMENT

LESSON 5	Immunological Techniques
TEXT ASSIGNMENT	Paragraphs 5-1 through 5-13.
LESSON OBJECTIVES	After completing this lesson, you should be able to identify principles and procedures for the following types of immunological techniques: precipitation reactions (including radial immunodiffusion and double diffusion), serum protein electrophoresis, immunoelectrophoresis, and enzyme immunoassay techniques.
SUGGESTION	After completing the assignment, complete the exercises at the end of this lesson. These exercises will help you to achieve the lesson objectives.

LESSON 5

IMMUNOLOGICAL TECHNIQUES

Section I. INTRODUCTION

5-1. CONTEXT

Since 1970, immunological laboratory methods have gradually become increasingly more refined and simplified. Because of their improved specificity and sensitivity, these methods have now achieved a major role in modern clinical laboratory science. As many new laboratory tests employing immunologic principles are developed, these methods of laboratory diagnosis have often been applied to clinical situations.

5-2. APPLICATION

You will be better able to interpret and apply the new knowledge about immunology as you develop an understanding of the methods now in use. In this lesson, the techniques and applications of the various immunological tests for the detection of antigens and antibodies are discussed.

Section II. PRECIPITATION REACTIONS

5-3. PRECIPITATION REACTIONS

a. In 1934 Marrack, a prominent Englishman, proposed a new model for antigen-antibody reactions. His hypothesis states that under appropriate experimental conditions, antigen-antibody complexes precipitate. Antibody molecules are bivalent, that is, they contain two antigen-binding sites. For this reason, when antibodies are complexed with antigen, they can form a cross-linked mass. At a proper antigen and antibody concentration, this cross-linked mass enlarges and precipitates.

b. At the onset of the antigen-antibody reaction, an invisible formation of antigen and antibody complexes occurs. A lattice of soluble complexes slowly develops and gradually expands into a visible precipitate (lattice formation) as the antibody and antigen reach a zone of equivalent concentration. If there is an excess of either antigen (postzone) or antibody (prozone) present, the proper lattice formation needed for precipitate formation cannot occur. The formation of the antigen-antibody complex is reversible and may dissolve if more antigen or antibody is added.

5-4. IMMUNODIFFUSION

Immunodiffusion techniques detect antigen-antibody precipitation reactions in a semisolid medium. The formation of antigen and antibody complexes can be influenced by a number of factors: relative concentration of antigens and antibodies, ionic strength of the buffer, pH, and temperature. Two techniques most often used in a clinical laboratory are single and double diffusion.

a. **Radial Immunodiffusion (RID).** In this method, a known concentration of antibody is incorporated into an agarose medium. The reactant (antigen) is applied to a well cut in the agarose and radially diffuses from the site of application (Figure 5-1). At the point of equivalence, the antigen and antibody react to form a visible precipitin ring. The size of the precipitin ring is proportional to the concentration of the antigen. In the clinical laboratory, radial immunodiffusion is primarily used to quantitate serum immunoglobulins and complement components such as C3 or C4.

b. **Double Diffusion (DD).** DD is based on the principle that antigen and antibody diffuse through a semisolid medium and form a precipitin line. In Ouchterlony's method, a layer of agar gel is deposited in a petri dish and circular wells are punched out near one another in the gel. Antibody is then added to one well while antigen is added to the other. These materials are allowed to diffuse radially from their respective wells. As the perimeter of the diffusing substance increases, the concentration of that substance within the perimeter continually decreases. When the optimal concentration of antigen and antibody is reached, a line of precipitation is formed in the gel. The precipitin line is relatively straight and is perpendicular to the axis line between the two wells. The immunologic reactions in double gel diffusion are of three types (Figure 5-2):




Figure 5-1. Single immunodiffusion.




Figure 5-2. Double gel diffusion

(1) <u>Reaction of identity</u>. A solution of the same antigen is placed in two wells and its corresponding antibody is placed in the center well. Two precipitin bands form, joining at their contiguous ends and fusing.

(2) <u>Reaction of partial identity</u>. If the antigen in one well and the antibody in the central well are homologous and if the antigen in the other well is a cross-reacting antigen, the precipitin bands fuse and in addition form a spike that extends toward the cross-reacting antigen.

(3) <u>Reaction of nonidentity</u>. When two unrelated antigens are placed in adjacent wells and diffuse toward a central well that contains antibodies for each, two precipitin bands form independently of each other and cross. Currently, double diffusion is utilized in the clinical laboratory for immune complex studies and comparing antigens or antibodies for the presence of identical or cross-reacting components.

Section III. SERUM PROTEIN ELECTROPHORESIS (SPE)

5-5. PRINCIPLE

Serum protein electrophoresis is a screening procedure utilized to detect abnormalities of the various protein fractions. The patient's serum is applied to a support medium (agarose gel) along with a normal control. The agarose gel with the serum applied is placed in a barbital buffer (pH 8.6) and then subjected to an electrical charge. Due to the pH of the barbital buffer, the serum proteins will assume a net negative charge. The serum protein components migrate to one of the five possible characteristic zones (albumin, alpha-1, alpha-2, beta, and gamma) (Figure 5-3) based upon their net negative electrical charge, size, and molecular weight. Following a staining procedure using a protein stain, the serum protein components are compared to those of the normal control. Changes or abnormalities may be identified by observing the electrophoretic pattern or a densitometer tracing of the pattern (electrophoretogram) for increases, decreases, or complete absence of normally occurring components.




Figure 5-3. Electrophoretic zones.

5-6. INTERPRETATION

a. **Normal.** Patients with normal serum protein fractions are identified when their serum protein electrophoretic patterns are similar to that of the normal control with no observable increase, decrease, or absence of any particular zone (Figure 5-4A).




Figure 5-4. Interpretation of serum protein electrophoresis.

b. **Hypogammaglobulinemia (agammaglobulinemia).** This is an immunological deficiency state characterized by an abnormally low level of generally all classes of gamma globulin. It is identified by an absent or decreased zone. In this situation, the patient is not producing immunoglobulins in sufficient quantities to maintain a normal immune state (Figure 5-4B).

c. **Polyclonal Hypergammaglobulinemia.** A broad increase in gammaglobulins due to numerous clones of plasma cells producing a heterogeneous group of immunoglobulins. It is identified by a diffuse increase in the gamma zone (Figure 5-4C). This condition is exhibited in a variety of clinical disorders and therefore is not indicative of any single disease state.

d. **Monoclonal Hypergammaglobulinemia.** An excess of homogeneous immunoglobulin molecules of a single specificity following the unexplained proliferation of a single clone of immunoglobulin-producing cells. It appears as a narrow, tall spike in the gamma zone (Figure 5-4D). The class of immunoglobulin and increased or detectable amounts of free light chains in the serum or urine are diagnostic as to the clinical condition of the patient.

Section IV. IMMUNOELECTROPHORESIS (IEP)

5-7. PRINCIPLE

Immunoelectrophoresis is a qualitative method that combines electrophoresis and immunoprecipitation. Both identification and approximate quantitation may be accomplished for individual proteins present in serum, urine, or other biological fluids. This technique is especially useful in the identification and diagnosis of the monoclonal gammopathies. It is a two stage procedure with the first step involving the electrophoretic separation of the patient's serum specimen and normal control. Following electrophoresis, specific antisera (anti-human IgG, IgM, IgA, kappa, and lambda) are placed in troughs parallel to the line of the fractionated proteins. The proteins and antisera diffuse in all directions with immunoprecipitin arcs forming where specific antisera and corresponding protein antigen meet. Following a staining procedure using a protein stain, increases or decreases of the individual's immunoglobulins may be observed by comparing the patient's immunoprecipitin arcs to those of the normal control.

5-8. MONOCLONAL GAMMOPATHIES

a. **Multiple Myeloma.** It is the most common of the monoclonal gammopathies and is characterized by neoplastic proliferation of plasma cells or morphologically abnormal plasma cells (myeloma cells), primarily occurring in the bone marrow. Bone pain is the most common symptom, with the presence of bone lesions and frequent bone fractures. SPE shows the presence of a monoclonal hypergammaglobulinemia while the IEP demonstrates an increase in one of the immunoglobulins, excluding an increase of IgM. The secretion of Bence Jones protein (light chains, either kappa or lambda) in the urine is common and diagnostic.

b. **Waldenstrom's Macroglobulinemia.** This disorder is characterized by an increase in the immunoglobulin IgM and one of the light chains. The associated symptoms are due to an increase in serum viscosity. Hyperviscosity and sludging of blood may lead to visual disturbances, neurological symptoms, impaired kidney function, and congestive heart failure. Bone pain and lesions are rare.

c. **Heavy Chain Disease.** A heterogeneous group of paraprotein disorders characterized by the presence of monoclonal but incomplete heavy chains without light chains in serum or urine. The heavy chain involved may be gamma, alpha, or mu with alpha being the most common. The key to diagnosis is the demonstration of the presence of the heavy chain without any discernable light chain.

Section V. ENZYME IMMUNOASSAY TECHNIQUES


5-9. INTRODUCTION

Enzyme immunoassays have emerged as quantitative techniques for detection of extremely small quantities of antigens, haptens, and antibodies. They all employ various enzymes linked to either an antigen or antibody to form an enzyme-labeled tag which can easily be detected by measurement of the enzyme activity.


5-10. TYPES OF ENZYME IMMUNOASSAYS

a. The most widely used assays are enzyme-linked immunoabsorbent assay (ELISA) and the enzyme immunoassay (EIA). The principles of ELISA and EIA tests are similar to those of radioimmunoassay (RIA) technique except enzyme activity is measured instead of radioactivity. See the following paragraphs for the meaning of **substrate** and **conjugate**.

b. To measure antibody, antigen is fixed to a solid phase, incubated with test serum (which contains the antibody to be detected), and then incubated with anti-human globulin tagged with an enzyme (conjugate). The tagged antihuman globulin reacts with the antibody being detected. Substrate is then added and the enzyme activity adherent to the solid phase is then related to the amount of antibody bound (Figure 5-5).



Immunological Sandwich



c. To measure antigen, antibody is bound to the solid phase, a test solution containing the antigen is added, and then a second enzyme-labeled antibody (conjugate) with specificity for the antigen being assayed is added and allowed to incubate. Substrate is then added and measurement of enzyme activity is related to the antigen concentration (Figure 5-6).




Figure 5-6. Sandwich enzyme immunoassay for antibody detection.

5-11. CONJUGATE ENZYMES

Conjugates are enzyme-labeled antigen or antibody that retains activity capable of converting the substrate into a product that can be easily detected. The enzymes most frequently used for conjugates include horseradish peroxidase (HRP) and alkaline phosphatase (AP).

a. The most commonly used conjugate enzyme in the EIA test procedures is horseradish peroxidase which has the capability of reacting with a wider array of highly chromogenic substances and is produced from a vegetable source.

b. The second most commonly used conjugate enzyme is alkaline phosphatase which has a greater resistance to environmental toxins and is derived from the mucosa of the calf intestines.

5-12. SUBSTRATES

A **substrate** is a substance upon which an enzyme acts. Substrates are chromogenic substances which are initially colorless but yield a colored product after enzyme degradation. The substrates most frequently used in the EIA procedures are ortho-phenylenediamine (OPD) and para-nitrophenyl phosphate (p-NPP).

a. Ortho-phenylenediamine, the most satisfactory and commonly used peroxidase substrate, yields a highly chromogenic orange product after enzyme degradation has occurred.

b. Para-nitrophenyl phosphate is the substrate used for the enzyme alkaline phosphatase and yields a highly chromogenic yellow-colored product after enzyme degradation. Both of the above mentioned substrates are highly soluble and extremely light sensitive.

5-13. CLINICAL APPLICATIONS

Clinical application of EIA procedures include but are not limited to quantitation and/or qualitation of serum components and various hormones. They also serve as clinical tools in the diagnosis, evaluation, and treatment of the many autoimmune and viral diseases.

Continue with Exercises

EXERCISES, LESSON 5

INSTRUCTIONS: Answer the following items by completing the statement or by writing the answer in the space provided.

After you have completed all of these items, turn to "Solutions to Exercises" at the end of the lesson and check your answers with the solutions.

- You will be better able to interpret and apply the new knowledge about immunology as you develop an understanding of the <u>m</u> s now in use. In this lesson, the techniques and applications of the various <u>i</u> cal tests for the detection of <u>a</u> s and <u>a</u> s are discussed.
- In Marrack's model, under appropriate experimental conditions, antigen-antibody complexes <u>p______tate</u>. Antibody molecules are bivalent, that is, they contain two <u>a_____</u>-binding sites. At a proper antigen and antibody concentration, a cross-linked <u>m_____s</u> enlarges and <u>p_____s</u>.

At the onset of the antigen-antibody reaction, an <u>i</u> ble formation of antigen and antibody complexes occurs. This is followed by an expanding visible precipitate, called a <u>l</u> ce f tion, as the antigen and antibody reach a zone of equivalent concentration. If there is an excess of either antigen or antibody present, the proper <u>l</u> ce formation needed for precipitate formation cannot occur. The formation of the antigen-antibody complex is <u>r</u> ble and may <u>d</u> ve if more antigen or antibody is added.

- Immunodiffusion techniques detect antigen-antibody precipitation reactions in a <u>semis d</u> medium. The formation of antigen and antibody complexes can be influenced by a number of factors: relative <u>c tion</u> of antigens and antibodies, <u>i c s th</u> of the buffer, pH, and <u>t e</u>. Two techniques most often used in a clinical laboratory are <u>s le</u> and <u>d le</u> diffusion.
- 4. In the <u>r l</u> immunodiffusion (RID) method, a known concentration of antibody is incorporated into an agarose <u>m m</u>. The reactant (antigen) is applied to a well cut in the <u>a e</u> and radially diffuses from the site of application. At the point of <u>e ce</u>, the antigen and antibody react to form a visible <u>p tin</u> ring. The size of the precipitin ring is proportional to the <u>c tion</u> of the antigen. In the clinical laboratory, radial immunodiffusion is primarily used to quantitate serum <u>i lins</u> and <u>c t</u> components such as C3 or C4.

5. Double diffusion (DD) is based on the principle that antigen and antibody diffuse through a semisolid medium and form a precipitin <u>l</u>_e. In Ouchterlony's method, a layer of agar gel is deposited in a petri dish and circular <u>w</u> <u>s</u> are punched out near one another in the gel. Antibody is then added to one well while <u>a</u> <u>n</u> is added to the other. These materials are allowed to <u>d</u> <u>e</u> radially from their respective wells. As the perimeter of the diffusing substance increases, the concentration of that substance within the perimeter continually (increases) (decreases). When the optimal concentration of <u>a</u> <u>n</u> and <u>a</u> <u>y</u> is reached, a line of <u>p</u> <u>n</u> is formed in the gel. The precipitin line is relatively <u>s</u> <u>t</u> and is <u>p</u> <u>r</u> to the axis line between the two wells. The immunologic reactions in double gel diffusion are of (two) (three) types.

Consider this: A solution of the same antigen is placed in two wells and its corresponding antibody is placed in the center well. Two precipitin bands form, joining at their contiguous ends and fusing. This is a reaction of $i ext{ty}$.

To produce a reaction or partial identity, the antigen in one well and the antibody in the central well are <u>h</u> s, and the antigen in the other well is a <u>cross</u>-reacting antigen. The precipitin bands fuse, but in addition form a <u>s</u> e that extends toward the cross-reacting antigen. This is a reaction of <u>p</u> I i <u>y</u>.

When two unrelated antigens are placed in adjacent wells and diffuse toward a central well that contains antibodies for each, two precipitin bands form \underline{i} ly of each other and \underline{c} . This is a reaction of non- \underline{i} y.

Currently, double diffusion is utilized in the clinical laboratory for immune complex studies and comparing antigens or antibodies for the presence of \underline{i} or \underline{c} s-reacting components.

6. A screening procedure utilized to detect abnormalities of the various protein fractions is serum protein <u>e</u> sis. The patient's serum is applied to a support medium along with a normal <u>c</u> <u>I</u>. The agarose gel with the serum applied is placed in a <u>b</u> <u>I</u> buffer (pH 8.6) and then subjected to an <u>e</u> <u>I</u> charge. Due to the pH of the barbital buffer, the serum proteins will assume a net <u>n</u> <u>e</u> charge. The serum protein components migrate to one of the five possible characteristic zones (<u>a</u> <u>n</u>, alpha-1, alpha-2, <u>b</u> <u>a</u>, and <u>g</u> <u>a</u>) based upon their net negative electrical charge, size, and molecular weight. Following a <u>s</u> <u>g</u> procedure using a protein stain, the serum <u>p</u> <u>n</u> components are compared to those of the normal control.

7. Patients with normal serum protein fractions are identified when their serum protein electrophoretic patterns are similar to that of the normal control with no observable i e, d e, or a e of any particular zone.

Hypogammaglobulinemia (agammaglobulinemia) is an immunological deficiency state characterized by an abnormally (low) (high) level of generally all classes of gamma globulin. It is identified by an <u>a t</u> or <u>d d</u> zone. In this situation, the patient is not producing immunoglobulins in sufficient quantities to maintain a normal <u>i e</u> state.

Polyclonal hypergammaglobulinemia is a broad (decrease) (increase) in gamma globulins due to numerous \underline{c} s of plasma cells producing a heterogeneous group of \underline{i} . It is identified by a diffuse increase in the \underline{g} a zone. This condition (is) (is not) indicative of a specific disease state.

Monoclonal hypergammaglobulinemia follows the unexplained proliferation of a single \underline{c} of immunoglobulin-producing cells. It appears as a narrow, tall spike in the \underline{g} a zone.

8. Immuno_______ is a qualitative method that combines e______s and i______n. This technique is especially useful in the identification and diagnosis of the m______ I gammopathies. It is a two-stage procedure with the first step involving the electrophoretic s______n of the patient's serum specimen and normal control. Following electrophoresis, specific a______ a are placed in troughs parallel to the line of the fractionated proteins. The proteins and antisera diffuse in all directions with immunoprecipitin a_____ forming where specific a______ and corresponding protein antigen meet. Following a staining procedure using a protein stain, increases or decreases of the individual's immunoglobulins may be observed by comparing the patient's i_______ n arcs to those of the normal c______.

9. The most common of the monoclonal gammopathies is <u>m_le my_a</u>, which is characterized by neo<u>c</u> prol<u>tion</u> of plasma cells or abnormal plasma cells (<u>m_a</u> cells), primarily occurring in the bone <u>m_w</u>. Serum protein electrophoresis (SPE) shows the presence of a <u>m_al</u> hypergammaglobulinemia while the immunoelectrophoresis (IEP) demonstrates an increase in one of the <u>i_s</u>.

Waldenstrom's macrog <u>mia</u> is characterized by an increase in the immunoglobulin <u>Ig</u> and one of the <u>I</u> <u>t</u> chains. The associated symptoms are due to an increase in serum <u>vi</u> <u>ity</u>. Hyperviscosity and sludging of blood may lead to <u>v</u> <u>I</u> disturbances, <u>n</u> <u>cal</u> symptoms, impaired <u>k</u> <u>y</u> function, and congestive <u>h</u> <u>t</u> failure.

Heavy chain disease is characterized by the presence of monoclonal but incomplete <u>h</u> <u>y</u> chains without <u>l</u> <u>t</u> chains in serum or urine. The heavy chain involved may be gamma, alpha, or mu with <u>a</u> <u>a</u> being the most common. The key to diagnosis is the demonstration of the presence of the heavy chain without any discernable <u>l</u> <u>t</u> chain.

- 10. Enzyme immunoassays have emerged as <u>qu</u> ive techniques for detection of extremely <u>s</u> <u>l</u> quantities of antigens, haptens, and <u>a</u> <u>s</u>. They all employ various <u>e</u> <u>s</u> linked to either an antigen or antibody to form an <u>e</u> <u>e</u>-labeled tag which can easily be detected by measurement of the <u>e</u> <u>e</u> activity.
- The most widely used immunoassays are enzyme-linked i ent assay (ELISA) and the enzyme i ay (EIA). The principles of ELISA and EIA tests are similar to those of r say (RIA) technique except e e activity is measured instead of r oactivity.

To measure antibody, antigen is fixed to a <u>s</u> <u>d</u> phase, incubated with test serum, and then incubated with anti-<u>h</u> <u>n</u> globulin tagged with an enzyme (conjugate). Substrate is then added and the enzyme activity adherent to the solid phase is then related to the amount of <u>a</u> <u>y</u> bound.

To measure antigen, <u>a</u> <u>y</u> is bound to the solid phase, a test solution containing the <u>a</u> <u>n</u> is added, and then a second <u>e</u> <u>e</u>-labeled antibody (conjugate) with specificity for the antigen being assayed is added and allowed to <u>in</u> <u>e</u>. Substrate is then added and measurement of <u>e</u> <u>e</u> activity is related to the antigen concentration. 12. Conjugates are <u>e</u>-labeled <u>a</u> or <u>a</u> <u>y</u> which retain activity capable of converting the substrate into a product that can be easily detected.

The conjugates (enzymes) most frequently used include <u>h</u> sh peroxidase (HRP) and alkaline <u>p</u> ase (AP). The most commonly used conjugate in the EIA test procedures is horseradish <u>p</u> ase.

The second most commonly used conjugate is <u>a</u> ine <u>p</u> ase, which has a greater resistance to environmental toxins and is derived from the mucosa of the <u>c</u> <u>f</u> <u>i</u> <u>s</u>.

13. Substrates are <u>c</u> nic substances which are initially colorless but yield a colored product after <u>e</u> e degradation.

The substrates most frequently used in the EIA procedures are:

Ortho-phenylenediamine (OPD), the most <u>s</u>ory and commonly used peroxidase substrate, which yields a highly <u>c</u>ic orange product after enzyme degradation has occurred.

Para-nitrophenyl phosphate (p-NPP), the substrate used for the enzyme alkaline phosphatase and which yields a highly chromogenic \underline{y} w-colored product after enzyme degradation. Both of the above mentioned substrates are highly <u>s</u> le and extremely <u>l</u> t sensitive.

Check Your Answers on Next Page

SOLUTIONS TO EXERCISES, LESSON 5

- 1. You will be better able to interpret and apply the new knowledge about immunology as you develop an understanding of the methods now in use. In this lesson, the techniques and applications of the various immunological tests for the detection of antigens and antibodies are discussed. (paras 5-1 thru 5-2)
- 2. In Marrack's model, under appropriate experimental conditions, antigen-antibody complexes precipitate. Antibody molecules are bivalent, that is, they contain two antigen-binding sites. At a proper antigen and antibody concentration, a crosslinked mass enlarges and precipitates.

At the onset of the antigen-antibody reaction, an invisible formation of antigen and antibody complexes occurs. This is followed by an expanding visible precipitate, called a lattice formation, as the antigen and antibody reach a zone of equivalent concentration. If there is an excess of either antigen or antibody present, the proper lattice formation needed for precipitate formation cannot occur. The formation of the antigen-antibody complex is reversible and may dissolve if more antigen or antibody is added. (para 5-3)

- 3. Immunodiffusion techniques detect antigen-antibody precipitation reactions in a semisolid medium. The formation of antigen and antibody complexes can be influenced by a number of factors: relative concentration of antigens and antibodies, ionic strength of the buffer, pH, and temperature. Two techniques most often used in a clinical laboratory are single and double diffusion. (para 5-4)
- 4. In the r l immunodiffusion (RID) method, a known concentration of antibody is incorporated into an agarose medium. The reactant (antigen) is applied to a well cut in the agarose and radially diffuses from the site of application. At the point of equivalence, the antigen and antibody react to form a visible precipitin ring. The size of the precipitin ring is proportional to the concentration of the antigen. In the clinical laboratory, radial immunodiffusion is primarily used to quantitate serum immunoglobulins and complement components such as C3 or C4.

(para 5-4a)

5. Double diffusion (DD) is based on the principle that antigen and antibody diffuse through a semisolid medium and form a precipitin <u>line</u>. In Ouchterlony's method, a layer of agar gel is deposited in a petri dish and circular <u>wells</u> are punched out near one another in the gel. Antibody is then added to one well while <u>antigen</u> is added to the other. These materials are allowed to <u>diffuse</u> radially from their respective wells. As the perimeter of the diffusing substance increases, the concentration of that substance within the perimeter continually <u>decreases</u>. When the optimal concentration of <u>antigen</u> and <u>antibody</u> is reached, a line of <u>precipitation</u> is formed in the gel. The precipitin line is relatively <u>straight</u> and is <u>perpendicular</u> to the axis line between the two wells. The immunologic reactions in double gel diffusion are of <u>three</u> types.

Consider this: A solution of the same antigen is placed in two wells and its corresponding antibody is placed in the center well. Two precipitin bands form, joining at their contiguous ends and fusing. This is a reaction of <u>identity</u>.

To produce a reaction or partial identity, the antigen in one well and the antibody in the central well are <u>homologous</u>, and the antigen in the other well is a <u>cross</u>-reacting antigen. The precipitin bands fuse, but in addition form a <u>spike</u> that extends toward the cross-reacting antigen. This is a reaction of <u>partial identity</u>.

When two unrelated antigens are placed in adjacent wells and diffuse toward a central well that contains antibodies for each, two precipitin bands form <u>independently</u> of each other and <u>cross</u>. This is a reaction of non-<u>identity</u>.

Currently, double diffusion is utilized in the clinical laboratory for immune complex studies and comparing antigens or antibodies for the presence of <u>identical</u> or <u>cross</u>-reacting components.

(para 5-4b)

6. A screening procedure utilized to detect abnormalities of the various protein fractions is serum protein <u>electrophoresis</u>. The patient's serum is applied to a support medium along with a normal <u>control</u>. The agarose gel with the serum applied is placed in a <u>barbital</u> buffer (pH 8.6) and then subjected to an <u>electrical</u> charge. Due to the pH of the barbital buffer, the serum proteins will assume a net <u>negative</u> charge. The serum protein components migrate to one of the five possible characteristic zones (<u>albumin</u>, alpha-1, alpha-2, <u>beta</u>, and <u>gamma</u>) based upon their net negative electrical charge, size, and molecular weight. Following a <u>staining</u> procedure using a protein stain, the serum <u>protein</u> components are compared to those of the normal control. (para 5-5)

7. Patients with normal serum protein fractions are identified when their serum protein electrophoretic patterns are similar to that of the normal control with no observable <u>increase</u>, <u>decrease</u>, or <u>absence</u> of any particular zone.

Hypogammaglobulinemia (agammaglobulinemia) is an immunological deficiency state characterized by an abnormally <u>low</u> level of generally all classes of gamma globulin. It is identified by an <u>absent</u> or <u>decreased</u> zone. In this situation, the patient is not producing immunoglobulins in sufficient quantities to maintain a normal <u>immune</u> state.

Polyclonal hypergammaglobulinemia is a broad <u>increase</u> in gamma globulins due to numerous <u>clones</u> of plasma cells producing a heterogeneous group of <u>immunoglobulins</u>. It is identified by a diffuse increase in the <u>gamma</u> zone. This condition <u>is not</u> indicative of a specific disease state.

Monoclonal hypergammaglobulinemia follows the unexplained proliferation of a single <u>clone</u> of immunoglobulin-producing cells. It appears as a narrow, tall spike in the <u>gamma</u> zone.

(para 5-6)

8. Immunoelectrophoresis is a qualitative method that combines <u>electrophoresis</u> and <u>immunoprecipitation</u>. This technique is especially useful in the identification and diagnosis of the <u>monoclonal</u> gammopathies. It is a two-stage procedure with the first step involving the electrophoretic <u>separation</u> of the patient's serum specimen and normal control. Following electrophoresis, specific <u>antisera</u> are placed in troughs parallel to the line of the fractionated proteins. The proteins and antisera diffuse in all directions with immunoprecipitin <u>arcs</u> forming where specific <u>antisera</u> and corresponding protein antigen meet. Following a staining procedure using a protein stain, increases or decreases of the individual's immunoglobulins may be observed by comparing the patient's <u>immunoprecipitin</u> arcs to those of the normal <u>control</u>.

(para 5-7)

9. The most common of the monoclonal gammopathies is <u>multiple myeloma</u>, which is characterized by neo<u>plastic</u> pro<u>liferation</u> of plasma cells or abnormal plasma cells (<u>myeloma</u> cells), primarily occurring in the bone <u>marrow</u>. Serum protein electrophoresis (SPE) shows the presence of a <u>monoclonal</u> hypergammaglobulinemia while the immunoelectrophoresis (IEP) demonstrates an increase in one of the <u>immunoglobulins</u>.

Waldenstrom's macroglobulinemia is characterized by an increase in the immunoglobulin <u>IgM</u> and one of the <u>light</u> chains. The associated symptoms are due to an increase in serum <u>viscosity</u>. Hyperviscosity and sludging of blood may lead to <u>visual</u> disturbances, <u>neurological</u> symptoms, impaired <u>kidney</u> function, and congestive <u>heart</u> failure.

Heavy chain disease is characterized by the presence of monoclonal but incomplete <u>heavy</u> chains without <u>light</u> chains in serum or urine. The heavy chain involved may be gamma, alpha, or mu with <u>alpha</u> being the most common. The key to diagnosis is the demonstration of the presence of the heavy chain without any discernable <u>light</u> chain.

(para 5-8)

- Enzyme immunoassays have emerged as <u>quantitative</u> techniques for detection of extremely <u>small</u> quantities of antigens, haptens, and <u>antibodies</u>. They all employ various <u>enzymes</u> linked to either an antigen or antibody to form an <u>enzyme</u>-labeled tag which can easily be detected by measurement of the <u>enzyme</u> activity. (para 5-9)
- 11. The most widely used immunoassays are enzyme-linked <u>immunoabsorbent</u> assay (ELISA) and the enzyme <u>immunoassay</u> (EIA). The principles of ELISA and EIA tests are similar to those of <u>radioimmunoassay</u> (RIA) technique except <u>enzyme</u> activity is measured instead of <u>radioactivity</u>.

To measure antibody, antigen is fixed to a <u>solid</u> phase, incubated with test serum, and then incubated with anti-<u>human</u> globulin tagged with an enzyme (conjugate). Substrate is then added and the enzyme activity adherent to the solid phase is then related to the amount of <u>antibody</u> bound.

To measure antigen, <u>antibody</u> is bound to the solid phase, a test solution containing the <u>antigen</u> is added, and then a second <u>enzyme</u>-labeled antibody (conjugate) with specificity for the antigen being assayed is added and allowed to <u>incubate</u>. Substrate is then added and measurement of <u>enzyme</u> activity is related to the antigen concentration.

(para 5-10)

12. Conjugates are <u>enzyme</u>-labeled <u>antigen</u> or <u>antibody</u> which retain activity capable of converting the substrate into a product that can be easily detected.

The conjugates (enzymes) most frequently used include <u>horseradish</u> peroxidase (HRP) and alkaline <u>phosphatase</u> (AP). The most commonly used conjugate in the EIA test procedures is horseradish <u>peroxidase</u>.

The second most commonly used conjugate is <u>alkaline phosphatase</u>, which has a greater resistance to environmental toxins and is derived from the mucosa of the <u>calf intestines</u>.

(para 5-11)

13. Substrates are <u>chromogenic</u> substances which are initially colorless but yield a colored product after <u>enzyme</u> degradation.

The substrates most frequently used in the EIA procedures are:

Ortho-phenylenediamine (OPD), the most <u>satisfactory</u> and commonly used peroxidase substrate, which yields a highly <u>chromogenic</u> orange product after enzyme degradation has occurred.

Para-nitrophenyl phosphate (p-NPP), the substrate used for the enzyme alkaline phosphatase and which yields a highly chromogenic <u>vellow</u>-colored product after enzyme degradation. Both of the above mentioned substrates are highly <u>soluble</u> and extremely <u>light</u> sensitive.

(para 5-12)

End of Lesson 5

LESSON ASSIGNMENT

LESSON 6	Antinuclear Antibodies and Testing
TEXT ASSIGNMENT	Paragraphs 6-1 through 6-10.
LESSON OBJECTIVES	After completing this lesson, you should be able to describe the principles and techniques of immunofluorescence, including the following: the direct method, the indirect method, the transmitted light microscope, the incident light microscope, antinuclear antibodies and related diseases, and the fluorescent antinuclear antibody test.
SUGGESTION	After completing the assignment, complete the exercises at the end of this lesson. These exercises will help you to achieve the lesson objectives.

LESSON 6

ANTINUCLEAR ANTIBODIES AND TESTING

Section I. IMMUNOFLUORESCENT MICROSCOPY

6-1. INTRODUCTION


Immunofluorescence is a method of detecting an antigen or antibody in tissue by the pattern of fluorescence resulting when the tissue is exposed to the specific antibody or antigen labeled with a fluorochrome such as fluorescein. The technique of immunofluorescence was introduced by Coons and his associates in 1941. Immunofluorescence, the use of fluorochrome-labeled antibodies for the detection of antigens, can be qualitative or quantitative. In a qualitative procedure, a fluorescent microscope is necessary to visualize the presence of a labeled antigen or antibody in the specimen. Fluorescence is the emission of light of one color or wavelength, while a substance is irradiated with light of a different color or wavelength. The emitted wavelength is at a lower energy level than the incident or absorbed light. Fluorescein isothiocyanate is one of the most common fluorochromes with an absorption maximum of 490-495 nm and a yellow-green emission maximum of 517 nm.

6-2. IMMUNOFLUORESCENT METHODS

The two most common methods used in the performance of immunofluorescent microscopy are the direct and indirect techniques.

a. **Direct Method.** In the direct method, the antibody is labeled with a fluorescent compound and is used to detect the presence of antigen in tissue fixed to a slide. The direct technique utilizes biopsy material obtained from a patient. The fluorescent-labeled antibodies are added to the antigen in an optimal dilution and allowed to react. The preparation is washed to remove any unreacted labeled antibodies. The tissue sections are blotted and the preparation mounted with buffered glycerol for examination with the fluorescent microscope (Figure 6-1a).

b. Indirect Method. The indirect method is used for the detection of serum antibodies utilizing an antigen-containing substrate and a fluorescein-labeled antibody specific for human immunoglobulins. The specific antigen-antibody (unlabeled) reaction may be visualized by the addition of labeled antihuman globulin directed against the antibody in the primary reaction. The antigen substrate **plus** patient's serum antibody **plus** labeled antihuman immunoglobulin complex results in fluorescence and detection of the specific patient's antibody in question (Figure 6-1b).



6-3. THE FLUORESCENT MICROSCOPE

The transmitted light microscope (Figure 6-2) and the incident light or epiillumination microscope (Figure 6-3) are the two types of microscopes used in immunofluorescent techniques. The two systems share some common component parts, but there are some structural and operational differences. One major difference is the direction from which the exciter light or energy strikes the specimen. The transmitted microscope light strikes the specimen from below through a condenser, while the incident microscope light strikes the specimen from above passing through the objective. This eliminates the need for a condenser and also eliminates the problems of centering a condenser. The incident microscope has more brightness, clearer images, and greater fluorescence since illumination and observation of the specimen are made from the same direction. With incident light, exciting and emitted fluorescence radiation are well separated since the exciting light passes through the specimen downwards and is lost and does not interfere with the fluorescence image. The component parts of the two types of microscopes are as follows (Figure 6-4):




Figure 6-2. Transmitted light




Figure 6-3 Incident light microscope.




Figure 6-4. Components of a fluorescent microscope.

a. Light System.

(1) <u>Light reflector</u>. Concave mirror located behind the light source which redirects lost energy (light) back into system.

(2) <u>Light source</u>. Mercury vapor lamp.

(3) <u>Collecting lenses</u>. Concentrates light from light source into a single beam.

b. Filter System.

(1) <u>Heat-absorbing filter</u>. Removes excess heat from exciting light that may damage the system.

(2) <u>Exciter filter (primary filter)</u>. Transmits only the effective or exciter light and suppresses all other energy from light source emission which are not required for specimen fluorescence.

(3) <u>Dichroic mirror</u>. Part of incident microscope only. Allows passage of light of selected wavelengths in one direction through the mirror but not in the opposite direction (Figure 6-5).

(4) <u>Barrier filter (secondary filter)</u>. Transmits only the emitted fluorescent light from the specimen and suppresses all other energy.




Figure 6-5. Dichroic mirror of incident light microscope.

Section II. ANTINUCLEAR ANTIBODIES

6-4. INTRODUCTION

Antinuclear antibodies are a collection of autoantibodies that are directed against nuclear constituents, usually in nucleoprotein, and that are present in various autoimmune diseases. The detection of one or more of these antinuclear antibodies is pathologically significant. The antinuclear antibody-related diseases belong to the systemic autoimmune disease classification and their etiology remains unknown.

6-5. RELATED DISEASES

a. **Rheumatoid Arthritis (RA)**. Rheumatoid arthritis is a chronic systemic disease characterized by inflammatory changes in joints and related structures that result in crippling deformities.

b. **Systemic Lupus Erythematosus (SLE).** SLE is a chronic inflammatory disease of connective tissue that affects the skin, joints, kidneys, nervous system, and mucous membranes. A characteristic light-induced butterfly rash or erythema may be present across the nose. The disease may begin acutely with fever, joint pain, and malaise or smolder over a period of years with intermittent fever and malaise. Symptoms from any organ system may be present. The disease occurs most often in women.

c. **Sjogren's Syndrome (SS).** This is a benign chronic disease characterized by a lack of tears and dryness of the eyes and mouth with little or no saliva. It often occurs secondary to RA or one of the other connective tissue disorders. The disease occurs most often in women.

d. **Progressive Systemic Sclerosis (PSS).** PSS is a chronic illness characterized by a fibrous thickening of the skin (scleroderma) and several internal organs (gastrointestinal tract, heart, kidney, and lungs). Two-thirds of the patients are female.

e. **Mixed Connective Tissue Disease (MCTD).** This is a relatively newly defined syndrome whose designation is reserved for patients with combined clinical features of RA, SLE, and PSS.

6-6. ANTINUCLEAR ANTIBODIES

a. **Anti-Native (Double-Stranded) DNA.** High levels of this antibody are associated with SLE and a positive correlation exists with associated nephritis.

b. **Anti-Deoxyribonucleoprotein (DNP).** A significant number of SLE patients demonstrate high levels of anti-DNP. Persons with other connective tissue diseases may display low levels of this antibody.

c. **Anti-Sm (Smith).** 30% of all patients with SLE are positive, but this is highly specific for SLE. Greater than 75% of patients with clinically active SLE are anti-Sm positive. It is absent in other autoimmune conditions.

d. **Anti-Ribonucleoprotein (RNP).** High titer found in all patients with MCTD. Low titers may be seen in SLE.

e. Antinucleolar. High titers are highly indicative of PSS.

Section III. FLUORESCENT ANTINUCLEAR ANTIBODY TEST (FANA)

6-7. PRINCIPLE

The FANA utilizes the indirect fluorescent antibody technique. Antinuclear antibodies in a patient's serum will bind with nuclear antigens of a tissue cell culture substrate affixed to a slide. Fluorescein-conjugated antihuman globulin interacts with nuclear antibodies attached to the cell nuclei in a positive assay which is indicated by an apple-green fluorescence.

6-8. REPORTING RESULTS

a. **Negative.** Fluorescent intensity of the cells' nuclei approximates that of the negative control, and there is no discernible pattern in the nucleus.

b. **Positive.** Fluorescent intensity of the cells' nuclei is greater than the negative control, and there is a clearly discernible pattern in the nucleus. Report positive controls and patients by the specific fluorescent pattern observed.

6-9. NUCLEAR PATTERNS

a. Homogeneous.

- (1) Smooth, even staining of the nucleus.
- (2) Antibodies indicated, anti-native DNA, anti-DNP.
- (3) Condition indicated-SLE (high titer), RA (low titer).

b. Peripheral.

- (1) Staining of the nuclear membrane only.
- (2) Antibodies indicated, anti-native DNA.
- (3) Condition indicated, SLE.

c. Speckled.

- (1) Grainy staining throughout the nucleus usually not affecting the nucleoli.
- (2) Antibodies indicated, anti-Sm, anti-RNP.
- (3) Conditions indicated, SLE, PSS, SS, MCTD.

d. Nucleolar.

- (1) Solid staining of the nucleoli.
- (2) Antibodies indicated, antinucleolar.
- (3) Condition indicated, PSS.

6-10. LIMITATIONS

a. The FANA is a laboratory diagnostic aid and by itself is not diagnostic. Positive results require further testing for specific antinuclear antibody identification and quantitation.

- b. SLE patients undergoing steroid therapy may have negative test results.
- c. Many commonly prescribed drugs may induce ANA positive results.

Continue with Exercises

EXERCISES, LESSON 6

INSTRUCTIONS: Answer the following items by completing the statement or by writing the answer in the space provided.

After you have completed all of these items, turn to "Solutions to Exercises" at the end of the lesson and check your answers with the solutions.

- Immunofluorescence is a method of detecting an <u>a n</u> or <u>a y</u> in tissue by the pattern of <u>f</u> <u>e</u> resulting when the tissue is exposed to the specific antibody or antigen-labeled with a <u>f</u> <u>me</u> such as fluorescein. Immunofluorescence can be <u>q</u> <u>tive</u> or <u>q</u> <u>tive</u>. In a qualitative procedure, a <u>f</u> <u>t</u> microscope is necessary to visualize the presence of a labeled antigen or antibody in the specimen. Fluorescence is the <u>e</u> <u>n</u> of light of one color from a substance being exposed to <u>l</u> <u>t</u> of a different color or wavelength. One of the most common fluorochromes is <u>f</u> <u>n</u> isothiocyanate.
- 2. The two most common methods used in the performance of immunofluorescent microscopy are the <u>d t</u> and <u>i t</u> techniques.

In the direct method, the antibody is labeled with a fluorescent compound and is used to detect the presence of <u>a n</u> in tissue fixed to a slide. The direct technique utilizes <u>b sy</u> material obtained from a patient. The fluorescent-labeled <u>a s</u> are added to the antigen in an optimal dilution and allowed to react. The preparation is washed to remove any un<u>r d</u> labeled antibodies. The tissue sections are blotted and the preparation mounted with buffered <u>g l</u> for examination with the fluorescent microscope.

3. The indirect method is used for the detection of serum <u>a</u> <u>s</u> utilizing an <u>a</u> <u>n</u>-containing substrate and a <u>f</u> <u>n</u>-labeled antibody specific for human im<u>m</u> <u>s</u>. The specific antigen-antibody (unlabeled) reaction may be visualized by the addition of labeled <u>a</u> <u>n</u> globulin directed against the <u>antibody</u> in the primary reaction. The antigen substrate **plus** patient's serum antibody **plus** labeled <u>anti</u> <u>n</u> <u>i</u> globulin complex results in <u>f</u> <u>e</u> and detection of the specific patient's <u>a</u> <u>y</u> in question.

- 4. Two types of microscopes used in immunofluorescent techniques are the <u>t</u> <u>d</u> <u>l</u> <u>t</u> microscope and the <u>i</u> <u>t</u> light or <u>e</u> -<u>i</u> <u>n</u> microscope. One major difference is the <u>d</u> <u>n</u> from which the light or energy strikes the <u>specimen</u>. In the transmitted light microscope, light strikes the specimen from (above) (below) through a <u>c</u> <u>r</u>. In the incident light microscope, light strikes the specimen from (above) (below), passing through the <u>o</u> <u>ve</u>; this eliminates the need for a <u>c</u> <u>r</u> and also eliminates the problems of <u>c</u> <u>g</u> a condenser. The incident microscope has more <u>b</u> <u>ness</u>, clearer <u>i</u> <u>ges</u>, and greater <u>f</u> <u>e</u> since illumination and observation of the specimen are made from the same <u>d</u> <u>n</u>.
- 5. The component parts of the two types of microscopes include the <u>l</u> system and the <u>f</u> system.

The light system includes the light \underline{r} \underline{r} , the light \underline{s} \underline{e} , and the collecting \underline{l} ses. The filter system includes the \underline{h} t-absorbing filter, the \underline{e} \underline{r} filter, the dic \underline{c} mirror, and the \underline{b} \underline{r} filter.

The light reflector is a concave \underline{m} <u>r</u> located behind the <u>l</u> <u>t</u> <u>s</u> <u>e</u> which redirects <u>l</u> <u>t</u> energy (light) back into system. The light source is a mercury <u>v</u> <u>r</u> lamp. The collecting lenses <u>c</u> <u>r</u>ate light from the light source into a single <u>b</u> <u>m</u>.

The heat-absorbing filter removes excess <u>h</u> t from the exciting light that may damage the system. The exciter filter (primary filter) transmits only the <u>e</u> ve light and supp <u>s</u> all other energy from light source emission which are not required for <u>s</u> <u>n</u> fluorescence. The dichroic mirror, which is part of the <u>i</u> <u>t</u> microscope only, allows passage of light of selected wave <u>l</u> <u>s</u> in one direction through the mirror but not in the <u>o</u> <u>e</u> direction. The barrier filter transmits only the <u>e</u> <u>t</u>ed fluorescent light from the specimen and suppresses all other <u>e</u> <u>y</u>.

 Antinuclear antibodies are a collection of <u>a</u>ntibodies which are directed against <u>n</u> r constituents, usually in nucleoprotein, and which are present in various aut<u>o</u> <u>e</u> diseases. The detection of one or more of these antinuclear antibodies is pathologically <u>s</u> <u>t</u>. Related diseases include rheumatoid arth<u>s</u>, systemic <u>l</u>s erythematosus, Sjogren's syn<u>e</u>, progressive systemic sc<u>l</u>s, and mixed <u>c</u>ve tissue disease.

Rheumatoid arthritis (RA) is a chronic systemic disease characterized by inflammatory changes in <u>j</u> s and related structures that result in crippling d ies.

Systemic lupus erythematosus (SLE) is a chronic $\underline{i} \quad \underline{y}$ disease of connective tissue that affects the <u>s</u> <u>n</u>, <u>j</u> <u>s</u>, <u>k</u> <u>s</u>, <u>n</u> <u>s</u> system, and <u>m</u> <u>s</u> membranes. A characteristic light-induced <u>b</u> fly rash or erythema may be present across the <u>n</u> <u>e</u>. The disease may be <u>a</u> <u>e</u> or chronic. Symptoms from any <u>o</u> <u>n</u> system may be present. The disease occurs most often in <u>w</u> <u>n</u>.

Sjogren's syndrome (SS) is a benign <u>c_c</u> disease characterized by a lack of <u>t_s</u> and <u>d_n</u>ess of the eyes and mouth with little or no <u>s_a</u>. It often occurs secondary to RA or one of the other <u>c_e</u> tissue disorders. The disease occurs most often in <u>w_n</u>.

Progressive systemic sclerosis (PSS) is a <u>(acute) (chronic)</u> illness characterized by a fibrous <u>t_ing</u> of the skin and several internal <u>o_s</u>. Two-thirds of the patients are <u>(male) (female)</u>.

Mixed connective tissue disease (MCTD) is a recently defined syndrome whose designation is reserved for patients with \underline{c} <u>d</u> clinical features of RA, SLE, and PSS.

8. Of the antinuclear antibodies discussed in this lesson, the ones strongly associated with SLE are anti-<u>n</u> e-DNA, anti-<u>D</u>, and anti-<u>S</u>.

High titers of anti- \underline{R} are found in all patients with MCTD. Low titers may be seen in SLE.

High titers of antinucleolar antibodies are highly indicative of <u>P___</u>.

9. The fluorescent anti<u>n</u> <u>r</u> antibody test (FANA) utilizes the indirect f<u>t</u> antibody technique. Antinuclear <u>a</u> <u>s</u> in a patient's serum will bind with nu<u>c</u> <u>r</u> antigens of a tissue <u>c</u> <u>l</u> <u>c</u> <u>e</u> substrate affixed to a slide. Fluorescein-conj<u>d</u> antihuman globulin interacts with <u>n</u> <u>r</u> antibodies attached to the cell nuclei in a positive assay which is indicated by an apple-green <u>f</u> <u>c</u>e.

 If the results for the FANA are negative, the fluorescent intensity of the cells' nuclei is about the same as that of the <u>(negative) (positive)</u> control, and there is no discernible <u>p</u> <u>n</u> in the nucleus.

If the results are positive, the fluorescent intensity of the cells' nuclei is (less)(greater) than the negative control, and there is a clearly dis <u>b</u>le pattern in the nucleus. Report positive controls and patients by the specific fl_t pattern observed.

11. For a homogeneous pattern, there is s<u>m h</u>, <u>e n</u> staining of the nucleus. The antibodies indicated are anti-native-<u>D</u> and anti-<u>D</u>. The condition indicated by a (high) (low) titer is SLE. The condition indicated by a (high) (low) titer is RA.

For a peripheral pattern, there is staining of the <u>n</u> r <u>m</u> e only. The antibody indicated is anti-native-<u>D</u>. The condition indicated is <u>S</u>.

For a speckled pattern, there is $\underline{g} \ \underline{y}$ staining throughout the nucleus usually not affecting the <u>n</u>_i. The antibodies indicated are anti-<u>S</u> and anti-<u>R</u>. Four possible conditions indicated are (<u>RA</u>) (<u>SLE</u>) (<u>PSS</u>) (<u>SS</u>) (<u>MCTD</u>).

For a nucleolar pattern, there is solid staining of the <u>n</u> i. The antibodies indicated are ant <u>r</u>. The condition indicated is <u>P</u>.

12. The FANA is a laboratory diagnostic <u>a d</u> and by itself is not <u>d</u>. Positive results require <u>f</u> r testing for specific antinuclear antibody <u>i</u> cation and quantitation.

Another limitation of the FANA is that SLE patients undergoing steroid therapy may have <u>(negative) (positive)</u> test results. Also, many commonly prescribed drugs may induce <u>(negative) (positive)</u> results.

Check Your Answers on Next Page

SOLUTIONS TO EXERCISES, LESSON 6

- Immunofluorescence is a method of detecting an <u>antigen</u> or <u>antibody</u> in tissue by the pattern of <u>fluorescence</u> resulting when the tissue is exposed to the specific antibody or antigen-labeled with a <u>fluorochrome</u> such as fluorescein. Immunofluorescence can be <u>qualitative</u> or <u>quantitative</u>. In a qualitative procedure, a <u>fluorescent</u> microscope is necessary to visualize the presence of a labeled antigen or antibody in the specimen. Fluorescence is the <u>emission</u> of light of one color from a substance being exposed to <u>light</u> of a different color or wavelength. One of the most common fluorochromes is <u>fluorescein</u> isothiocyanate. (para 6-1)
- 2. The two most common methods used in the performance of immunofluorescent microscopy are the <u>direct</u> and <u>indirect</u> techniques.

In the direct method, the antibody is labeled with a fluorescent compound and is used to detect the presence of <u>antigen</u> in tissue fixed to a slide. The direct technique utilizes <u>biopsy</u> material obtained from a patient. The fluorescent-labeled <u>antibodies</u> are added to the antigen in an optimal dilution and allowed to react. The preparation is washed to remove any un<u>reacted</u> labeled antibodies. The tissue sections are blotted and the preparation mounted with buffered <u>glycerol</u> for examination with the fluorescent microscope.

(para 6-2a)

- The indirect method is used for the detection of serum <u>antibodies</u> utilizing an <u>antigen</u>-containing substrate and a <u>fluorescein</u>-labeled antibody specific for human im<u>munoglobulins</u>. The specific antigen-antibody (unlabeled) reaction may be visualized by the addition of labeled <u>antihuman</u> globulin directed against the <u>antibody</u> in the primary reaction. The antigen substrate **plus** patient's serum antibody **plus** labeled <u>antihuman</u> immunoglobulin complex results in <u>fluorescence</u> and detection of the specific patient's <u>antibody</u> in question. (para 6-2b)
- 4. Two types of microscopes used in immunofluorescent techniques are the transmitted light microscope and the incident light or epi-illumination microscope. One major difference is the direction from which the light or energy strikes the specimen. In the transmitted light microscope, light strikes the specimen from below through a condenser. In the incident light microscope, light strikes the specimen from above, passing through the objective; this eliminates the need for a condenser and also eliminates the problems of centering a condenser. The incident microscope has more brightness, clearer images, and greater fluorescence since illumination and observation of the specimen are made from the same direction.

(para 6-3)

5. The component parts of the two types of microscopes include the <u>light</u> system and the <u>filter</u> system.

The light system includes the light <u>reflector</u>, the light <u>source</u>, and the collecting <u>lens</u>es. The filter system includes the <u>heat</u>-absorbing filter, the <u>exciter</u> filter, the <u>dichroic</u> mirror, and the <u>barrier</u> filter.

The light reflector is a concave <u>mirror</u> located behind the <u>light source</u> which redirects <u>lost energy</u> (light) back into system. The light source is a mercury <u>vapor</u> lamp. The collecting lenses <u>concentrate</u> light from the light source into a single <u>beam</u>.

The heat-absorbing filter removes excess <u>heat</u> from the exciting light that may damage the system. The exciter filter (primary filter) transmits only the <u>effective</u> light and suppresses all other energy from light source emission which are not required for <u>specimen</u> fluorescence. The dichroic mirror, which is part of the <u>incident</u> microscope only, allows passage of light of selected wave <u>lengths</u> in one direction through the mirror but not in the <u>opposite</u> direction. The barrier filter transmits only the <u>emitted</u> fluorescent light from the specimen and suppresses all other <u>energy</u>.

(para 6-3)

 Antinuclear antibodies are a collection of <u>autoa</u>ntibodies which are directed against <u>nuclear</u> constituents, usually in nucleoprotein, and which are present in various aut<u>oimmune</u> diseases. The detection of one or more of these antinuclear antibodies is pathologically <u>significant</u>. (para 6-4) Related diseases include rheumatoid art<u>hritis</u>, systemic <u>lupus</u> erythematosus, Sjogren's syndrome, progressive systemic sc<u>lerosis</u>, and mixed <u>connective</u> tissue disease.

Rheumatoid arthritis (RA) is a chronic systemic disease characterized by inflammatory changes in joints and related structures that result in crippling <u>deformiti</u>es.

Systemic lupus erythematosus (SLE) is a chronic <u>inflammatory</u> disease of connective tissue that affects the <u>skin</u>, joints, <u>kidneys</u>, <u>nervous</u> system, and <u>mucous</u> membranes. A characteristic light-induced <u>butterfly</u> rash or erythema may be present across the <u>nose</u>. The disease may be <u>acute</u> or chronic. Symptoms from any <u>organ</u> system may be present. The disease occurs most often in <u>women</u>.

Sjogren's syndrome (SS) is a benign <u>chronic</u> disease characterized by a lack of <u>tears</u> and <u>dryn</u>ess of the eyes and mouth with little or no <u>saliva</u>. It often occurs secondary to RA or one of the other <u>connective</u> tissue disorders. The disease occurs most often in <u>women</u>.

Progressive systemic sclerosis (PSS) is a <u>chronic</u> illness characterized by a fibrous <u>thickening</u> of the skin and several internal <u>organs</u>. Two-thirds of the patients are <u>female</u>.

Mixed connective tissue disease (MCTD) is a recently defined syndrome whose designation is reserved for patients with <u>combined</u> clinical features of RA, SLE, and PSS.

(para 6-5)

8. Of the antinuclear antibodies discussed in this lesson, the ones strongly associated with SLE are anti-<u>native</u>-DNA, anti-<u>DNP</u>, and anti-<u>Sm</u>.

High titers of anti-<u>RNP</u> are found in all patients with MCTD. Low titers may be seen in SLE.

High titers of antinucleolar antibodies are highly indicative of <u>PSS</u>.

(para 6-6)

- 9. The fluorescent anti<u>nuclear</u> antibody test (FANA) utilizes the indirect fluorescent antibody technique. Antinuclear <u>antibodies</u> in a patient's serum will bind with nuclear antigens of a tissue <u>cell culture</u> substrate affixed to a slide. Fluoresceinconjugated antihuman globulin interacts with <u>nuclear</u> antibodies attached to the cell nuclei in a positive assay which is indicated by an apple-green <u>fluorescenc</u>e. (para 6-7)
- 10. If the results for the FANA are negative, the fluorescent intensity of the cells' nuclei is about the same as that of the <u>negative</u> control, and there is no discernible <u>pattern</u> in the nucleus.

If the results are positive, the fluorescent intensity of the cells' nuclei is <u>greater</u> than the negative control, and there is a clearly di<u>scernib</u>le pattern in the nucleus. Report positive controls and patients by the specific <u>fluorescent</u> pattern observed.

(para 6-8)

11. For a homogeneous pattern, there is smooth, even staining of the nucleus. The antibodies indicated are anti-native-<u>DNA</u> and anti-<u>DNP</u>. The condition indicated by a <u>high</u> titer is SLE. The condition indicated by a <u>low</u> titer is RA.

For a peripheral pattern, there is staining of the <u>nuclear</u> <u>membrane</u> only. The antibody indicated is anti-native-<u>DNA</u>. The condition indicated is <u>SLE</u>.

For a speckled pattern, there is <u>grainy</u> staining throughout the nucleus usually not affecting the <u>nucleoli</u>. The antibodies indicated are anti-<u>Sm</u> and anti-<u>RNP</u>. Four possible conditions indicated are <u>SLE</u>, <u>PSS</u>, <u>SS</u>, and <u>MCTD</u>.

For a nucleolar pattern, there is solid staining of the <u>nucleoli</u>. The antibodies indicated are ant<u>inucleolar</u>. The condition indicated is <u>PSS</u>.

(para 6-9)

12. The FANA is a laboratory diagnostic <u>aid</u> and by itself is not <u>diagnostic</u>. Positive results require <u>further</u> testing for specific antinuclear antibody <u>identific</u>ation and quantitation.

Another limitation of the FANA is that SLE patients undergoing steroid therapy may have <u>negative</u> test results. Also, many commonly prescribed drugs may induce <u>positive</u> results.

(para 6-10)

End of Lesson 6

LESSON ASSIGNMENT

- **LESSON ASSIGNMENT** Paragraphs 7-1 through 7-30.
- **LESSON OBJECTIVES** After completing this lesson, you should be able to:
 - 7-1. Describe the structure and classification of viruses.
 - 7-2. Describe the human immunodeficiency virus (HIV), its effects upon the immune system, and laboratory procedures for HIV antibodies and antigens.
 - 7-3. Describe viral hepatitis, its symptoms, and causative agents, and immunological markers for hepatitis. Describe the virus, mode of transmission, incubation period and infectivity, and immunological assays for the hepatitis A virus (HAV), the hepatitis B virus (HBV), the hepatitis D virus (HDV), and hepatitis non-A, non-B (NANB).

SUGGESTION After completing the assignment, complete the exercises at the end of this lesson. These exercises will help you to achieve the lesson objectives.

LESSON 7

VIRAL IMMUNITY

Section I. VIROLOGY

7-1. STRUCTURE OF A VIRUS

A virus is an intracellular parasite that will develop both acute and chronic infections that may or may not lead to host cell transformation and malignancy. The structure of a virus consists of a core, a capsid, and an envelope. The core consists mainly of a nucleic acid, either DNA or RNA, never both together. The capsid is a protective protein coat around the core. It is constructed of individual subunits termed capsomers. The envelope is a lipid outer covering; it may or may not be present depending on the virus.

7-2. CLASSIFICATION OF VIRUSES

Viruses are classified by the following properties: morphology, structure, and cytopathic effects in cell cultures.

Section II. HUMAN IMMUNODEFICIENCY VIRUS

7-3. HISTORY OF HUMAN IMMUNODEFICIENCY VIRUS

Acquired Human Immunodeficiency Virus (HIV) [immunodeficiency syndrome (AIDS)] is a new disease entity that was first recognized in the late 1970's. The origin of the virus is unclear. Epidemiological data and serological data suggest that the viral infection began in Central Africa.

7-4. CLASSIFICATION

The virus that causes AIDS belongs to a unique class of viruses distinguished by the presence of an enzyme that catalyzes the formation of DNA from RNA. The catalyzing enzyme is a reverse transcriptase; viruses that contain it are called retroviruses. Human Immunodeficiency Virus (HIV) is a cytopathic retrovirus that appears to be genetically related to some of the other cytopathic retroviruses, such as visna virus, which causes a dementing disease in sheep.

7-5. STRUCTURE

The virus is approximately 110-140 nanometers in size and has an outer envelope surrounding the core. The core contains RNA (the genetic information), reverse transcriptase, and a protein identified as p24. The p24 protein is antigenic, and antibodies against it are detected in the ELISA test and Western Blot. The envelope contains two important glycoproteins. Glycoprotein 41 (gp 41) spans the membrane and is also antigenic. The other protein, gp 120, is the major outer membrane glycoprotein of HIV (figure 7-1). The envelope gene that codes for a portion of the virus's outer membrane varies considerably from isolate to isolate. An effective vaccine for AIDS would therefore need to protect against many different strains of the virus. Human Immunodeficiency Virus contains a gene, called the TAT (trans-activator) gene, whose product acts as a powerful promotor of viral DNA replication. This promotion of viral replication at the expense of cellular replication may be an important mechanism in virally induced cell death.





Figure 7-1. Human retroviruses.

7-6. HUMAN IMMUNODEFICIENCY VIRUS REPLICATION AND TRANSMISSION

The HIV contains a unique enzyme that enables the viruses to make DNA copies of its RNA. This enzyme, commonly referred to as reverse transcriptase, is an RNA-dependent DNA polymerase that catalyzes the reverse flow of genetic information from RNA to DNA. Once the DNA is made, these viruses use other enzymes to insert or integrate the DNA copies of their genes into the chromosomal DNA of the host cell. Insertion having been accomplished, the proviral DNA genes become a part of the genes of the host cell. Once present in the cellular DNA, retrovirus "proviral" genes may be: (1) nonfunctional or silent, (2) partially transcribed with subsequent expression of individual viral proteins within the cell or on its surface, or (3) fully transcribed to produce new viral RNA genes that are encapsulated in viral structural proteins to form new virus particles, which subsequently "bud" from the surface of the host cell. These new virons may then infect any cell they contact (figure 7-2).



Notes:

- 1. Binding of viruse to target cell.
- 2. Uncoating of virus and transcription of viral RNA to DNa by reverse transcriptase.
- 3. Viral circularization an integration into host genome.
- 4. Transcription and protein synthesis.
- 5. Assembly of viral proteins and RNA at cell surface.
- 6. Budding of mature viral particle from host.

Figure 7-2. Life cycle of retroviruses.

7-7. HUMAN IMMUNODEFICIENCY VIRUS-CELL INTERACTIONS

The HIV is cytopathic for many of the lymphocytes in which the virus actively replicates. The primary targets for HIV are the T4 helper (also called Th) lymphocytes. However, other cells, including some of the monocyte/macrophage lineage, B lymphocytes, dendritic reticular cells, and some glial and endothelial cells in the brain may become infected.

7-8. DAMAGE TO THE IMMUNE SYSTEM

The HIV virus destroys many of the body's T4 helper cells. The infected T4 cells, that are not destroyed, are functionally defective. The infected monocytes appear to be nonfunctional. The virus appears to stimulate all B cells into producing antibodies, thereby, leaving no unstimulated B cells available to respond to new infections.

7-9. LABORATORY DETECTION

The most widely used screening tests for HIV are ELISA or EIA procedures. These procedures test for antibodies formed against various proteins or glycoproteins from HIV. There are new procedures available now to test directly for HIV antigens. This allows for earlier and more definitive detection of the disease. The procedure, which is presently used for confirmation of positive screening tests (ELISA, EIA), is the Western blot.

Section III. VIRAL HEPATITIS

7-10. INTRODUCTION

Viral hepatitis has been recognized by the medical community for almost two centuries and remains a disease of major significance in the world today. It is an infection which results in inflammation of the liver caused by one of at least four distinct viral agents. The diagnosis of acute viral hepatitissometimes can be made on the basis of clinical features and history that suggest a particular causative agent. In most cases and because of recent immunological advances, specific tests exist which accurately detect, diagnose, and monitor the progression of hepatitis.

7-11. SYMPTOMS OF HEPATITIS

Early symptoms of hepatitis are similar to the common flu with accompanying fatigue, joint and muscle pain, and loss of appetite. Low-grade fever, nausea, vomiting, and diarrhea or constipation may occur. As the disease progresses, the liver may enlarge and become tender. Jaundice (the yellowing of the skin and eyes) appears as bilirubin accumulates in the blood. The severity of the symptoms varies from patient to patient, and symptoms are not specific for the causative agent.

7-12. CAUSATIVE AGENTS

Of the several viruses capable of producing hepatitis, four are considered to be the most predominant causative agents of the disease today. These agents are:

- a. Hepatitis A virus (HAV).
- b. Hepatitis B virus (HBV).
- c. Hepatitis D virus (HDV, "Delta Hepatitis").
- d. Hepatitis Non-A, Non-B (NANB).

7-13. HEPATITIS IMMUNOLOGICAL MARKERS

Testing for the specific type of viral hepatitis involved in the disease process is based on detecting certain possible viral antigens present in the patient's serum as well as the detection of specific antibodies produced in the immune response to the viral agent. Antibodies associated with viral hepatitis are either IgM or IgG immunoglobulins. IgM immunoglobulins are involved in the primary immune response and serve as good immunological test markers of recent or acute infection since they appear at the onset of the infection and are fairly short lived. IgG immunoglobulins usually appear at about the same time as IgM but result in a longer sustained response and generally serve as good immunological markers of past exposure and possible immunity. The most common methodology utilized to detect the serological markers of hepatitis is the enzyme immunoassay.

Section IV. HEPATITIS A VIRUS

7-14. VIRUS STRUCTURE

The hepatitis A virus (HAV) is a small nonenveloped, single-stranded RNA virus that belongs to the picornavirus class of viruses. It consists of an outer capsid containing the hepatitis A antigen. The capsid surrounds the single strand of RNA and the viral protein genome (VPG). The VPG aids the virus in attaching to the host cytoplasmic ribosomes for self-replication (figure 7-3).

Hepatitis A Virus

Picornavirus




Figure 7-3. Structure of HAV.

7-15. MODE OF TRANSMISSION

The hepatitis A virus is transmitted via the oral-fecal (enteric) route. The HAV may be found in feces and may be transmitted to others through poor personal hygiene, through the sharing of eating utensils, through oral-anal sexual contact, or through the sharing of common items which are contaminated with infectious fecal material such as children's toys. Contaminated food and water are frequent modes of transmission.

7-16. INCUBATION PERIOD AND INFECTIVITY

The appearance of symptoms and infectivity ranges from 15 to 45 days following the first exposure to the hepatitis A virus. The virus is rapidly cleared from the body at the onset of symptoms. The highest period of infectivity occurs during the late incubation period. The patient is considered potentially infectious for up to 2 weeks after the onset of symptoms. There are no reported cases of a chronic carrier (infection longer than 6 months) HAV state.

7-17. HUMAN IMMUNODEFICIENCY VIRUS IMMUNOLOGICAL ASSAYS

See figure 7-4.

a. **Anti-Human Immunodeficiency Virus IgM.** Detects IgM antibody produced in the initial response to hepatitis A antigen. It is specific for diagnosing or confirming an acute HAV infection.

b. Anti-Human Immunodeficiency Virus. Measures total antibody (IgM and IgG) to hepatitis an indicator of recent infection as well as past infection. It is primarily useful in confirming previous exposure and immunity to hepatitis A.




Figure 7-4. Antibody response in Hepatitis A.

Section V. HEPATITIS B VIRUS

7-18. VIRUS STRUCTURE

The hepatitis B virus (HBV) consists of a central core containing the core antigen (HBcAg) and a surrounding envelope containing the surface antigen (HBsAg). (figure 7-5). DNA, hepatitis Be antigen (HBeAg), and an enzyme (DNA polymerase) required to help the DNA reproduce are also located in the central core. The intact virus particle containing these components is referred to as the "Dane particle" and is considered the infectious virus. Hepatitis B belongs to the hepadna class of viruses.




Figure 7-5. Structure of HBV.


7-19. MODE OF TRANSMISSION

Hepatitis B virus is predominantly transmitted via the parenteral route. Parenteral transmission occurs mainly through exposure to contaminated blood or blood products (blood transfusions, dialysis patients, hemophiliacs, infected needles, and so forth). Though transmission appears to be primarily parenteral, HBV can also be transmitted through a number of nonparenteral routes such as close intimate contact.

7-20. INCUBATION PERIOD AND INFECTIVITY

The length of the incubation period for HBV correlates inversely with the amount of virus to which the individual is exposed. (Large dose of HBV = short incubation time.) The average incubation period for hepatitis B is about 45 days with a typical range from 30 to 120 days. Hepatitis B is potentially highly infectious. As long as HBsAg is detectable, the individual should be considered infectious. A chronic carrier state does exist for hepatitis B infections.

7-21. HEPATITIS B VIRUS IMMUNOLOGICAL ASSAYS



See figure 7-6.

Figure 7-6. Hepatitis B core window identification.

a. **HBsAg.** The first marker to appear during an acute HBV infection is hepatitis B surface antigen (HBsAg). It can be detected in the serum of infected patients during the incubation period. The presence of HBsAg in serum indicates the possible presence of HBV and the potential infectious state of that person. The presence of HBsAg beyond six months and the failure of seroconversion to anti-HBs implies progression to the chronic carrier state.

b. **HBeAg.** This marker appears shortly after HBsAg and acts as an early indicator of acute infection. It indicates that the virus is actively replicating and that the individual is highly infectious. Its presence is usually short lived (3-6 weeks) and its persistence beyond six months without seroconversion to anti-HBe is indicative of progression to chronic carrier state.

c. **Anti-HBe.** Seroconversion from HBeAg to anti-HBe should occur during the acute phase and is prognostic for resolution of the infection. The presence of anti-HBe is an indicator of the patient's reduced infectious state. The failure to seroconvert to anti-HBe and the continued presence of HBeAg beyond six months implies progression to chronic carrier state.

d. **Anti-HBc IgM.** IgM antibody produced in the initial response to hepatitis B core antigen. It is an early marker of acute infection and is used to distinguish an acute HBV infection from a chronic carrier state. Anti-HBc IgM is also used to distinguish hepatitis B from non-A, non-B hepatitis.

e. **Anti-HBc.** Measures total antibody (IgM and IgG) to hepatitis B core antigen. It is a lifelong marker and acts as an indicator of current or previous hepatitis B infection. It does not appear to be associated with recovery from or immunity to hepatitis B.

f. **Anti-HBs.** This immunological marker does not appear during the acute phase of the disease, but rather during convalescence. Anti-HBs is not detectable in the serum until HBsAg has disappeared and therefore acts as an indicator of recovery and immunity. The "window period" is the gap of time between the disappearance of the surface antigen and the appearance of anti-HBs. This antibody is the major protective antibody against the virus and results from either past exposure to the virus or as the result of successful vaccination.

7-22. TYPES OF HEPATITIS B VIRUS INFECTIONS

Hepatitis B infections may present themselves in a number of ways. The severity and course of the infection depends upon several factors to include initial dose of virus, immunocompetency of the host, and overall health of the individual prior to infection.

a. **Asymptomatic Infection.** The asymptomatic infection is the most frequent response. In this case, the patient's symptoms are so mild that the patient is unaware of the infection or considers the illness as minor. Anti-HBs and anti-HBc levels are detectable and lasting immunity results.

b. **Acute Infection.** The period of acute infection usually lasts one to six months. The symptoms may be mild to quite severe. The infection is considered resolved with the production of anti-HBs.

c. **Chronic Carrier Infection.** The classic definition of chronic hepatitis is a person who exhibits HBsAg positivity and/or elevated liver enzymes for more than six months. It can last as little as one year or as long as several decades. Chronic HBV can be mild or quite severe. Two classifications of chronic hepatitis B exist: chronic persistent hepatitis (CPH) and chronic active hepatitis (CAH). Chronic persistent hepatitis is a nonprogressive benign condition that is characterized by fluctuating low enzyme levels, mild liver changes, and occasional mild symptoms and physical findings. Chronic active hepatitis usually results in liver degeneration that can progress to cirrhosis and possible liver cancer.

d. **Fulminant Infection.** One to three percent of acute HBV infections progress to this stage. The diagnosis of fulminant hepatitis is reserved for patients with signs and symptoms of liver failure during the course of acute hepatitis. Serum bilirubin and liver enzymes are extremely high and immunological markers are similar to those in typical acute hepatitis. Death usually results from the destruction of at least 90 percent of the body's liver.

Section VI. HEPATITIS D VIRUS (HEPATITIS B VIRUS, HEPATITIS D VIRUS)

7-23. VIRUS STRUCTURE

Little is known as to the true structure and classification of the hepatitis D virus (delta). It is thought to be a single-stranded RNA virus and is considered to be a defective agent since it requires the presence of HBsAg in order to replicate.

7-24. MODE OF TRANSMISSION

The HDV is transmissible via the parenteral route. Persons with frequent and repeated blood exposures (drug addicts, hemophiliacs, multiple blood transfusions, and so forth) appear to be at higher risk for contacting this virus. Since HDV requires the presence of HBV, contact with body fluids contaminated with HBV may also result in the transmission of HDV. A delta infection should be suspected in patients with fulminant hepatitis and in chronic HBV carriers who have a sudden deterioration in clinical course.

7-25. INCUBATION PERIOD AND INFECTIVITY

Since the hepatitis D virus is strictly dependent upon HBV, its incubation period is considered the same as HBV (45 days, range 30-120 days). The patient with a delta infection is considered infectious as long as the HBsAg is detectable.

7-26. HEPATITIS D VIRUS IMMUNOLOGICAL ASSAYS

- a. Anti-HDV IgM indicates acute infection.
- b. Anti-HDV indicates recent HDV infection or progression to chronic infection.

7-27. TYPES OF HEPATITIS D VIRUS INFECTIONS

The clinical course of HDV infection depends upon the type of infection: coinfection with HBV or superinfection in a patient who is already infected with HBV.

a. **Coinfection.** This type of infection is a simultaneous acute HDV infection in conjunction with an acute HBV infection. Since the majority of the cases of acute HBV are short lived, the severity of the HDV infection is limited. However, the liver damage can become extensive and, when combined with the damage caused by the hepatitis B virus, can induce a more severe case of hepatitis.

b. **Superinfection.** A superinfection of HDV in a hepatitis B chronic carrier produces the most severe damage. It may produce new hepatitis symptoms or may aggravate existing conditions. This type of infection is often severe and may cause fulminant hepatitis. Many superinfected carriers go on to develop chronic delta infections.

Section VII. HEPATITIS NON-A, NON-B

7-28. VIRUS STRUCTURE

The exact structure and classification of the virus attributable for hepatitis non-B (NANB) is unknown at this time. It is believed there are two or more viruses involved due to recurrent episodes of hepatitis which have not been related to the other types of hepatitis (HAV, HBV, or delta). The identification and classification of this infectious agent is the focus of intense research.

7-29. MODE OF TRANSMISSION

a. Hepatitis non-A, non-B is believed to be capable of both parenteral and enteric transmission. However, there is strong evidence that the parenteral route is predominant since hepatitis NANB accounts for 80-90 percent of all post-transfusion hepatitis cases in the United States (US) and is a major source of hepatitis among dialysis patients. Proposed nomenclature for blood-borne hepatitis NANB is hepatitis C (HCV).

b. Enteric (epidemic) NANB has been responsible for several large, well-documented waterborne outbreaks of hepatitis. Most cases have been reported in developing countries or among travelers who have recently returned from areas in which the disease is known to be endemic. Proposed nomenclature for enteric hepatitis NANB is hepatitis E (HEV).

7-30. NON-B IMMUNOLOGICAL ASSAYS

a. No hepatitis non-A, non-B immunological markers have been positively identified at this time. However, promising research has provided for a possible immunological assay in the near future.

b. Presently a diagnosis of NANB is made through clinical symptoms, patient history, elevated liver enzymes, and the exclusion of the other types of hepatitis through immunological assays.

Continue with Exercises

EXERCISES, LESSON 7

INSTRUCTIONS: Answer the following items by completing the statement or by writing the answer in the space provided.

After you have completed all of these items, turn to "Solutions to Exercises" at the end of the lesson and check your answers with the solutions.

- The structure of a virus consists of a <u>c</u> <u>e</u>, a <u>c</u> <u>d</u>, and an <u>e</u> <u>e</u>. The core consists mainly of a <u>n</u> <u>c</u> acid, either DNA or RNA, never both together. The capsid is a protective protein coat around the <u>c</u> <u>e</u>. It is constructed of individual subunits termed <u>c</u> <u>s</u>. The envelope is a <u>l</u> <u>d</u> outer covering; it may or may not be <u>pr</u> <u>t</u> depending on the virus.
- 2. Viruses are classified by the following properties: <u>m gy</u>, structure, and cytopathic effects in cell <u>c es</u>.
- Acquired immunodeficiency syndrome (AIDS) is caused by the human <u>i y</u> virus (HIV). Epidemiological data and serological data suggest that the viral infection began in Central <u>A a</u>.
- 4. Human Immunodeficiency Virus belongs to a unique class of viruses, distinguished by the presence of an e____e that catalyzes the formation of _____ from RNA. The catalyzing enzyme is ______a reverse t_____e, and viruses that contain it are called r____s. The HIV is a cytopathic retrovirus that appears to be genetically related to some of the other c____C r___s.
- 5. The virus is approximately 110-140 <u>n</u> meters in size and has an outer envelope surrounding the core. The core contains ______ (the genetic information), reverse t_______e, and p24, which is a p_____n. The p24 protein is antigenic, and a_____s against it are detected in the ELISA test and Western blot. The envelope contains two important glycop_____s. Glycoprotein 41 (gp 41) spans the m_____e and is also antigenic. The other protein, gp 120, is the major o_____r membrane glycoprotein of HIV. The envelope gene that codes for a portion of the virus's outer membrane v______s considerably from isolate to isolate. An effective vaccine for AIDS would therefore need to protect against many different s______s of the virus. The HIV contains a gene, called the TAT (trans-a_____or) gene, whose product acts as a powerful promotor of viral DNA r______tion. This promotion of viral replication at the expense of c_____r replication may be an important mechanism in virally induced cell death.

- 6. The HIV contains a unique enzyme that enables the viruses to make _____ copies of its _____. This enzyme, commonly referred to as r e t ase, is an RNA-dependent DNA polymerase that catalyzes the reverse flow of g c information from RNA to DNA. Once the DNA is made, these viruses use other e s to insert, or integrate, the DNA copies of their genes into the ch l DNA of the host cell. Insertion having been accomplished, the proviral DNA genes become a part of the genes of the h t cell. Once present in the c ar DNA, retrovirus "proviral" genes may be: (1) nonfunctional or s t, (2) p ly transcribed with subsequent expression of individual viral p s within the cell or on its surface, or (3) fully tr d to produce new viral RNA genes that are encapsulated in viral structural p s to form new virus particles. These new virons may then i t any cell they contact.
- 7. The HIV is cytopathic for many of the <u>I</u> ytes in which the virus actively replicates. The primary targets for HIV are the T4 <u>h</u> r lymphocytes. However, other cells may become infected; these other cells include the <u>m</u> cytes, <u>m</u> ges, _ lymphocytes, dendritic reticular cells, and some glial and endo <u>-I</u> cells in the brain may become infected.
- The HIV virus destroys many of the body's T4 <u>h</u> r cells. The infected T4 cells that are not destroyed are functionally <u>de</u> ve. The infected monocytes appear to be non<u>f</u> <u>I</u>. The virus appears to stimulate all B cells into producing <u>a</u> <u>s</u>, thereby, leaving no unstimulated B cells available to respond to new <u>i</u> <u>s</u>.
- 9. ELISA or EIA procedures are the most widely used <u>s</u>ing tests for HIV. These procedures test for <u>a</u> <u>s</u> formed against various proteins or glycoproteins from HIV. There are new procedures available now to test directly for HIV <u>a</u> <u>ns</u>. This allows for <u>e</u> <u>r</u> and more <u>d</u> <u>v</u>e detection of the disease. The procedure, which is presently used for confirmation of positive screening tests (ELISA, EIA), is the Western <u>b</u> <u>t</u>.
- 10. Viral hepatitis has been recognized by the medical community for almost two decades) (centuries) and remains a disease of major significance in the world today. It is an infection which results in inflammation of the liver caused by one of at least (2) (3) (4) distinct viral agents. The diagnosis of acute viral hepatitis sometimes can be made on the basis of c l features and history that suggest a particular c ve agent. In most cases and due to recent immunological advances, specific tests exist which accurately d t, d e, and m r the progression of hepatitis.

- 11. Early symptoms of hepatitis are similar to the common flu with accompanying \underline{f} e, joint and muscle p n, and loss of a te. Low-grade fever, n a, v g, and d a or constipation may occur. As the disease progresses, the liver may \underline{en} e and become tender. Jaundice or the yellowing of the skin and eyes appears as <u>b n</u>, accumulates in the blood. The severity of the symptoms varies from p t to p t, and symptoms are not specific for the <u>c</u> ve agent.
- 12. The predominant causative agents of hepatitis are: hepatitis _ virus (HAV), hepatitis _ virus (HBV), hepatitis _ virus (HDV), and hepatitis non-_, non-_ (NANB).
- 13. Testing for the specific type of viral hepatitis involved in the disease process is based on detecting viral <u>a s</u> present in the patient's serum as well as the detection of specific <u>a ies</u> produced in the immune response to the viral agent. Antibodies associated with viral hepatitis are either IgM or IgG <u>im ns</u>. IgM immunoglobulins are involved in the primary immune response and serve as good <u>im cal</u> test markers of recent or acute infection since they appear at the <u>o t</u> of the infection and are short <u>I d</u>. IgG immunoglobulins usually serve as good immunological markers of <u>p t</u> exposure and possible <u>i y</u>. The most common methodology utilized to detect the serological markers of hepatitis is the <u>e e</u> immunoassay.
- 14. Does the hepatitis A virus have an envelope? ____. It is a single-stranded RNA virus which belongs to the p____virus class of viruses. It consists of an outer c_____d containing the hepatitis A antigen. The capsid surrounds the single s_____d of RNA and the viral protein g_____e (VPG). The VPG aids the virus in attaching to the host cytoplasmic ri_____somes for self-replication.
- 15. The hepatitis A virus is transmitted via the <u>o</u> <u>I-f</u> <u>I</u> (enteric) route. HAV may be found in <u>f</u> <u>s</u> and may be transmitted to others through poor personal <u>h</u> <u>e</u>, through the sharing of <u>e</u> <u>g</u> utensils, through oral-anal <u>s</u> <u>I</u> contact, or through the sharing of common items which are contaminated with infectious <u>f</u> <u>I</u> material such as children's toys. Contaminated <u>f</u> <u>d</u> and <u>w</u> <u>r</u> are frequent modes of transmission.

- 16. The appearance of symptoms and infectivity ranges from 15 to 45 (hours) (days)(weeks) following the first exposure to the hepatitis A virus. The virus is rapidly cleared from the body at the onset of <u>s</u>. The highest period of infectivity occurs during the (early) (late) incubation period. The patient is considered potentially infectious for up to 2 (days) (weeks) (months) after the onset of symptoms. There are no reported cases of a <u>c</u> <u>c</u> carrier (infection longer than 6 months) HAV state.
- 17. Considering HAV immunological assays, the anti-HAV IgM detects _____ antibody produced in the <u>i I r se</u> to hepatitis A antigen. It is specific for diagnosing or confirming an <u>a e</u> HAV infection. The anti-HAV measures total <u>a v</u> (IgM and I gG) to hepatitis A antigen. It is an indicator of <u>r t</u> infection as well as <u>p t</u> infection. It is primarily useful in confirming <u>p s</u> exposure and immunity to hepatitis A.
- 18. The hepatitis B virus consists of a central core containing the core <u>a</u> n (HBcAg) and a surrounding <u>e</u> <u>e</u> containing the surface antigen (HBsAg). DNA, hepatitis Be antigen, and an DNA polymerase are located in the central <u>c</u> <u>e</u>. The intact virus particle containing these components is referred to as the "<u>D</u> <u>e</u> particle."
- 19. Hepatitis B virus is predominantly transmitted via the p_l route. Parenteral transmission occurs mainly through exposure to contaminated <u>b</u> d or <u>b</u> d products (blood transfusions, <u>d</u> is patients, <u>h</u> cs, infected <u>n</u> les, and so forth). Though transmission appears to be primarily parenteral, HBV can also be transmitted through a number of nonparenteral routes such as close intimate contact.
- 20. The length of the incubation period for HBV correlates inversely with the <u>a</u> t of virus to which the individual is exposed. (Large dose of HBV = (long) (short) incubation time.) The average incubation period for hepatitis B is about 45 (hours) (days) with a typical range from 30 to 120. Hepatitis B is potentially highly i <u>s</u>. As long as HBsAg is <u>d</u> ble, the individual should be considered infectious. A chronic carrier state (does) (does not) exist for hepatitis B infections.

21. Considering HBV immunological assays, the first marker to appear during an acute HBV infection is hepatitis B <u>s</u> <u>e</u> antigen (HBsAg). It can be detected in the <u>s</u> <u>m</u> of infected patients during the incubation period. The presence of HBsAg in serum indicates the possible presence of <u>___</u> and the potential <u>i</u> <u>s</u> state of that person. The presence of HBsAg beyond six months and the failure of seroconversion to anti-HBs implies progression to the chronic <u>c</u> <u>r</u> <u>s</u> <u>e</u>.

The HBeAg marker appears shortly after <u>HB</u> and acts as an early indicator of (<u>acute</u>) (chronic) infection. It indicates that the virus is actively <u>r g</u> and that the individual is highly <u>i s</u>.

Seroconversion from HBeAg to anti-HBe should occur during the acute phase and is prognostic for <u>r</u> <u>n</u> of the infection. The presence of anti-HBe is an indicator of the patient's (increased) (reduced) infectious state. The failure to seroconvert to anti-HBe and the continued presence of HBeAg beyond six months implies progression to <u>c</u> <u>c</u> <u>c</u> <u>r</u> state.

Anti-HBc IgM is an IgM antibody produced in the <u>i</u> response to hepatitis B core antigen. It is an early <u>m</u> r of acute infection and is used to distinguish an <u>a</u> e HBV infection from a chronic <u>c</u> r state. Anti-HBc IgM is also used to distinguish hepatitis B from <u>non-</u>, <u>non-</u> hepatitis.

Anti-HBc measures total antibody (IgM and IgG) to hepatitis B <u>c</u> <u>e</u> antigen. It is a <u>l</u> <u>g</u> marker and acts as an indicator of current or <u>p</u> <u>s</u> hepatitis B infection. It does not appear to be associated with <u>r</u> <u>ry</u> from or <u>i</u> <u>y</u> to hepatitis B.

The immunological marker anti-HBs does not appear during the acute phase of the disease but rather during <u>c</u> <u>ce</u>. Ant-HBs is not detectable in the serum until HBsAg has disappeared and therefore acts as an indicator of <u>r</u> <u>y</u> and <u>i</u> <u>y</u>. The "window period" is the gap of time between the disappearance of the <u>s</u> <u>e</u> antigen and the appearance of anti-HBs. This antibody is the major <u>pr</u> <u>ve</u> antibody against the virus and results from either past exposure to the virus or as the result of successful <u>va</u> <u>n</u>.

22. The severity and course of hepatitis B infections depends upon several factors, including the initial <u>d</u> e of virus, <u>i</u> cy of the host, and overall <u>h</u> of the individual prior to infection.

The most frequent response is an <u>a</u> <u>-</u> <u>ic</u> infection. In this case, the patient's symptoms are so <u>m</u> <u>d</u> that the patient is <u>un</u> <u>e</u> of the infection or considers the illness as minor. Anti-HBs and anti-HBc levels are detectable and lasting immunity results.

The period of acute infection usually lasts one to six <u>(weeks) (months)</u>. The symptoms may be mild to quite severe. The infection is considered resolved with the production of anti-<u>HB</u>.

The classic definition of chronic hepatitis is a person who exhibits HBsAg <u>p_ty</u> and/or elevated liver <u>e_s</u> for more than six months. It can last as little as one (month) (year) or as long as several <u>d_s</u>. Chronic HBV can be mild or quite <u>s_e</u>. Two classifications of chronic hepatitis B exist: chronic <u>p_t</u> hepatitis (CPH) and chronic <u>a_e</u> hepatitis (CAH).

One to three percent of acute HBV infections progress to the stage \underline{f} t infection. The diagnosis of fulminant hepatitis is reserved for patients with signs and symptoms of \underline{l} r failure during the course of acute hepatitis. Serum bili n and liver \underline{e} s are extremely high and immunological markers are similar to those in typical acute hepatitis. Death usually results from the destruction of at least (50, 70, and 90 percent of the body's liver.

- 23. Little is known as to the true structure and classification of the hepatitis _ virus. It is thought to be a <u>s</u>_e-stranded RNA virus and is considered to be a <u>d</u>_ve agent since it requires the presence of HBsAg in order to <u>r_e</u>.
- 24. The HDV is transmissible via the <u>p</u> I route. Persons with frequent and repeated blood exposures (drug <u>a</u> <u>s</u>, hemophiliacs, multiple blood <u>t</u> <u>ns</u>, and so forth) appear to be at higher risk for contacting this virus. Since HDV requires the presence of <u>H</u>, contact with body fluids contaminated with HBV may also result in the transmission of <u>H</u>. Delta infection should be suspected in patients with fulminant hepatitis and in <u>c</u> <u>c</u> HBV carriers who have a sudden deterioration in clinical course.
- Considering HDV immunological assays, anti-HDV IgM indicates (acute) (chronic) infection. Anti-HDV indicates r t HDV infection or progression to c c infection.

26. The clinical course of HDV infection depends upon the type of infection: <u>c</u>_____infection with HBV or <u>s____infection</u> in a patient who is already infected with HBV.

In coinfection, there is a simultaneous acute \underline{H} infection in conjunction with an acute \underline{H} infection.

A superinfection of HDV in a hepatitis B chronic carrier produces (<u>little</u>) (severe) damage. It may cause f thepatitis. Many superinfected carriers go on to develop (acute) (chronic) delta infections.

- 27. The identification and classification of the infectious agent for hepatitis NANB is the focus of intense <u>r h</u>.
- 28. Concerning mode of transmission, hepatitis non-A, non-B is believed to be capable of both <u>p_l</u> and <u>e_c</u> transmission. However, there is strong evidence that the (<u>parenteral</u>) (<u>enteric</u>) route is predominant since hepatitis NANB accounts for 80-90% of all post-t_n hepatitis cases in the U.S. and is a major source of hepatitis among <u>d_s</u> patients. Proposed nomenclature for blood-borne hepatitis NANB is hepatitis _ (HCV).

Enteric (epidemic) NANB has been responsible for several large, well-documented <u>w</u> borne outbreaks of hepatitis. Most cases have been reported in <u>d</u> ing countries or among travelers who have recently returned from areas in which the disease is known to be <u>e</u> <u>c</u>. Proposed nomenclature for enteric hepatitis NANB is hepatitis _ (HEV).

29. Regarding NANB immunological assays, promising <u>r h</u> has provided for a possible immunological assay in the near future. Presently a diagnosis of NANB is made through <u>c l</u> symptoms, patient <u>h y</u>, elevated liver <u>e s</u>, and the exclusion of the other types of hepatitis through <u>i l</u> assays.

Check Your Answers on Next Page

SOLUTIONS TO EXERCISES, LESSON 7

- The structure of a virus consists of a <u>core</u>, a <u>capsid</u>, and an <u>envelope</u>. The core consists mainly of a <u>nucleic</u> acid, either DNA or RNA, never both together. The capsid is a protective protein coat around the <u>core</u>. It is constructed of individual subunits termed <u>capsomers</u>. The envelope is a <u>lipid</u> outer covering; it may or may not be <u>present</u> depending on the virus. (para 7-1)
- Viruses are classified by the following properties: <u>morphology</u>, structure, and cytopathic effects in cell <u>cultures</u>. (para 7-2)
- Acquired immunodeficiency syndrome (AIDS) is caused by the human <u>immunodeficiency</u> virus (HIV). Epidemiological data and serological data suggest that the viral infection began in Central <u>Africa</u>. (para 7-3)
- 4. The HIV belongs to a unique class of viruses, distinguished by the presence of an <u>enzyme</u> that catalyzes the formation of <u>DNA</u> from RNA. The catalyzing enzyme is a reverse <u>transcriptase</u>, and viruses that contain it are called <u>retroviruses</u>. HIV is a cytopathic retrovirus that appears to be genetically related to some of the other <u>cytopathic retroviruses</u>. (para 7-4)
- 5. The virus is approximately 110-140 <u>nanometers in size and has an outer envelope surrounding the core</u>. The core contains <u>RNA</u> (the genetic information), reverse <u>transcriptase</u>, and p24, which is a <u>protein</u>. The p24 protein is antigenic, and <u>antibodies</u> against it are detected in the ELISA test and Western blot. The envelope contains two important glycoproteins. Glycoprotein 41 (gp 41) spans the <u>membrane</u> and is also antigenic. The other protein , gp 120, is the major <u>outer</u> membrane glycoprotein of HIV. The envelope gene that codes for a portion of the virus's outer membrane <u>varies</u> considerably from isolate to isolate. An effective vaccine for AIDS would therefore need to protect against many different <u>strains</u> of the virus. HIV contains a gene, called the TAT (trans-<u>activator</u>) gene, whose product acts as a powerful promotor of viral DNA <u>replication</u>. This promotion of viral replication at the expense of <u>cellular</u> replication may be an important mechanism in virally induced cell death. (para 7-5)

- 6. The HIV contains a unique enzyme that enables the viruses to make <u>DNA</u> copies of its RNA. This enzyme, commonly referred to as reverse transcriptase, is an RNA-dependent DNA polymerase that catalyzes the reverse flow of genetic information from RNA to DNA. Once the DNA is made, these viruses use other enzymes to insert, or integrate, the DNA copies of their genes into the chromosomal DNA of the host cell. Insertion having been accomplished, the proviral DNA genes become a part of the genes of the host cell. Once present in the <u>cellular</u> DNA, retrovirus "proviral" genes may be: (1) nonfunctional or <u>silent</u>, (2) partially transcribed with subsequent expression of individual viral proteins within the cell or on its surface, or (3) fully transcribed to produce new viral RNA genes that are encapsulated in viral structural proteins to form new virus particles. These new virons may then infect any cell they contact. (para 7-6)
- 7. Human Immunodeficiency Virus is cytopathic for many of the lymphocytes in which the virus actively replicates. The primary targets for HIV are the T4 helper lymphocytes. However, other cells may become infected; these other cells include the monocytes, macrophages, B lymphocytes, dendritic reticular cells, and some glial and endothelial cells in the brain may become infected. (para 7-7)
- 8. The HIV virus destroys many of the body's T4 helper cells. The infected T4 cells that are not destroyed are functionally defective. The infected monocytes appear to be nonfunctional. The virus appears to stimulate all B cells into producing antibodies, thereby, leaving no unstimulated B cells available to respond to new infections. (para 7-8)
- 9. ELISA or EIA procedures are the most widely used screening tests for HIV. These procedures test for antibodies formed against various proteins or glycoproteins from HIV. There are new procedures available now to test directly for HIV antigens. This allows for earlier and more definitive detection of the disease. The procedure, which is presently used for confirmation of positive screening tests (ELISA, EIA), is the Western blot. (para 7-9)
- 10. Viral hepatitis has been recognized by the medical community for almost two centuries and remains a disease of major significance in the world today. It is an infection which results in inflammation of the liver caused by one of at least 4 distinct viral agents. The diagnosis of acute viral hepatitis sometimes can be made on the basis of <u>clinical</u> features and history that suggest a particular causative agent. In most cases and due to recent immunological advances, specific tests exist which accurately detect, diagnose, and monitor the progression of hepatitis.

(para 7-10)

- Early symptoms of hepatitis are similar to the common flu with accompanying <u>fatigue</u>, joint and muscle <u>pain</u>, and loss of <u>appetite</u>. Low-grade fever, <u>nausea</u>, <u>vomiting</u>, and <u>diarrhea</u> or constipation may occur. As the disease progresses, the liver may e<u>nlarge</u> and become tender. Jaundice or the yellowing of the skin and eyes appears as <u>bilirubin</u> accumulates in the blood. The severity of the symptoms varies from <u>patient</u> to <u>patient</u>, and symptoms are not specific for the <u>causative</u> agent. (para 7-11)
- The predominant causative agents of hepatitis are: hepatitis <u>A</u> virus (HAV), hepatitis <u>B</u> virus (HBV), hepatitis <u>D</u> virus (HDV), and hepatitis non-<u>A</u>, non-<u>B</u> (NANB).
 (para 7-12)
- 13. Testing for the specific type of viral hepatitis involved in the disease process is based on detecting viral <u>antigens</u> present in the patient's serum as well as the detection of specific <u>antibodies</u> produced in the immune response to the viral agent. Antibodies associated with viral hepatitis are either IgM or IgG <u>immunoglobulins</u>. IgM immunoglobulins are involved in the primary immune response and serve as good <u>immunological</u> test markers of recent or acute infection since they appear at the <u>onset</u> of the infection and are short <u>lived</u>. IgG immunoglobulins usually serve as good immunological markers of <u>past</u> exposure and possible <u>immunity</u>. The most common methodology utilized to detect the serological markers of hepatitis is the <u>enzyme</u> immunoassay. (para 7-13)
- 14. Does the hepatitis A virus have an envelope? <u>No</u>. It is a single-stranded RNA virus which belongs to the <u>picornav</u>irus class of viruses. It consists of an outer <u>capsid</u> containing the hepatitis A antigen. The capsid surrounds the single <u>strand</u> of RNA and the viral protein <u>genome</u> (VPG). The VPG aids the virus in attaching to the host cytoplasmic <u>ribos</u>omes for self-replication. (para 7-14)
- 15. The hepatitis A virus is transmitted via the <u>oral-fecal</u> (enteric) route. HAV may be found in <u>feces</u> and may be transmitted to others through poor personal <u>hygiene</u>, through the sharing of <u>eating</u> utensils, through oral-anal <u>sexual</u> contact, or through the sharing of common items which are contaminated with infectious <u>fecal</u> material such as children's toys. Contaminated <u>food</u> and <u>water</u> are frequent modes of transmission.

(para 7-15)

- 16. The appearance of symptoms and infectivity ranges from 15 to 45 <u>days</u> following the first exposure to the hepatitis A virus. The virus is rapidly cleared from the body at the onset of <u>symptoms</u>. The highest period of infectivity occurs during the <u>late</u> incubation period. The patient is considered potentially infectious for up to 2 <u>weeks</u> after the onset of symptoms. There are no reported cases of a <u>chronic</u> carrier (infection longer than 6 months) HAV state. (para 7-16)
- 17. Considering HAV immunological assays, the anti-HAV IgM detects IgM antibody produced in the <u>initial response</u> to hepatitis A antigen. It is specific for diagnosing or confirming an <u>acute</u> HAV infection. The anti-HAV measures total <u>antibody</u> (IgM and IgG) to hepatitis A antigen. It is an indicator of <u>recent</u> infection as well as past infection. It is primarily useful in confirming <u>previous</u> exposure and immunity to hepatitis A. (para 7-17)
- The hepatitis B virus consists of a central core containing the core <u>antigen</u> (HBcAg) and a surrounding <u>envelope</u> containing the surface antigen (HBsAg). DNA, hepatitis Be antigen, and an DNA polymerase are located in the central <u>core</u>. The intact virus particle containing these components is referred to as the "<u>Dane</u> particle." (para 7-18)
- Hepatitis B virus is predominantly transmitted via the <u>parenteral</u> route. Parenteral transmission occurs mainly through exposure to contaminated <u>blood</u> or <u>blood</u> products (blood transfusions, <u>dialysis</u> patients, <u>hemophiliac</u>s, infected <u>needles</u>, etc.). Though transmission appears to be primarily parenteral, HBV can also be transmitted through a number of nonparenteral routes such as close intimate contact. (para 7-19)
- 20. The length of the incubation period for HBV correlates inversely with the <u>amount</u> of virus to which the individual is exposed. (Large dose of HBV = <u>short</u> incubation time.) The average incubation period for hepatitis B is about 45 <u>days</u> with a typical range from 30 to 120. Hepatitis B is potentially highly <u>infectious</u>. As long as HBsAg is <u>detectable</u>, the individual should be considered infectious. A chronic carrier state <u>does</u> exist for hepatitis B infections. (para 7-20)

21. Considering HBV immunological assays, the first marker to appear during an acute HBV infection is hepatitis B <u>surface</u> antigen (HBsAg). It can be detected in the <u>serum</u> of infected patients during the incubation period. The presence of HBsAg in serum indicates the possible presence of <u>HBV</u> and the potential <u>infectious</u> state of that person. The presence of HBsAg beyond six months and the failure of seroconversion to anti-HBs implies progression to the chronic <u>carrier state</u>.

The HBeAg marker appears shortly after <u>HBsAg</u> and acts as an early indicator of <u>acute</u> infection. It indicates that the virus is actively <u>replicating</u> and that the individual is highly <u>infectious</u>.

Seroconversion from HBeAg to anti-HBe should occur during the acute phase and is prognostic for <u>resolution</u> of the infection. The presence of anti-HBe is an indicator of the patient's <u>reduced</u> infectious state. The failure to seroconvert to anti-HBe and the continued presence of HBeAg beyond six months implies progression to <u>chronic carrier</u> state.

Anti-HBc IgM is an IgM antibody produced in the <u>initial</u> response to hepatitis B core antigen. It is an early <u>marker</u> of acute infection and is used to distinguish an <u>acute</u> HBV infection from a chronic <u>carrier</u> state. Anti-HBc IgM is also used to distinguish hepatitis B from <u>non-A</u>, <u>non-B</u> hepatitis.

Anti-HBc measures total antibody (IgM and IgG) to hepatitis B <u>core</u> antigen. It is a <u>lifelong</u> marker and acts as an indicator of current or <u>previous</u> hepatitis B infection. It does not appear to be associated with <u>recovery</u> from or <u>immunity</u> to hepatitis B.

The immunological marker anti-HBs does not appear during the acute phase of the disease but rather during <u>convalescence</u>. Ant-HBs is not detectable in the serum until HBsAg has disappeared and therefore acts as an indicator of <u>recovery</u> and <u>immunity</u>. The "window period" is the gap of time between the disappearance of the <u>surface</u> antigen and the appearance of anti-HBs. This antibody is the major <u>protective</u> antibody against the virus and results from either past exposure to the virus or as the result of successful <u>vaccination</u>.

(para 7-21)

22. The severity and course of hepatitis B infections depends upon several factors, including the initial <u>dose</u> of virus, <u>immunocompetency</u> of the host, and overall <u>health</u> of the individual prior to infection.

The most frequent response is an <u>asymptomatic</u> infection. In this case, the patient's symptoms are so <u>mild</u> that the patient is <u>unaware</u> of the infection or considers the illness as minor. Anti-HBs and anti-HBc levels are detectable and lasting immunity results.

The period of acute infection usually lasts one to six <u>months</u>. The symptoms may be mild to quite severe. The infection is considered resolved with the production of anti-<u>HBs</u>.

The classic definition of chronic hepatitis is a person who exhibits HBsAg <u>positivity</u> and/or elevated liver <u>enzymes</u> for more than six months. It can last as little as one <u>year</u> or as long as several <u>decades</u>. Chronic HBV can be mild or quite <u>severe</u>. Two classifications of chronic hepatitis B exist: chronic <u>persistent</u> hepatitis (CPH) and chronic <u>active</u> hepatitis (CAH).

One to three percent of acute HBV infections progress to the stage of <u>fulminant</u> infection. The diagnosis of fulminant hepatitis is reserved for patients with signs and symptoms of <u>liver</u> failure during the course of acute hepatitis. Serum bili<u>rubin</u> and liver <u>enzymes</u> are extremely high and immunological markers are similar to those in typical acute hepatitis. Death usually results from the destruction of at least <u>90%</u> of the body's liver.

(para 7-22)

- 23. Little is known as to the true structure and classification of the hepatitis <u>D</u> virus. It is thought to be a <u>single</u>-stranded RNA virus and is considered to be a <u>defective</u> agent since it requires the presence of HBsAg in order to <u>replicate</u>. (para 7-23)
- 24. HDV is transmissible via the <u>parenteral</u> route. Persons with frequent and repeated blood exposures (drug <u>addicts</u>, hemophiliacs, multiple blood <u>transfusions</u>,and so forth) appear to be at higher risk for contacting this virus. Since HDV requires the presence of <u>HBV</u>, contact with body fluids contaminated with HBV may also result in the transmission of <u>HDV</u>. Delta infection should be suspected in patients with fulminant hepatitis and in <u>chronic</u> HBV carriers who have a sudden deterioration in clinical course. (para 7-24)
- Considering HDV immunological assays, anti-HDV IgM indicates <u>acute</u> infection. Anti-HDV indicates <u>recent</u> HDV infection or progression to <u>chronic</u> infection. (para 7-26)

26. The clinical course of HDV infection depends upon the type of infection: <u>co</u>infection with HBV or <u>super</u>infection in a patient who is already infected with HBV.

In coinfection, there is a simultaneous acute \underline{HDV} infection in conjunction with an acute \underline{HBV} infection.

A superinfection of HDV in a hepatitis B chronic carrier produces <u>severe</u> damage. It may cause <u>fulminant</u> hepatitis. Many superinfected carriers go on to develop <u>chronic</u> delta infections.

(para 7-27)

- The identification and classification of the infectious agent for hepatitis NANB is the focus of intense <u>research</u>. (para 7-28)
- 28. Concerning mode of transmission, hepatitis non-A, non-B is believed to be capable of both <u>parenteral</u> and <u>enteric</u> transmission. However, there is strong evidence that the <u>parenteral</u> route is predominant since hepatitis NANB accounts for 80-90 percent of all <u>post-trans</u>fusion hepatitis cases in the US and is a major source of hepatitis among <u>dialysis</u> patients. Proposed nomenclature for blood-borne hepatitis NANB is hepatitis <u>C</u>. (HCV).

Enteric (epidemic) NANB has been responsible for several large, well-documented <u>water</u>borne outbreaks of hepatitis. Most cases have been reported in <u>developing</u> countries or among travelers who have recently returned from areas in which the disease is known to be <u>endemic</u>. Proposed nomenclature for enteric hepatitis NANB is hepatitis <u>E</u> (HEV).

(para 7-29)

 Regarding NANB immunological assays, promising <u>research</u> has provided for a possible immunological assay in the near future. Presently a diagnosis of NANB is made through <u>clinical</u> symptoms, patient <u>history</u>, elevated liver <u>enzymes</u>, and the exclusion of the other types of hepatitis through <u>immunological</u> assays. (para 7-30)

End of Lesson 7

APPENDIX

REFERENCES

Barrett, James T. <u>Textbook of Immunology</u>, 5th ed. The C.V. Mosby Co., St. Louis, 1988.

Bellanti, Joseph A. Immunology III, 3rd ed. W.B. Saunders, Philadephia, 1985.

Bryant, Neville. <u>Laboratory Immunology & Serology</u>, 2nd ed. W.B. Saunders, Philadelphia, 1986.

Coslett, G.D. <u>Hepatitis Learning Guide</u>. Abbott Diagnostics, 1985.

Henry, John B., et al. <u>Clinical Diagnosis and Management by Laboratory Methods</u>, 7th ed. W.B. Saunders, Philadelphia, 1984

Immunoglobulin Abnormality Detection. Millipore Corporation, 1974

Peter, G. <u>Report of the Committee on Infectious Diseases</u>, 20th ed. American Academy of Pediatrics, Elk Grove Village, 1986.

Reese, R.E. <u>A Practical Approach to Infectious Diseases</u>, 2nd ed. Little, Brown and Co., Boston, 1986.

Roitt, Ivan, et al. Immunology. The C.V. Mosby Co., St Louis, 1985

Sonnenwith, J., et al. <u>Gradwohl's Clinical Laboratory Methods and Diagnosis</u>, 8th ed. The C.V. Mosby Co., St Louis, 1980.

Stites, D.P., et al. <u>Basic and Clinical Immunology</u>, 6th ed. Lange Medical Publications, Los Altos, 1982.

Tietz, Norbert W. <u>Textbook of Clinical Chemistry</u>. W.B. Saunders., Philadelphia, 1986.

End of Appendix